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Abbreviations 
1. ABBREVIATIONS 
 
All units of measurement are abbreviated according to the International System of 
units (SI). 
 
A Adenosine 
AR Androgen receptor 
ARE Androgen responsive element 
ATP Adenosine triphosphate 
bp Base pair 
BSA Bovine serum albumin 
C Cytosine 
cDNA Complementary DNA 
CIP Calf intestinal phosphatase 
DAPI 4', 6'-diamidino-2-phenylindole, dihydrochloride 
DBD DNA binding domain 
DEX Dexamethasone 
DHS DNase I hypersensitive site 
DHT Dihydrotestosterone 
dI-dC Poly(deoxyinosine-deoxycytidine) 
DMEM Dulbecco’s Minimal Essential Medium 
DNA Deoxyribonucleic acid 
DNase Deoxyribonuclease 
dNTPs 2'-deoxynucleoside-5'-triphosphates 
DTT Dithiothreitol 
et al. and others 
EDTA Ethylene diaminetetraacetic acid 
EMSA Electrophoretic mobility shift assay 
EtBr Ethidium bromide 
FCS Fetal calf serum 
G Guanosine or gravity force 
GR Glucocorticoid receptor 
HEPES (2-Hydroxyethyl)-1-piperazineethanesulphonic acid 
HRP Horse radish peroxidase 
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Abbreviations 
kb Kilobase pair 
kD Kilodalton 
MMTV Mouse mammary tumor virus 
NaCl Sodium chloride 
ONPG ο-nitrophenyl-β-D-galactopyranoside 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PIPES 1,4-Piperazinediethanesulfonic acid 
PMSF Phenylmethylsulfonyl fluoride 
PSA Prostate specific antigen 
RLU Relative luminescence unit 
RSV Rous sarcoma virus 
RNA Ribonucleic acid 
RNase Ribonuclease 
rpm Revolutions per minute 
RT-PCR Reverse transcription PCR 
SDS Sodium-dodecyl-sulphate 
SSC Standard sodium citrate buffer 
T Thymine 
TAE Tris-acetate-EDTA buffer 
TBE Tris-borate-EDTA buffer 
TE Tris-EDTA 
Tris Tris(hydroxymethyl)-amino-methane 
U Unit 
UV Ultraviolet 
wt Wild type 
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Introduction 
2. INTRODUCTION 
2.1 Transcriptional regulation in eukaryotic cells 
Transcription is defined as the process of RNA synthesis complementary to a DNA 
template. In eukaryotic cells transcription is performed by three different RNA 
polymerases. Ribosomal RNA is transcribed by RNA polymerase I, messenger RNA 
by RNA polymerase II, tRNAs and other small RNAs by RNA polymerase III. 
Because the investigated gene SCGB 2A1 is encoding an mRNA, transcriptional 
regulation operating through RNA polymerase II will be reviewed here. 
Whereas bacterial RNA polymerase can bind to promoters and initiate 
transcription on its own and accessory factors are only needed for initiation, but are 
not required subsequently (McClure, 1985), eukaryotic RNA polymerase II requires 
the presence of additional transcription factors. These factors must bind to the 
promoter before the polymerase is incorporated into a preinitiation complex via 
protein-protein interactions. These transcription factors, rather than the polymerase 
itself, are thus responsible for the recognition of a eukaryotic promoter. 
All eukaryotic RNA polymerases are multi-subunit complexes with a molecular 
weight of 500,000 Daltons or more. RNA polymerase II transcribes heterogeneous 
nuclear RNA (hnRNA), the precursor for mRNA (Young, 1991). In electron 
microscopical analyses, actively transcribing polymerase II complexes always appear 
as globular particles with a single RNA tail. But most transcription complexes appear 
as single globular units, without RNA-tail. This observation indicates that most genes 
are transcribed only infrequently, so that one polymerase finishes transcription before 
another round of transcription begins. In fact, only few genes are transcribed at high 
frequency. 
In eukaryotes mature mRNA is produced in several steps. The precursors of 
mRNA, hnRNA, are freshly synthesized by RNA polymerase II. These precursors are 
defined as primary transcripts and covalently modified at both their 5' and 3' ends 
subsequently. Those modifications clearly distinguish them from the transcripts made 
by other RNA polymerases. The 5' end is capped immediately after synthesis 
beginning with the addition of a methylated G nucleotide, which is not only used as a 
signal in translation but also protects the growing RNA transcript from degradation. 
Modification of the 3' end begins with cleavage of the nascent RNA chain 
downstream of the polyadenylation signal AAUAAA. Subsequently a poly-A tail is 
added by poly (A) polymerase. Poly (A) tail formation is a significant component of 
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3' processing, a link in the chain of events, including transcription, splicing, and 
cleavage/polyadenylation of hnRNA. Transcription, capping, splicing, 
polyadenylation, and transport take place as coupled processes that can regulate each 
other. Although the rate of production of hnRNA typically accounts for about half of a 
cell's RNA synthesis, the mRNA eventually produced represents only about 3% of the 
steady-state quantity of RNA in a cell (Lodish et al., 1995). 
2.1.1 Transcription factors 
Different cells in an individual contain the same genome, but show a different gene 
expression pattern, even if those cells are of the same cell type. Cells can quickly 
change their expression pattern in response to a plethora of changes in their 
environment, like in temperature, light conditions, redox potential, nutrient supply or 
in response to external signaling molecules like hormones, growth factors and 
cytokines. Although gene expression can in principle be regulated at all steps 
including opening of chromatin structure, initiation of transcription, translation of 
mRNA and post-translational modification of proteins, most genes appear to be 
regulated at the transcriptional level. 
Because RNA polymerase II cannot initiate transcription itself, it is absolutely 
dependent on auxiliary transcription factors. There is a plethora of protein factors that 
can act in conjunction with RNA polymerase II. Those factors can be divided into 
three general groups. The first group contains the general transcription factors, which 
are required for the initiation of RNA synthesis on all promoters. They form a 
complex with RNA polymerase II surrounding the transcription start point, and 
determine the site of initiation. The second group is called the upstream factors. They 
are DNA-binding proteins that recognize specific short DNA elements located 
upstream of the transcription start point. They increase the efficiency of initiation, and 
are required for the full activity of many promoters. Those factors are not regulated 
and are present in all cells. The third group is the inducible factors. They function like 
the upstream factors, but are synthesized or activated at specific times or in specific 
tissues. 
In eukaryotic cells, the basal transcription apparatus is needed for transcription 
from all promoters. It is assembled by the general transcription factors (TF) of RNA 
polymerase II (TFII) named as TFIIX, where ‘X’ is a letter that identifies the 
individual factor that originates from early chromatographic purification schemes. 
These factors assemble in a particular order as illustrated in Figure 2.1. Complex 
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assembly begins with the binding of TFIID to the TATA box. Next, TFIIA joins the 
complex; and after binding of TFIIB, RNA polymerase II is incorporated together 
with TFIIF. Following the addition of factors TFIIE, TFIIH and TFIIJ the assembly of 
the initiation complex is complete. The ordered assembly of general transcription 
factors provides several steps at which the initiation of transcription can be regulated 
(Zawel and Reinberg, 1993). 
 
Fig. 2.1 Model for assembly of the RNA polymerase II initiation complex (from Lodish). 
Assembly begins with the binding of TFIID to the TATA box. TFIID is composed of 
TATA box binding protein (TBP) and more than eight other TBP-associated factors 
(TAFs). TFIIA and TFIIB then add to the TFIID-promoter complex in turn, followed 
by binding of a preformed complex between TFIIF and RNA polymerase II. 
Transcription is not initiated by the bound polymerase, until TFIIE, TFIIH, and TFIIJ 
have joined the complex in that order. 
 
Binding of TFIID to the TATA box is the first step in initiation complex assembly. 
TFIID is composed of two types of subunits. The component that is responsible for 
recognition of the TATA box is called TATA box binding protein (TBP). A number of 
TBP-associated factors (TAFs) are interacting with TBP thus forming TFIID. TFIIDs 
containing different TAFs may recognize different promoters (Verrijzer et al., 1995; 
Verrijzer and Tjian, 1996). Within the initiation complex, TFIIH has a key role in 
initiating transcription, because one of its subunits has protein kinase activity and 
phosphorylates the carboxy-terminal domain (CTD) of the largest polymerase II 
subunit, which is a prerequisite for the start of transcription (Lu et al., 1992). 
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Although the initiation complex surrounding the transcription start point already 
involves the coordinate interaction of many general transcription factors in 
conjunction with the multi-subunit RNA polymerase II enzyme, it is still not sufficient 
for starting transcription of a gene (Kornberg 1996). For efficient transcription two 
additional classes of transcription factors have to act on a gene. Ubiquitous upstream 
factors are DNA-binding proteins that recognize the specific short consensus elements 
located upstream of the transcription start point. Usually the DNA binding elements 
are located within ~100 bp upstream of the transcription start point, occasionally they 
are somewhat more distant. Upstream factors act on any promoter containing their 
binding sites by increasing the efficiency of transcription.  
 
Table 2.1: Prototypic upstream and inducible transcription factors (from Lewin 2000) 
A. Upstream transcription factors 
Module Consensus Factor Size (daltons) Distribution 
CAAT box GGCCAATCT CBF/NF-Y 60,000 General 
GC box GGGCGG Sp1 105,000 General 
Octamer ATTTGCAT Oct-1 76,000 General 
Octamer ATTTGCAT Oct-2 52,000 Lymphoid 
κB GGGACTTTCC NFκB 44,000 Lymphoid 
κB GGGACTTTCC H2-TF1 ? General 
ATF GTGACGT ATF ? General 
B. Inducible transcription factors 
Regulatory Agent Module Consensus Factor Size (Daltons)
Heat shock HSE CNNGAANNTCCNNG HSTF 93,000 
Androgens ARE TGGTACAAATGTTCT AR 94,000 
Phorbol ester TRE TGACTCA AP1 39,000 
Serum SRE CCATATTAGG SRF 52,000 
Module abbreviations in the table are: HSE: heat shock response element; 
ARE: androgen response element; SRE: serum response element; TRE: phorbol 
12-O-tetradecanoate-13 acetate-response element. 
 
The second class of transcription factors that is required for efficient transcription 
either in conjunction with the initiation complex alone or together with a number of 
upstream factors are the inducible factors (Lewin, 2000). They have a regulatory role 
and are synthesized or activated at specific times or in specific tissues. Therefore, they 
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are responsible for the control of transcription patterns in space and time. The 
DNA-binding elements of inducible factors that are regulated in response to certain 
stimuli are called response elements, such as the heat shock response element (HSE), 
the steroid hormone response element (SHR), or the serum response element (SRE). 
Binding of factors to their DNA elements is followed by protein-protein interactions 
with other components of the general transcription apparatus. Any one of several 
different elements can independently or synergistically activate gene transcription. In 
Table 2.1 a few prototypic upstream and inducible transcription factors are listed. 
Some genes may be further stimulated by enhancers, which can act at a distance, 
and independent of orientation and position - upstream or downstream of the 
transcription start site. Enhancers consist of a number of DNA-binding elements for 
upstream and/or inducible factors that are arranged in a compact manner. Enhancers 
probably function by assembling a protein complex that interacts with promoter 
bound transcription factors, which requires that the intervening DNA is ‘looped out’.  
2.1.2 Chromatin structure and the regulation of transcription 
The human genome has to be compacted into a tiny nucleus using structures that can 
reversibly fold and unfold within a chromosome. Due to its staining properties this 
compacted DNA is called chromatin. The fundamental units of chromatin are the 
nucleosomes consisting of DNA and basic histone proteins. Using nucleases DNA in 
chromatin is degraded to a series of discrete fragments differing by multiples of 
180-200 bp in size. DNA of this repeat unit length is wrapped around a histone 
octamer containing two copies each of the core histones H2A, H2B, H3, and H4. 146 
bp of DNA are tightly wrapped around a histone octamer forming the nucleosome 
core particle. Some 40-50 bp of linker DNA are needed to connect one core particle to 
the next (Wolffe, 1999). A single 'linker'-histone H1 molecule is associated with each 
nucleosome core particle forming the chromatosome that contains some 160-170 bp 
of DNA and significantly stabilizes the DNA within the core particle. Histone H2A 
forms a heterodimer with H2B, and H3 forms a heterodimer with H4. Two H3/H4 
heterodimers form the tetramer core of a nucleosome that is flanked by two H2A/H2B 
heterodimers on opposing sides. At last nucleosomes are packed into regular arrays 
forming a 30 nm fiber. Some chromosomal regions have properties distinct from the 
rest of the chromosome. This heterochromatin was found to be highly condensed and 
to replicate late in S-phase. The most common observed consequence of 
heterochromatin formation is the repression of transcription (Hennig, 1999).  
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How do gene regulatory proteins and the general transcription factors gain access 
to DNA that is packaged into chromatin? Generally, nucleosomes do not present a 
serious barrier for either gene regulatory proteins or RNA polymerases. Enhancers can 
still function, positioned nucleosomes that block a promoter can be rearranged, and, 
once transcription has begun, polymerase II can transcribe through nucleosomes 
without dislodging them. The rearrangement could either be due to a separate activity 
of the gene activator proteins or could be an indirect consequence of the activator 
contacting the general transcription factors to facilitate their assembly on DNA 
(Croston and Kadonaga, 1993). 
For gene expression, the chromatin in the vicinity of a gene must be decondensed 
before and during transcription. Sometimes a locus control region (LCR) that lies far 
upstream from a gene cluster is required for an extensive change in chromatin 
structure and for enabling expression of all genes in that domain. DNase I 
hypersensitive site experiments have confirmed the poor chromatin structure in such a 
region (Cockerill, 2000). Although several proteins that specifically bind to the LCR 
have been identified, the mechanism that alters the chromatin structure is still 
unknown. Some forms of higher-order DNA packaging render the DNA inaccessible 
both to gene regulatory proteins and to the general transcription factors. Higher-order 
DNA packaging thus plays a crucial part in the control of gene expression in 
eukaryotes, serving to silence large sections of the genome, in some cases reversibly, 
in other cases not. These inactive forms of chromatin, including the highly condensed 
heterochromatin (Croston and Kadonaga, 1993), are assumed to contain special 
proteins that make the DNA unusually inaccessible. 
There is increasing evidence that modification of histones is associated with 
structural changes that occur in chromatin during replication and transcription. 
Acetylation and methylation occur on the free amino group of lysine, which removes 
its positive charge. Methylation occurs on arginine and histidine (Razin and Cedar, 
1993). Phosphorylation occurs on the hydroxyl group of serine and also histidine, 
which introduces a negative charge. Acetylation is associated with changes in 
chromatin similar to those found during gene activation (Sternglanz, 1996) and which 
render the chromatin more sensitive to deoxyribonuclease. A cycle of phosphorylation 
occurs with H1, but its timing is different from the modification cycle of the other 
histones (Wolffe, 1999). All of these modifications affect internal residues and are 
transient. They change the charge of the protein molecule and have been viewed as 
potentially able to change the functional properties of the histones. Recent data 
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indicate an indirect regulatory pathway in which ubiquitination of H2B (Lys 123) is a 
prerequisite for the methylation of H3 (Lys 4) and leads to transcriptional silencing 
(Sun and Allis, 2002). 
Methylation of C residues in CpG dinucleotides also occurs in special regions 
called CpG islands, which show an accumulation of CpG doublets and often surround 
the promoters of constitutively expressed genes, although they are also found in the 
promoters of regulated genes (Antequera and Bird, 1993). An island included in a 
promoter must be unmethylated to be able to initiate transcription. A specific protein 
binds to the methylated CpG doublets and prevents initiation of transcription.  
In conclusion, the genes are regulated in two steps. In the first step the chromatin 
of the target gene locus is decondensed, which is presumed to allow some of the gene 
regulatory proteins to access the DNA. In the second step the remaining gene 
regulatory proteins assemble on the DNA and direct the expression of individual 
genes.  
2.2 Steroid hormones and their receptors 
The gonads and adrenal gland produce five major groups of steroid hormones (SHs): 
estrogens, progestins, androgens, glucocorticoids, and mineralocorticoids. Steroid 
hormones can pass the cell membrane by simple diffusion due to their lipophilic 
nature. Within the target cells, SHs bind to high affinity steroid hormone receptors 
(SHRs). All unliganded SHRs are associated with a large multiprotein complex of 
chaperones, including heat shock protein 90 (Hsp90), which maintains the receptor in 
an inactive state but keeps it well prepared for hormone binding (Pratt and Toft, 1997). 
Most likely these chaperones play an active role in keeping the SHRs functional. 
Hormone binding activates the hormone receptor complex in order to induce 
expression of hormone responsive genes. Therefore, SHRs are ligand induced 
transcription factors. 
2.2.1 Structure and distribution of SHRs  
All steroid hormone receptors are modular proteins composed of distinct regions, 
which correspond to functional and structural units called domains. The most 
important domains are a central DNA-binding domain (DBD), which targets the 
receptor to the hormone response elements, and a ligand binding domain (LBD), 
required for switching the receptors’ function (Beato, 1989). 
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Comparison of the amino acid sequences of various hormone receptors reveals a 
remarkable conservation. The DBD maps near the center of the primary sequence, and 
comprises ~80 amino acids containing the C2-C2- zinc-finger motif. Only very few 
amino acids within the first SHR zinc finger are responsible for specific recognition 
of the cognate HRE (Beato and Klug, 2000). 
The ligand binding domain lies near the carboxy-terminal end of the receptor. The 
lipophilic steroid hormones and synthetic compounds with agonistic or antagonistic 
effects can bind to this domain and induce a transformation of the heterocomplexes of 
chaperones and SHR. Hormone induced transformatioin of the SHR heterocomplexes 
is associated with an increase in affinity for DNA, and a decrease in the size of the 
complex. The ligand binding domain is required for switching the receptors’ functions. 
When this domain is deleted in the glucocorticoid receptor (GR), the remaining DBD 
is in a constitutively active state, and no longer requires steroids for activity 
(Cadepond et al., 1991). Contrary to the GR, the ER is unable to activate transcription, 
when the LBD is deleted, although it continues to bind to an ERE (Gandini et al., 
1997). 
Ligand binding confers transcriptional competence onto SHRs that is exerted in 
most receptors by two independent transactivation functions, a constitutively active 
one located close to the DBD, referred to as activation function 1 (AF-1) and a 
ligand-inducible activation function in the LBD, called AF-2. The two AFs act 
synergistically and connect the receptor to the transcription apparatus through direct 
interactions with basal transcription factors, sequence-specific transcription factors 
and/or transcriptional co-activators (Beato and Klug, 2000). 
Most members of the SHR family bind as homodimers to the palindromic 
hormone response elements (HREs) within the promoters of target genes, in contrast 
to other members of the nuclear receptor superfamily, which bind as heterodimers to 
their cognate recognition sequences.  
The intracellular distribution of steroid receptors is the result of nuclear 
cytoplasmic export and ATP-dependent cytoplasmic-nuclear shuttling (Guiochon et al., 
1991). At equilibrium the majority of ER, AR and PR is in the nucleus due to the 
presence of so-called nuclear localization signals (NLSs) that are believed to be 
required for nuclear pore recognition. The number and location of NLSs varies among 
SHRs. 
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2.2.2 Interaction between SHRs and other factors 
To regulate transcription, the activated SHRs must interact with other factors 
including general transcription factors (GTFs), co-activators, co-repressors, sequence 
specific factors or chromatin factors (see Figure 2.2). 
The interaction between SHRs and GTFs can be achieved either by a direct 
contact (Beato and Sanchez-Pacheco, 1996) or by means of co-activators, also called 
transcription intermediary factors (TIFs), mediators or bridging factors. Co-activators 
are supposed to bridge between DNA-bound sequence-specific transcription factors 
and GTFs. Today, many of these co-activators have been characterized. One of them 
is the steroid receptor co-activator-1 (SRC-1) (Onate et al., 1995). SRC-1 interacts 
with AF-2 of PR, GR and ERα in a ligand dependent fashion and enhances their 
hormone dependent transcriptional activities without altering the basal activity of a 
target promoter. Another important and general co-activator shown to interact with 
SHRs and SRC-1 is the CREB (for cAMP responsive element binding protein) 
binding protein (CBP), and the related protein p300 (Kamei et al., 1996). Some other 
co-activators have also been identified recently, which can interact with 
sequence-specific transcription factors or with general transcription factors and are 
necessary for the transactivation process. 
Fig 2.2 Overview over 
nuclear partners of steroid 
hormone receptors required 
for activation or repression 
of transcription (from Beato 
and Klug, 2000). 
For each class (general 
transcription factors, sequence 
specific transcription factors, 
co-activators, co-repressors and 
chromatin factors) typical 
examples are shown. 
 
 
For some members of the nuclear receptor family, such as retinoid acid receptors 
(RARs), it is well known that they repress basal transcription in the unliganded state. 
This silencing effect is mediated by co-repressors like nuclear receptor co-repressor 
(N-CoR) and silencing mediator for retinoid and thyroid hormone receptors (Chen 
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and Evans, 1995; Hörlein et al., 1995). Transactivation by SHRs not only appears to 
be a simple net activation but the sum of relief from repression by co-repressors and 
activation by co-activators. The switch from the repressed to the activated state is 
promoted by the hormone ligand through an allosteric change in the SHR structure. 
In addition to their HRE-mediated effects, SHRs control the activity of natural 
promoters also through positive and negative interactions with other sequence specific 
transcription factors (Beato et al., 1995). It is known that the interaction between GR 
and the heterodimeric transcription factor activator protein-1 (AP-1) can repress the 
activity of both partners. Similar repressive interactions have been described between 
GR and the p65 subunit of the transcription factor NF-κB and the transcription factor 
GATA-1. Because most immunomodulatory genes and genes involved in 
inflammation are positively regulated by the transcription factors AP-1 and NF-κB, it 
is well conceivable that the immunosuppressive and anti-inflammatory activities of 
glucocorticoids are mediated through inhibition of AP-1 and NF-κB mediated 
transactivation by GR. 
The interaction of SHRs with DNA and other factors takes place in the nucleus 
with its DNA compacted into chromatin. Genetic analyses have demonstrated a wide 
spread involvement of chromatin structure in gene regulation in general. Some 
nucleosome remodeling factors are ATP-dependent chromatin remodeling machines 
required for the transactivation of SHRs. In an in vitro system derived from 
Drosophila embryos, receptor binding to minichromosomes recruits ISWI and NURF 
38 and triggers a chromatin remodeling event that facilitates access of NF1. NF1 
plays only a structural role acting as a wedge to stabilize the open conformation of 
chromatin, thus facilitating full occupancy of the HREs and full transactivation (Di 
Croce et al., 1999; Eisfeld et al., 1997). 
All observations lead to the current two step model for transcriptional activation 
by SHRs: (i) the hormone mediated recruitment of co-activators and other 
transcription factors with chromatin remodeling results in the local destabilization of 
repressive histone-DNA interactions, (ii) direct or most likely co-activator-mediated 
interactions with the basal transcription machinery initiate transcription (Beato and 
Klug, 2000). 
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2.2.3 Androgens and androgen receptor  
Androgens, most notably testosterone and dihydrotestosterone, have numerous 
clinically improtant actions in the developing embryo as well as in the pubertal and 
adult male. Androgens are important for the development and maintenance of 
characteristic male properties and specific reproductive organs and tissues. The action 
of androgens in target cells depends on the concentration in the serum and within the 
cells, the metabolic conversion of testosterone to dihydrotestosterone within the cells, 
the interactions with the receptor protein, and the action of the androgen receptor on 
the genomic level and on other signal transduction pathways. 
In humans, the major androgen is testosterone, most of which is synthesized by 
the Leydig cells of the testis (Ewing and Zirkin, 1983). The adrenal cortex also 
contributes to the production of androgens. In brief, the steroidogenic cascade starts 
with the cleavage of the side chain of cholesterol. The biologically active androgens 
are generated by a stepwise degradation of the cleavage product pregnenolone. The 
final step in the biosynthetic pathway of testosterone is the reduction of the 17-keto 
group by 17β-hydroxysteroid dehydrogenase (17β-HSD) (Labrie et al., 1997). In 
target cells, the prohormone testosterone is converted to the active androgen 
5α-dihydrotestosterone (DHT) by the enzyme 5α-reductase, which is localized at the 
surface of the nuclear membrane. 
The major action of androgens is through direct activation of gene tanscription via 
high affinity interaction with the androgen receptor. The androgen receptor is a 
member of the steroid hormone receptor family. It is localized to the long arm of the 
X chromosome at Xq11-q12 (Brown et al., 1989). The AR gene is a single copy gene 
that spans 75-90 kilobases of genomic DNA and comprises 8 exons (Lubahn et al., 
1989). In man, androgen receptor is detectable in testis, prostate, liver, cardiac muscle, 
sweat glands, hair follicles, pineal gland, vascular cells and various cell types in the 
temporal cortex. The prostate cancer cell line LNCaP and the breast cancer cell lines 
T47D and MCF-7 are also androgen receptor positive. 
The predominant form of the AR is a 100-114 kDa protein of 918 amino acids. 
The full length AR is a single polypeptide comprised of discrete functional domains: 
an amino-terminal domain; a DNA-binding domain (DBD); a hinge region; and a 
ligand-binding domain (LBD). (i) The amino-terminal domain is the most variable in 
size and least homologous in sequence to other members of the steroid hormone 
receptor family. Within this domain resides a transcription activation region called 
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activation function 1 (AF1). This region is important in transcriptional regulation via 
protein-protein interactions with other transcription factors (McEwan and Gustafsson, 
1997). (ii) There are four cysteine residues invariably present in the DNA-binding 
domains of all steroid receptors, which bind a zinc ion with each of two loop 
structures known as zinc fingers. The DBD determines the specificity of receptor 
binding to DNA, with each of the zinc fingers serving distinct functions. The first zinc 
finger is responsible for recognition of the target DNA sequence, the second zinc 
finger stabilizes the DNA-receptor interaction by contacting the DNA phosphate 
backbone (Berg, 1989). (iii) The hinge region, located between DBD and LBD, is a 
region of low sequence homology. It provides an interface for interactions with other 
proteins such as c-Jun (Bubulya et al., 1996). In addition, the hinge contains one of 
the AR phosphorylation sites required for optimal transcriptional activity (Zhou et al., 
1995). (iv) The ligand-binding domain encompasses approximately the 
carboxy-terminal one third of the protein. A principal function of the LBD is the 
specific, high-affinity binding of androgens. The ligand binding domain is folded into 
a three-layered antiparallel α-helical sandwich that creates a wedge-shaped molecular 
scaffold forming the ligand binding cavity. This cavity is completely partitioned from 
the external environment and closed by helices 11 and 12 of the LBD, operating as a 
‘lid’ after androgen has entered the binding pocket (Wurtz et al., 1996). It was 
suggested that ligand binding alters the structure of the LBD to a more compact one, 
less sensitive to the actions of proteases (Renaud et al., 1995). 
 
Fig. 2.3 Model of androgen dependent 
gene activation by the androgen receptor 
(AR).  
In the absence of hormone, AR is bound in 
a heterocomplex with Hsp90 in the 
cytoplasm via its ligand-binding domain. 
Androgen diffuses through the plasma 
membrane and binds to the AR 
ligand-binding domain, causing a 
conformational change that releases the 
receptor from Hsp90. The dimerized 
receptor is then translocated into the 
nucleus where it binds to response 
elements via its DNA-binding domain, 
allowing the activation of target genes. 
 
 
In its unliganded state, the androgen receptor forms large heterocomplexes with 
chaperon proteins, including Heat Shock Protein 90 (HSP90). AR stays complexed 
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with HSP90 until androgen binds the ligand-binding pocket. The interaction with 
HSP90 retains the AR in an inactive state and is important for maintenance of a 
conformation optimal for high affinity ligand binding (Smith and Toft, 1993). It is 
known that androgen binding induces a conformational change, as a result of removal 
of proteins such as HSP90, unmasking certain functional domains. These changes 
facilitate receptor dimerization, nuclear transport, interaction with target DNA, and 
activation of target gene transcription (Figure 2.3). Whereas the LBD mediates 
activation in the presence of hormone, it seems to repress AR function in the absence 
of androgens. This is suggested by experiments using a mutant AR with its LBD 
deleted that is constitutively active in the absence of hormone (Jenster et al., 1991). 
Phosphorylation by protein kinases A and C is a common post-translational 
modification in steroid hormone receptors. AR is phosphorylated at serine and 
threonine residues particularly in the amino-terminal domain and hinge region. AR 
phosphorylation is increased by androgen binding and appears to enhance the 
transcriptional activity of the receptor, perhaps by altering the interaction of 
ligand-activated AR with other proteins in the transcription complex (Ikonen et al., 
1994). 
AR is located in the cytoplasmic compartment prior to the binding of androgen. 
Nuclear uptake of the AR is an androgen dependent process mediated by a nuclear 
localization signal located in the C-terminal segment of the second zinc finger and the 
hinge region (Jenster et al., 1993). AR dimerization is also an androgen dependent 
process. The interaction between the amino terminus of one AR molecule and the 
LBD of another results in an anti-parallel homodimer (Langley, et al. 1995).  
Like other steroid hormone receptors, AR specifically binds to DNA sequences 
called androgen responsive elements (AREs). AREs are also recognized by GR and 
PR. Therefore the induction of an ARE containing gene depends on the receptor status 
of the cell. In addition, some studies suggest that the AR may heterodimerize with GR 
so that they can influence each other’s transcriptional activity (Chen et al., 1997). 
AREs have been identified in the promoter regions of a number of androgen regulated 
genes, including prostate-specific antigen (PSA) and kallikrein-2 (KLK-2) (Riegman 
et al., 1991), sex-limited protein (Adler et al., 1991), and probasin (Rennie et al., 
1993).  
In order to regulate transcription, AR has to interact with many proteins as was 
similarly shown for other SHRs. AR directly interacts with the basal transcription 
factors TFIIF and TBP via AF1, and this interaction appears to stimulate recruitment 
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of the transcriptional machinery to the promoter region of the target gene (McEwan 
and Gustafsson, 1997). The c-Jun component of AP-1 directly interacts with AR, 
probably through the leucine zipper region of c-Jun and the DBD of AR, thereby 
repressing AR transactivation (Sato et al., 1997). Similarly, interaction between the 
amino terminal region of AR and RelA, a member of the NF-κB family of 
transcription factors, represses AR mediated transactivation (Palvimo et al., 1996). 
Interestingly, there is evidence for ligand independent activation of AR 
transcriptional activity by peptide growth factors, such as insulin-like growth factor I 
(IGF-I) and epidermal growth factor (EGF) (Culig et al., 1995). In addition, the 
protein kinase A activator, forskolin, can induce AR in the absence of androgens, 
which likely involves receptor phosphorylation. This activation requires the DBD of 
the receptor and may be important in androgen-independent growth of prostatic 
tumors (Nazareth and Weigel, 1996). 
2.2.4 Non-genomic effects of androgens 
Until recently it was believed that transcription activation by AR is mainly mediated 
by genomic actions, i.e. by binding of AR to AREs in the promoter of target genes. 
Meanwhile, a number of rapid non-genomic effects of steroids, often involving 
ion fluxes, have been reported, like for progesterone (Baldi et al., 1995), estrogens 
(Aronica et al., 1994), corticosterone (Ibarrola et al., 1991), and aldosterone (Wehling 
et al., 1994). Androgens have also been shown to induce rapid calcium fluxes in a 
variety of classical androgen-dependent cell types. In the human prostate cancer cell 
line LNCaP for example intracellular calcium concentrations are increased within two 
minutes after addition of 5α-dihydrotestosterone or testosterone (Steinsapir et al., 
1991). In most of these studies it could be shown that this change in intracellular 
calcium concentration is caused by a transmembrane influx of extracellular calcium 
through the plasma membrane, but the structure of the receptive unit and the 
biological significance of these membrane effects are not known yet.  
Another example, which cannot be explained by the classical androgen response 
pathway, is that testosterone can modify the susceptibility of T-cells to infectious 
diseases. Recently, effects of testosterone and testosterone covalently coupled to 
albumin on the calcium flux through the plasma membrane of T-cells were reported 
(Benten et al., 1997). Since T-cells do not possess classical androgen receptors, this 
biological response indicates that plasma membrane receptors are involved in this 
non-genomic androgen effect. 
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The fact that spermatogenesis depends on high levels of testosterone also can’t be 
easily explained on the basis of classical androgen receptor action, because the 
concentration of testosterone required for the maintenance of spermatogenesis is 
much higher than required for saturating the androgen receptor. Therefore an 
alternative sensing system, different from the androgen receptor, might be active in 
spermatogenesis. Some data support the view that alternative low-affinity interactions 
of steroids with yet undefined receptive structures in the plasma membrane may be 
essential for maintenance of spermatogenesis and the coordination of this process 
with steroidogenesis (Gorczynska and Handelsman, 1995). 
2.3 Secretoglobins 
The secretoglobins form a family of small secretory proteins with unclear 
physiological functions. After the first member of this family, uteroglobin, was 
identified from rabbit uterus secretions some 30 years ago (Beier, 1968; Krishnan and 
Daniel, 1967), more than 20 members were found in mammals within the last few 
years (Ni et al., 2000).  
2.3.1 The secretoglobin family of proteins 
The secretoglobin family can be grouped into three subfamilies and six groups, as 
shown in Figure 2.4. All genes are composed of three exons with intron positions 
strongly conserved. The encoded proteins are very similar in length and all except two 
contain two conserved cysteines, one close to the amino-terminus and the other close 
to the carboxy-terminus, and one conserved central lysine (Ni et al., 2000).  
Subfamily 1, group A contains the orthologous uteroglobins from different species. 
Most members of this family have been described to form antiparallel homodimers 
via two intermolecular disulfide bonds between the two conserved cysteines. From 
X-ray crystallographical and NMR analyses it is known that a uteroglobin monomer 
consists of a bundle of four alpha-helices (Mornon et al., 1980 and Umland et al., 
1994). Between the two antiparallel molecules of a homodimer a pocket is formed in 
which a number of small hydrophobic ligands like progesterone can be bound. The 
hydrophobic pocket is accessible through a channel that is closed by the two disulfide 
bonds in the oxidized form (Mornon et al., 1980). In addition, a central lysine, which 
is conserved in all family members, is described as a calcium binding site of the 
phospholipase A2 type for human uteroglobin (Lys 42 in uteroglobin) (Barnes et al., 
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1996). The same region within helix 3 had been shown to be responsible for the 
inhibitory activity of uteroglobin on soluble phospholipase A(2) (sPLA(2)). Therefore 
it was suggested that uteroglobin may inhibit sPLA(2) activity by binding and 
sequestering Ca2+, essential for sPLA(2) activation. Because the conserved lysine can 
also form an exposed salt bridge with an aspartate side chain in its vicinity, it had to 
be postulated that this salt bridge must be dissolved before binding of calcium to Lys 
42 is enabled. Recently it was shown that recombinant wild-type uteroglobin does not 
bind Ca2+ unless it is expressed with a histidine-tag suggesting that the calcium binding 
ability of uteroglobin is only an artifact (Chowdhury et al., 2002). 
From biochemical data it can be predicted that members of subfamily 1, group B 
form heterodimers with members of subfamily 1, group C and members of 
subfamily 1, group D will likely form heterodimers with members of subfamily 2, 
group A (Ni et al., 2000 and see Figure 2.4). Therefore, the heterodimer is the 
fundamental unit of secretoglobin quaternary structure. Interestingly, all subfamily 1, 
group B-D and subfamily 2 members contain a third conserved cysteine that is 
forming a third disulfide bridge between the heteromers. A few secretoglobins show 
another quaternary structure feature. Prostatic binding protein (PBP) for example is a 
well characterized non-covalent heterodimer of two covalent heterodimers C1/C3 and 
C2/C3 (Heyns et al., 1978). In the exorbital lacrimal gland C1 and C2 are absent, and 
C3 forms a heterodimer with a hitherto unknown secretoglobin called the lacrimal 
component, and two C3/lacrimal component heterodimers form again a 
heterotetramer (Vercaeren et al., 1996). A mammaglobin/lipophilin B heterodimer that 
is heterodimerizing with itself has been found in the human mammary gland (Carter et 
al., 2002; Colpitts et al., 2001). 
Although all secretoglobin family proteins are classical secretory proteins, only a 
few members have been shown to be glycosylated. The precise N-glycosylation site 
within exon 2 is known for rat PBP C3 (Peeters et al., 1981) and cat Fel dI Chain 2 
(Morgenstern et al., 1991). Glycosylation of mammaglobin has been observed, which 
is consistent with the two predicted N-linked glycosylation sites in its primary 
sequence (Carter et al., 2002). 
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Fig. 2.4 Phylogenetic tree of the secretoglobin family. 
The branch lengths are drawn to scale. Subfamilies 1-3 are defined as the last most internal 
branches. Members of subfamily 1, group A are all known to form homodimers, whereas at 
least one member of subfamily 1, group B and D is known to form heterodimers with a 
member of subfamily 1, group C or subfamily 2, group A, respectively (angular brackets in 
second row). The first two letters of each gene symbol denote the species (e.g. Hs for Homo 
sapiens). For explanation of gene symbols see Fig. 4 in (Ni et al., 2000) and Fig. 1 in 
(Reynolds, et al 2002).  
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2.3.2 Human members of the secretoglobin family 
Nine secretoglobins are known in man, but the sequence of the human orthologue of 
rat Ryd5 (Figure 2.4) is not deposited in public databases and is the only gene that is 
located on chromosome 17 (unpublished observation). Furthermore, the two late 
additions Lu103/UGRP1 and Lu105/UGRP2/HIN-1 (Porter et al., 2002.) are only 
distantly related to all other secretoglobins, have only one conserved cysteine and are 
localized on chromosome 5. The other six human family members of the 
secretoglobin family, uteroglobin, lipophilins A, B and C (SCGB 2A1), mammaglobin, 
and lymphoglobin, are localized on chromosome 11q12.2 in a dense cluster spanning 
not more than approximately 530 kb (Ni et al., 2000; see Table 2 for a compilation of 
protein names that are in use). Of these six members, mammaglobin and SCGB 2A1 
are highly homologous to rat prostatic binding protein (PBP) subunit C3, showing 
41% and 34% identity, respectively. Mammaglobin and SCGB 2A1 differ in only 39 
out of 93 amino acid residues (58% identity) (Zhao et al., 1999). Lipophilin A and B 
have been described as homologues of the rat prostatic binding protein subunits C1 
and C2, and, similar to the rat homologues, lipophilin A/SCGB 2A1 heterodimers 
have been shown to occur in human tears (Lehrer et al., 1998).  
Table 2 Nomenclature name of human secretoglobin family members 
Official Gene Symbol Trivial Names 
SCGB 1A1 
Clara Cell 10kDa Protein 
Clara Cell Phospholipid-Binding Protein 
Clara Cell Protein (CC16) 
Clara Cell-Specific 10 kD Protein 
Polychlorinated Biphenyl Binding Protein 
Protein 1/Urinary Protein 1 
Uteroglobin 
Uteroglobin-like Antigen 
SCGB 1D1 Lipophilin A 
SCGB 1D2 Lipophilin B 
SCGB 1D3 Lymphoglobin 
SCGB 2A1 
Lacryglobin  
Lipophilin C, 
Mammaglobin B, 
SCGB 2A2 Mammaglobin Mammaglobin A 
Taken from (Klug, J., 2000). See also: 
http://www.gene.ucl.ac.uk/nomenclature/genefamily/scgb.html 
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As long as a generally accepted physiological function is not known for any 
secretoglobin, the expression pattern of each member is a decisive characteristic, and 
many proteins have been named accordingly: uteroglobin – uterus, mammaglobin – 
mammary gland, prostatein – prostate, lacryglobin – lacrimal gland. Uteroglobin 
expression is prominent in the prostate, testis, ovary, mammary gland, and salivary 
gland (Ni et al., 2000). Lipophilin A expression is found in lacrimal gland, thymus, 
and low level expression occurs in testis, kidney and ovary. Lipophilin B is found to 
be moderately expressed in heart, skeletal muscle, kidney and pancreas, whereas 
lipophilin C (SCGB 2A1) is strongly expressed in lacrymal gland, pancreas, prostate, 
testis, and ovary, but only weakly in thymus (Zhao et al., 1999). Mammaglobin is 
strongly and almost exclusively expressed in the mammary gland. One study found 
weak expression in prostate tissue (Ni et al., 2000). Mammaglobin has been used to 
evaluate primary, metastatic and occult breast cancer, and provides a new tool for 
breast cancer diagnosis and patient management (Watson et al., 1999; Fanger et al., 
2002; Zehentner et al., 2002, and references therein). Lymphoglobin is expressed only 
in spleen and peripheral blood lymphocytes and is thus the only secretoglobin that is 
specifically expressed in lymphocytes (Ni et al., 2000). 
Although each secretoglobin has a peculiar expression pattern, the expression 
patterns of all family members are overlapping and limited to a characteristic set of 
epithelial tissues separating the body interior from the exterior world. Most common 
are expression in lung, male and female genital organs like testis, prostate and uterus, 
as well as in mammary and salivary glands.  
Although the homologies between secretoglobin family genes extend into 
regulatory regions, the expression pattern of each gene is remarkably distinct. Unlike 
other secretoglobins that are regulated by steroid hormones such as uteroglobin and 
PBP, mammaglobin expression is not induced by estrogens in estrogen receptor 
positive breast cancer cell lines such as MCF7 and T47D (Watson et al., 1998). 
Therefore, it will be interesting to explore which mechanisms govern tissue specific 
expression and how these mechanisms are modified between different secretoglobin 
genes. 
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2.4 Aim of the Project 
SCGB 2A1 (lacryglobin, lipophilin C, mammaglobin B) belongs to the secretoglobin 
family of small secretory proteins (formerly called uteroglobin/CC10/CCSP proteins). 
Though all members share many similarities – gene and protein structure (one 
structure known (Umland et al., 1994), the other five predicted to be very similar 
(Callebaut et al., 2000)), dimerization behaviour and genomic localization – the 
expression pattern of each gene is remarkably distinct. Of the six known human 
proteins only uteroglobin is well investigated in terms of gene regulation (Wolf et al., 
1992). Therefore, it was intended to study the expression of one of the recently 
discovered secretoglobin genes. SCGB 2A1 seemed to be an interesting candidate 
because it is homologous to mammaglobin, that is almost exclusively expressed in the 
mammary gland independent of steroid hormones, and to subunit C3 of the rat 
prostatic binding protein that is under androgen control. Because SCGB 2A1 was 
already known to be expressed in the prostate it was first tested if SCGB 2A1 is 
controlled by androgens. For an immunohistochemical analysis of SCGB 2A1 
expression in the prostate the histidine-tagged protein had to be expressed in E. coli 
and an antiserum produced in rabbits.  
As a model system for all investigations the androgen responsive prostate cancer 
derived cell line LNCaP was used. In a systematic “top-to-bottom” approach it was 
intended to look first for DNase I hypersensitive sites within the SCGB 2A1 gene in 
the chromatin of LNCaP cells. These sites are highly indicative for regions 
functionally involved in gene regulation. In case of androgen regulation one could 
expect to find one or more androgen dependent DNase I hypersensitive sites involved 
in the opening of chromatin triggered by binding of the androgen receptor. After 
knowing the position(s) of DNase I hypersensitive site(s) the identified gene regions 
could be investigated more carefully by transfecting cognate promoter deletion- 
reporter gene constructs into LNCaP cells. By using computer analysis, DNase I 
footprinting and EMSA analyses potential transcription factor candidates should be 
identified. Finally, the functional relevance of binding of the identified transcription 
factors to their DNA elements for transcription of the SCGB 2A1 gene should be 
investigated by testing reporter gene constructs containing mutations in these DNA 
elements that were known to abrogate binding. Surprisingly, this rather descriptive 
approach led to an unexpected result concerning the mechanism of androgen 
induction of the SCGB 2A1 gene. 
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3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Chemicals and equipment 
Chemicals 
Acrylamide/Bis-acrylamide Roth, Karlsruhe 
Agarose Gibco-BRL, Neu Isenburg 
Bacto-Tryptone Gibco-BRL, Neu Isenburg 
Bacto-yeast extract Gibco-BRL, Neu Isenburg 
Boric acid Merck, Darmstadt 
Bromophenol blue sodium salt Serva, Heidelberg 
Calcium chloride Merck, Darmstadt 
Chloroform Merck, Darmstadt 
Coomassie Brilliant Blue R250 Roth, Karlsruhe 
2’-Deoxynucleoside 5’-triphosphates Gibco-BRL, Neu Isenburg 
Dihydrotestosterone (DHT) Sigma-Aldrich, Seelze 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt 
Dipotassium hydrogenphosphate Merck, Darmstadt 
Disodiumhydrogen phosphate Merck, Darmstadt 
1,4-Dithiothreitol Roth, Karlsruhe 
Ethanol Merck, Darmstadt 
Ethidiumbromide Roth, Karlsruhe 
Ethylene diaminetetraacetic acid disodium salt (EDTA) Merck, Darmstadt 
Ficoll 400 Sigma-Aldrich, Seelze 
Formamide Merck, Darmstadt 
Glacial acetic acid Merck, Darmstadt 
Glycerol Merck, Darmstadt 
Glycine Sigma-Aldrich, Seelze 
Guanidine hydrochloride Sigma-Aldrich, Seelze 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) Roth, Karlsruhe 
Igepal CA-630 (indistinguishable from NP-40) Sigma-Aldrich, Seelze 
Isopropylthio-β-D-galactoside (IPTG) Applichem, Darmstadt 
Leupeptin Sigma-Aldrich, Seelze 
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Magnesium chloride Merck, Darmstadt 
Manganese chloride Merck, Darmstadt 
Methanol Merck, Darmstadt 
Phenol/chloroform/isopropanol (25:24:1)  Roth, Karlsruhe 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Seelze 
Poly (dI-dC) Sigma-Aldrich, Seelze 
Polyvinylpyrrolidone Sigma-Aldrich, Seelze 
Ponceau S Sigma-Aldrich, Seelze 
Potassium chloride Merck, Darmstadt 
Rotiphorese Gel 30, 40 Roth, Karlsruhe 
Sodium acetate Roth, Karlsruhe 
Sodium azide Merck, Darmstadt 
Sodium chloride Sigma-Aldrich, Seelze 
Sodium citrate Merck, Darmstadt 
Sodium dodecyl sulfate (SDS) Merck, Darmstadt 
N,N,N´,N´-Tetramethylethylenediamine (TEMED) Roth, Karlsruhe 
Tris(hydroxymethyl)aminomethane (Tris) Roth, Karlsruhe 
Triton X-100 Sigma-Aldrich, Seelze 
Urea Merck, Darmstadt 
Xylene cyanol FF Serva, Heidelberg 
 
Cell Culture Media and Antibiotics 
Ampicillin sodium salt Ratiopharm® 
Chloramphenicol Sigma, München 
DMEM medium (11965-092) Gibco-BRL, Karlsruhe 
FCS, trypsin, glutamine Gibco-BRL, Karlsruhe 
RPMI 1640 medium (72400-021) Gibco-BRL, Karlsruhe 
Penicillin/Streptomycin (15140-114) Gibco-BRL, Karlsruhe 
Radioactive reagents 
[α-32P] dCTP (370 MBq/ml) Amersham, Braunschweig 
[γ-32P] ATP (370 MBq/ml) Amersham, Braunschweig 
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Equipment 
Agarose gel electrophoresis chambers Biorad, München 
AutoLumat 953 luminometer Berthold Technologies, Bad Wildbad 
Cell culture incubator BBD6220 Kendro, Hanau 
Clean bench HA2448GS Kendro, Hanau 
Geiger counter Mini 900 Mini Instruments, Burnham-on-Crouch 
Gel dryer model 583 Biorad, München 
GeneAmp® PCR system 9700 Applied Bioystems, Darmstadt 
Inverted microscope (DMIL) Leica, Wetzlar 
Power supply units Biorad, München 
Phosphorimager Fuji FLA3000G and screens Raytest, Straubenhardt 
Semi-dry blot apparatus (Fastblot B33) Biometra, Göttingen 
Sorvall Superspeed refrigerated centrifuge Kendro, Hanau 
Szintillation counter Packard 
Miscellaneous 
Bio-Rad Protein Assay Biorad, München 
Biodyne® B nylon membranes Pall, Dreieich 
DNA and protein size markers Roche, Mannheim 
Hybond ECL nitrocellulose membrane Amersham Biosciences, Freiburg 
Kodak BioMax X-ray film Integra Biosciences, Fernwald 
Sterile plastic ware for cell culture Greiner, Germany 
3.1.2 Cell lines 
HeLa: Established in 1951, the HeLa cell line was the first continuously cultured 
human epitheloid cell line from an adenocarcinoma of the cervix of a 31-year-old 
black female named Henrietta Lacks (Gey et al., 1952). HeLa cells are aneuploid and 
steroid hormone receptor negative. Cells were grown in DMEM medium 
supplemented with 10% FCS at 37°C with 5% CO2. Confluent cultures were split 1:4 
to 1:6 using trypsin/EDTA. 
LNCaP: LNCaP clone FGC was isolated in 1977 by J.S. Horoszewicz et al., from a 
needle aspiration biopsy of the left supraclavicular lymph node of a 50-year-old 
Caucasian male with confirmed diagnosis of metastatic prostate carcinoma (Murphy, 
1980). The cells are expressing an androgen receptor point mutant which shows a 
broader steroid binding specificity than the wild type receptor (Veldscholte et al., 1992) 
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and are responsive to 5-alpha- dihydrotestosterone. The cells do not produce uniform 
monolayer, but grow in clusters which should be broken apart by repeated pipetting 
when subcultures are prepared. They attach only lightly to the substrate, do not become 
confluent and rapidly acidify the medium. Cells were grown in RPMI 1640 medium 
supplemented with 10% FCS at 37°C with 5% CO2. Subconfluent cultures were split 
1:4 once a week using trypsin/EDTA (occasionally cells could be detached by tapping). 
For storage cells were frozen with 70% medium, 20% FBS, 10% DMSO at about 2×106 
cells/ampoule. After thawing or trypsinization cells may need 1-2 days to become 
adherent again. Due to strong cell aggregation, it is difficult to perform an exact cell 
count. The cells should be allowed to incubate undisturbed for the first 24 hours after 
subculture. 
3.1.3 Buffers and solutions 
The following standard solutions were used: 
Denhardt’s reagent: Denhardt’s reagent is ususlly made up as a 50× stock solution, 
which contains 1% (w/v) Ficoll 400, 1% (w/v) polyvinylpyrrolidone, 1% (w/v) 
bovine serum albumin in H2O, and is stored at -20°C after filtration. 
Formamide loading buffer: 95% deionized formamide, 10mM EDTA (pH 8.0), 
0.05% bromophenol blue, 0.05% xylene cyanol. The formamide is deionized by 
stirring on a magnetic stirrer with Dowex XG8 mixed bed resin for 1 hour and 
filtering it twice through Whatman No. 1 paper. Deionized formamide is stored in 
small aliquots at -70°C. 
6× Gel-loading buffer: 0.25% (w/v) bromophenol blue, 30% (v/v) glycerol in H2O. 
PBS (pH 7.4): Dissolve 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, and 0.24 g of 
KH2PO4 in 800 mL of distilled H2O. Adjust the pH to 7.4 with HCl. Add H2O to 1 
liter. Sterilize by autoclaving and store at room temperature. The final 
concentrations of the ingredients are 137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.4 mM KH2PO4. 
RNA Gel-loading Buffer: 95% deionized formamide, 0.025% (w/v) bromophenol 
blue, 0.025% (w/v) xylene cyanol FF, 5 mM EDTA (pH 8.0), 0.025% (w/v) SDS. 
6× SDS gel-loading buffer: 280 mM Tris-Cl (pH 6.8), 12 % (v/v) SDS, 60 % (v/v) 
glycerol, 0.25% bromophenol blue. 
20× SSC: Dissolve 175.3 g of NaCl and 88.2 g of sodium citrate in 800 ml of H2O. 
Adjust the pH to 7.0 with a few drops of concentrated HCl. Adjust the volume to 1 
liter with H2O. Dispense into aliquots. Sterilize by autoclaving. The final 
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concentrations of the ingredients are 3.0 M NaCl and 0.3 M sodium citrate. 
TAE (pH 8.0) electrophoresis buffer: Prepare a 50× stock solution in 1 liter of H2O: 
242 g of Tris base, 57.1 mL of glacial acetic acid, 100 mL of 0.5 M EDTA (pH 
8.0). The 1× working solution is 40 mM Tris-acetate/1 mM EDTA. 
TBE: Prepare a 5× stock solution in 1 liter of H2O: 54 g of Tris base, 27.5 g of boric 
acid, 20 ml of 0.5 M EDTA (pH 8.0). The 0.5× working solution is 90mM 
Tris-borate/2 mM EDTA. The pH of the concentrated stock buffer should be 
approx. 8.3. Dilute the concentrated stock buffer just before use and make the gel 
solution and the electrophoresis buffer from the same concentrated stock solution. 
Passing the 5× buffer stocks through a 0.22-µm filter can prevent or delay 
formation of precipitates. 
TE8: 10mM Tris (pH 8.0), 1mM EDTA (pH 8.0). Sterilize by autoclaving and store 
the buffer at room temperature. 
10× Tris-glycine SDS electrophoresis buffer: Prepare a 10× stock of electrophoresis 
buffer by dissolving 30.2 g of Tris base and 188 g of glycine in 800 mL of 
deionized H2O, then add 100 mL of a 10%(w/v) stock solution of electrophoresis 
grade SDS and adjust the volume to 1000 mL with H2O. The 1× working solution 
is 250 mM glycine, 25 mM Tris-Cl, 0.1% SDS.  
3.1.4 Enzymes and Antibodies 
All restriction endonucleases, T4 DNA ligase and T4 DNA polymerase were supplied 
by Gibco Invitrogen, Karlsruhe. AmpliTaq DNA polymerase (Stoffel fragment) was 
supplied by Applied Bioystems, Darmstadt. PfuTurbo high fidelity DNA polymerase 
was supplied by Stratagene. Klenow fragment and DNase I was supplied by Roche, 
Mannheim.  
Goat NF-Y antibody (catalogue number sc-7711) was obtained from Santa Cruz 
Biotechnology, Heidelberg. Rabbit polyclonal anti Sp1 and anti Sp3 antibodies 
(Hagen et al., 1994) were kindly provided by Guntram Suske, Universität Marburg. 
The Sp1 antibody is directed against the full length Sp1 protein, whereas the Sp3 
antibody is directed against B-domain and C-terminus but not the A-domain 
(N-terminus). For the generation of a rabbit polyclonal anti SCGB 2A1 antibody, see 
chapter 3.2.15. The donkey anti rabbit IgG, HRP-linked whole antibody from 
Amersham Biosciences, Freiburg, was used in combination with the ECL™ Plus 
detection system from Amersham Biosciences, Freiburg. 
 
 27
Materials and Methods 
3.1.5 Oligonucleotides  
The oligonucleotides used for PCR, cloning, subcloning and mutagenesis are listed 
below. Oligonucleotides were either synthesized on an Applied Biosystems 380A 
oligonucleotide synthesizer using deoxynucleoside phoshoramidite chemistry 
(Beaucage and Caruthers, 1981), or were supplied by MWG-Biotech, Ebersberg. 
 
Oligonucleotide Sequence 
SCGB 2A1 UTR+50/KpnI-3′ 5′-GGCGGTACCTGTCTGTGTTCAGTCGTGC-3′ 
SCGB 2A1 -53/XhoI-5′ 5′-ATTCTCGAGAGGGACTAAGGTGCCTCCCT-3′
SCGB 2A1 -136/XhoI-5′ 5′-TACCTCGAGAGCACAGGCTGGCTGTGTTC-3′
SCGB 2A1 -382/XhoI-5′ 5′-GAACTCGAGGAAGAGGAGGAGACCAAGAG-3′
SCGB 2A1 -575/XhoI-5′ 5′-AACCTCGAGAACAACAGCAACAAAACCCC-3′
SCGB 2A1 -963/XhoI-5′ 5′-GTACTCGAGAATTAACTTAGTGTTGTAAT-3′
SCGB 2A1 –1314/XhoI-5′ 5′-TGGCTCGAGGGGCAAGACTCTGTCTCGAA-3′
SCGB 2A1 -1476/XhoI-5′ 5′-CCACTCGAGAGAAACCCCGTCTCTACTAA-3′
SCGB 2A1 –53/TK/XhoI-3′ 5′-TAGCTCGAGCCAGGAATGAGGCAATGTG-3′ 
SCGB 2A1 –28/TK/XhoI-3′ 5′-CTACTCGAGCCCCAGGGAGGCACCTTAG-3′ 
SCGB 2A1 HS Xba I-5′ 5′-CCTGAGCCAACTTTGTTTTTCT-3′ 
SCGB 2A1 HS Xba I-3′ 5′-GGTATGAGAAAGTGGTCATTGC-3′ 
SCGB 2A1 NF-Y mut 5′-AGTGTACACTCATGGGAACACAGCC-3′ 
SCGB 2A1 NF-1 mut 5′-GCAGTAATATTTTTATCCCTGA-3′ 
SCGB 2A1 dim-IR-GC box 
distal mut 5′-TCCCCAGGGAGGCACCTTAGTCACTCAAAGGAAT-3′ 
SCGB 2A1 dim-IR-GC box 
proximal mut 5′-TCCCCATTGAGTCACCTTAGTCCCTCCCAGGAAT-3′ 
SCGB 2A1 dim-IR-GC box 
mut 5′-TCCCCATTGAGTCACCTTAGTCACTCAAAGGAAT-3′ 
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3.1.6 Plasmids 
1. pGAW luciferase reporter vector: pGAW is a promoter probe vector in which a test 
promoter drives expression of the reporter gene luciferase. It was constructed 
by Braun & Suske (Braun and Suske, 1998), and is based on the commercial 
vector pGL3 (Promega, Mannheim). In pGAW the single BamHI site of pGL3 
is destroyed by blunt end religation and the polylinker of pGL3 is replaced by a 
polylinker containing the recognition sequences for the restriction enzymes Pst 
I, EcoR I, EcoR V, Hind III, BamH I, Bgl II, Xho I, Sma I, Nhe I, Sac I and Kpn 
I. It was used for the SCGB 2A1 promoter deletion constructs (see chapter 
3.2.7 and Fig. 3.2-A). 
2. TK-short construct: this construct was prepared by inserting a short tk promoter 
into the pGL 3 vector. The short tk promoter contains a TATA box and one Sp1 
binding site as shown in Fig. 3.1 See also Fig. 3.2-B. 
 
Fig. 3.1 Schematic view of the TK-short promoter.  
The proximal (-90 to +51 bp) regulatory region is linked to the 
Luciferase reporter gene. This portion of tk-short contains a 
TATA box and an Sp1 binding site. 
3. pRSV-Luc: In this construct the strong Rous Sarcoma Virus promoter drives the 
expression of the luciferase gene (de Wet et al.,1987). The plasmid was used 
as a positive control for the luciferase assay and for comparing transfection 
efficiencies. 
4. pRSV-lacZ (pCH110): Plasmid pCH110 (Amersham Biosciences, Freiburg) 
contains the E. coli β-galactosidase gene under control of the simian virus 40 
promoter. It was used to normalize transfection efficiencies for plate to plate 
variations. 
5. pRSV-GR: This construct contains the Rous Sarcoma Virus promoter in front of a 
6.3 kb cDNA encoding the rat glucocorticoid receptor (Miesfeld et al., 1986). 
The plasmid was used to ectopically express glucocorticoid receptor (GR) in 
LNCaP cells.  
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6. pRSET B vector: this vector is a pUC-derived expression vector designed for 
high-level protein expression and purification in E. coli. The fusion protein 
contains a polyhistidine tag that functions as a metal binding domain for 
simple purification of recombinant proteins by immobilized metal affinity 
chromatography. See Fig. 3.2-C. 
 
 
. 
 
Fig 3.2-A Schematic diagram of SCGB 
2A1 promoter deletion constructs. 
 
Fig 3.2-B Schematic diagram of SCGB 2A1 
promoter fragment transferred to TK 
constructs. 
 
 
 
Fig 3.2-C Schematic diagram of pRSETB/ 
SCGB 2A1. The cDNA was cloned into Bam 
H I / Xho I sites. 
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3.2 Methods 
3.2.1 Cell culture and preparation of charcoal treated FCS  
HeLa cells were cultured as monolayers in DMEM with 10% FCS, 2 mM 
L-glutamine, penicillin (100U/mL) and streptomycin (100µg/mL). LNCaP cells were 
maintained as monolayers in RPMI 1640 medium, supplemented as described above. 
Cells were grown at 37°C in 5% CO2. The cells were passaged with trypsin/EDTA at 
80% confluency. LNCaP Cells were grown in RPMI 1640 medium supplemented with 
10% FCS at 37°C with 5% CO2. Subconfluent cultures were split 1:4 once a week using 
trypsin/EDTA (occasionally cells could be detached by tapping). For storage cells were 
frozen with 70% medium, 20% FBS, 10% DMSO at about 2×106 cells/ampoule. After 
thawing or trypsinization cells may need 1-2 days to become adherent again. Due to 
strong cell aggregation, it is difficult to perform an exact cell count. The cells should be 
allowed to incubate undisturbed for the first 24 hours after subculture. Before 
transfection, cells were grown 24 hours in DMEM supplemented with 10% charcoal 
treated FCS. 
To prepare charcoal stripped FCS, 25 g activated charcoal (Sigma) was coated 
with 2.5 g dextran (200,000 MW, Sigma) in 100 mL 0.01 M Tris-Cl (pH 7.4) buffer. 
The suspension was shaken at 4°C overnight. The dextran-coated charcoal was spun 
down at 14,000 G for 10 minutes at 4 °C and added to 500 ml of FCS. After shaking 
at room temperature for 2 h (or at 56°C for 30 min) the charcoal was pelleted by 
centrifugation at 14,000 G for 10 minutes at 4°C. The FCS supernatant was removed. 
Fresh charcoal (25 g) was added to the serum and shaken at room temperature for 
another 2 hours. After spinning down the charcoal at 14,000 G for 10 minutes at 4°C 
temperature the serum was filtered through 0.45 µm and stored at –20°C. Before use 
treated FCS was filtered through 0.2 µm filters. 
3.2.2 Purification of nucleic acids 
3.2.2.1 Preparation of high molecular weight DNA from cultured cells 
DNA extraction was performed essentially as described (Sambrook and Russell, 
2001). Briefly, after washing cells grown to confluency twice with PBS, 3ml of TE 
buffer per 5×107 cells were added. After 10 min incubation at room temperature, a cell 
scraper was used to harvest the cells. Per mL of cell suspension 10 mL of cell lysis 
buffer were added. After 1 hour incubation at 37°C, proteinase K (20 mg/mL) was 
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added to a final concentration of 100 µg/mL and incubation was continued at 56°C 
overnight. Finally, the solution was extracted with phenol/ chloroform/isoamylalcohol 
(25:24:1), and DNA was ethanol precipitated, dissolved in TE and stored at 4°C.  
Cell lysis buffer: 10 mM Tris-Cl, pH 8.0; 0.1 M EDTA, pH 8.0; 0.5% (w/v) SDS, 
20 µg/mL DNase-free pancreatic RNase. 
3.2.2.2 Preparation of total RNA from cultured cells 
Total RNA was extracted from LNCaP and HeLa cells using the monophasic lysis 
reagent Trizol (Invitrogen, Karlsruhe), according to the manufacturer’s instructions. 
Cells are lysed in a solution of guanidine isothiocyanate and phenol. Addition of 
chloroform generates a second (organic) phase into which DNA and proteins are 
extracted, leaving RNA in the aqueous supernatant. RNA in the aqueous phase was 
precipitated with isopropyl alcohol and washed with 75% ethanol. The RNA pellet 
was dissolved in RNase-free water and stored at -70°C. 
3.2.3 Gel electrophoresis 
3.2.3.1 DNA agarose gel electrophoresis 
2% to 0.5% agarose gels were routinely used to separate DNA fragments in a size 
range of 100 to 10, 000 bp (Sambrook and Russell, 2001). The appropriate amount of 
agarose was dissolved in 1× TAE buffer (see chapter 3.1.3) by boiling for a few 
minutes in a microwave oven. When the gel solution has cooled down to some 60°C 
ethidium bromide was added to a final concentration of 0.5 µg/mL. The clear solution 
was then poured into a gel mold using a suitable comb for generating the sample wells 
and allowed to harden for some 30-45 min. The gel was mounted in the 
electrophoresis chamber which was filled with 1× TAE running buffer until the gel 
was just submersed. DNA samples and a suitable size standard were mixed with 0.2 
volume of 6× loading buffer and applied to the wells. A voltage of 2-10V/cm was 
applied until the bromophenol blue and xylene cyanol FF dyes had migrated an 
appropriate distance through the gel. After completion of electrophoresis the gel was 
examined on a 305 nm UV transilluminator and photographed using a gel 
documentation system (Intas, Göttingen). 
3.2.3.2 SDS polyacrylamide gel electrophoresis and Coomassie Blue staining 
Discontinuous SDS polyacrylamide gel electrophoresis (Davis, 1964 and Ornstein, 
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1964) was performed in a vertical system in order to analyze SCGB 2A1 expression 
in E. coli or to detect the native protein in tear fluid. The denatured polypeptides bind 
SDS and become negatively charged. Because the amount of SDS bound is usually 
proportional to the molecular weight of the polypeptide and is independent of its 
sequence, the mobility of protein-SDS complexes in polyacrylamide gels is inverse 
proportional to the size of the protein. By using markers of known size it is therefore 
possible to estimate the molecular weight of a protein. 
SDS polyacrylamide gel electrophoresis was carried out in a discontinuous gel 
system consisting of an upper stacking gel, a lower resolving gel and an 
electrophoresis buffer with different pH and ionic strength than the gel buffers. The 
sample and the stacking gel contain Tris-Cl (pH 6.8), both buffer reservoirs contain 
Tris-glycine (pH 8.3), and the resolving gel contains Tris-Cl (pH 8.8). All components 
of the system contain 0.1% SDS (Laemmli, 1970). The fast chloride ions in the 
sample and stacking gel form the leading edge of a moving ion boundary, and the 
trailing edge is composed of slow glycine molecules. Between both edges of the 
moving boundary is a zone of lower conductivity and steeper voltage gradient, which 
sweeps the polypeptides of the sample and deposits them on the surface of the 
resolving gel. There the higher pH of 8.3 favors the ionization of glycine, so that the 
charged glycine molecules are moving fast through the stacked polypeptides and 
travel through the resolving gel immediately behind the chloride ions. Freed from the 
moving boundary the SDS-polypeptide complexes move through the resolving gel in 
a zone of uniform voltage and pH and are separated to size by sieving. 
For most purposes a 15 or 18% resolving gel was prepared. The gel solution was 
poured into the assembled gel mold between two glass plates separated by 1 mm thick 
spacers leaving some 1 cm space for the stacking gel. The gel surface was overlaid 
with n-butanol in order to prevent inhibition of polymerization by oxygen. After 
polymerization was complete (30 min) the stacking gel (always 3%) was poured on 
top of the resolving gel, and the comb was inserted.  
Samples were prepared in 1× SDS gel-loading buffer by means of a 6× 
concentrated stock solution. After having added 5% (v/v) β-mercaptoethanol or 10% 
(v/v) 1 M DTT all samples were boiled for 3 min to denature the proteins. After 
polymerization of the stacking gel (30 min) the comb was removed and the gel 
mounted in the electrophoresis chamber. Both electrode reservoirs were filled with 
SDS electrophoresis buffer, the wells were cleaned and samples loaded. 
Electrophoresis was performed at 25 mA constant power until the bromophenol blue 
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dye had reached the bottom of the gel. 
Coomassie Brilliant Blue is an aminotriarylmethane that forms strong but not 
covalent complexes with proteins. The uptake of dye is approximately proportional to 
the amount of protein. Two forms of the dye, R-250 and G-250, are available. The 
SDS gel was immersed for several hours in a filtered methanol:H2O:acetic acid 
solution (500:400:100 mL) that contained 0.25 g Coomassie Brilliant Blue R-250 per 
100 mL. Subsequently, the gel was destained in the methanol/acetic acid solution that 
had to be changed 4 to 6 times. The stained gel was photographed with a gel 
documentation system.  
Alternatively, an improved staining procedure was applied which utilizes the 
colloidal properties of Coomassie Brilliant Blue (Neuhoff et al., 1988). This method is 
based on addition of 20% v/v methanol and higher concentrations of ammonium sulfate 
to the staining solution previously described. A commercial formulation with 
Coomassie Brilliant Blue G-250 was used (Roth, Karlsruhe). The gel was incubated in 
the colloidal Coomassie staining solution that was prepared according to the 
instructions of the supplier for a few hours on a tumbling shaker. The gel was briefly 
washed in 25% (v/v) methanol and dried or photographed as described above.  
Coomassie blue staining solution: Dissolve 0.25 g of Coomassie Brilliant Blue 
R-250 in 90 mL of methanol:H2O (1:1, v/v) and 10 mL of glacial acetic acid. 
Filter the solution through a Whatman No. 1 filter to remove any particulate 
matter. Store at room temperature. 
3.2.4 Northern blotting analysis 
3.2.4.1 Electrophoresis of glyoxylated RNA through agarose gels 
Separation of RNAs according to size is the first step in northern blotting and 
hybridization. Glyoxal was used to denature the RNA, ethidium bromide to stain it, 
and agarose gel electrophoresis to separate the resulting glyoxal-RNA-ethidium 
adducts (McMaster G and Carmichael, 1977).  
10 µL RNA (up to 30 µg) were mixed with 10 µL of glyoxal reaction mixture and 
incubated for 60 min at 55°C. 2 µL of RNA gel-loading buffer (see chapter 3.1.3) 
were added to the glyoxylated RNA samples immediately before loading into the 
wells of a 1.5% agarose gel (see chapter 3.2.3.1) prepared in 1× BPTE electrophoresis 
buffer (Sambrook and Russell, 2001), Electrophoresis was carried out at 5V/cm in 
1× BPTE electrophoresis buffer that obviates the need for recirculation (Burnett, 
 34
Materials and Methods 
1997). 
10× BPTE Electrophoresis buffer: The 10× buffer was made by adding 3 g 
PIPES (free acid), 6 g Bis-Tris (free base), and 2 mL 0.5 M EDTA pH 8.0 to 
90 mL of distilled H2O, treating the solution with DEPC (final concentration 
0.1%) for 1 hour at 37°C, followed by autoclaving. The final pH of the 
10× buffer is approx. 6.5 and the final concentrations of the ingredients are 
100 mM PIPES, 300 mM Bis-Tris, 10 mM EDTA. 
Glyoxal reaction mixture: 6 mL DMSO (HPLC grade, stored in aliquots at 
–20°C), 2 mL deionized glyoxal, 1.2 mL 10× BPTE electrophoresis buffer, 
0.6 mL 80% glycerol in H2O, 0.2 mL ethidium bromide solution (10 mg/mL 
in H2O). To deionize the glyoxal an equal volume mixed bed ion-exchange 
resin (Bio-Rad AG-510-X8) was added. After stirring for 30 min the resin 
was removed by filtration. When the pH of the glyoxal was still below 5.5 
stirring with a fresh volume of resin was repeated. When the pH of the 
glyoxal was >5.5 aliquots were stored at –20°C. 
DEPC-treated H2O: 10% (v/v) DEPC in ethanol was diluted in H2O to 
0.1% (v/v) final DEPC concentration. The DEPC-containing water was 
incubated at 37°C overnight and autoclaved the next day. 
3.2.4.2 Transfer and fixation of denatured RNA to membranes  
The separated glyoxylated RNAs in the agarose gel were transferred to a positively 
charged nylon membrane by upward capillary transfer with 0.01 N NaOH/3 M NaCl 
for one hour (Thomas, 1980). During transfer the glyoxal groups are hydrolyzed due 
to the alkaline pH. The membrane was washed for 5 min in 6× SSC (see chapter 3.1.3) 
at room temperature, dried on air for a few minutes and then irradiated at 254 nm for 
105 seconds at 1.5 J/cm2 in order to fix the RNA to the membrane.  
3.2.4.3 Northern hybridization 
Northern hybridizations were carried out at high stringency in hybridization buffer 
(6× SSC, 2× Denhardt’s reagent, 0.1% SDS, and 100 µg/mL denatured salmon sperm 
DNA). Initially, the membrane was prehybridized for 2 hours at 68°C in 0.1 mL of 
prehybridization solution per cm2 of membrane in a sealed plastic bag. A 
double-stranded DNA probe was labeled with [α-32P] dCTP using the MegaprimeTM 
DNA labeling kit (Amersham Biosciences, Freiburg) to high specific activity 
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(>5×108 cpm/µg) following the instructions of the supplier. The labeled probe was 
denatured by heating for 5 minutes at 100°C, chilled on ice and added directly to the 
prehybridization solution (1×106 cpm/mL). Incubation was continued at 68°C for 
12-16 hours.  
The membrane was removed from the plastic bag and transferred into 100-200 mL 
of 1× SSC, 0.1% SDS at room temperature. After gentle agitation on a platform 
shaker for 10 min the membrane was transferred to 100-200 mL of 0.5× SSC, 0.1% 
SDS prewarmed to 68°C in a water bath. After 10 min the fluid was replaced by fresh 
solution and the washing was repeated again for a total of three washes at 68°C. The 
membrane was briefly dried on air for a few minutes. The still damp membrane was 
wrapped in plastic foil and exposed to a PhosphorImager screen (Fuji, Raytest) 
overnight or to X-ray film (BioMax, Kodak) in a cassette equipped with intensifying 
screens at –80°C for a minimum of 24 hours.  
3.2.5 Southern blotting analysis 
3.2.5.1 Electrophoresis of DNA through agarose gels 
Purified genomic DNA was digested with restriction enzymes. At the end of the 
digestion DNA fragments were ethanol precipitated and dissolved in TE (pH 8.0) 
buffer. To 15 µg DNA in 25 µL TE buffer 5 µL of 6× gel-loading buffer were added 
(see chapter 3.1.3). DNA fragments were separated by electrophoresis through a 0.7% 
agarose gel prepared in 1× TAE electrophoresis buffer (<1 V/cm). After 
electrophoresis was complete, the gel was stained with 0.1µg/mL ethidium bromide 
and photographed with a gel documentation system.  
3.2.5.2 Transfer and fixation of denatured DNA to membranes 
After fractionating the DNA by gel electrophoresis, the DNA was denatured by 
soaking the gel in several gel volumes of alkaline transfer buffer for 15 minutes at 
room temperature with constant but gentle agitation on a rotary platform. The solution 
was changed and soaking of the gel was continued for a further 20 minutes. The 
denatured DNA was then transferred to a positively charged nylon membrane by 
upward capillary transfer with alkaline transfer buffer over about 18 hours. The 
membrane was neutralized in neutralization buffer for 15 minutes at room temperature. 
Because alkaline transfer results in covalent attachment of DNA to positively charged 
nylon membranes, it is not necessary to irradiate the membrane with UV in order to 
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fix the DNA to the membrane. 
Alkaline transfer buffer: 0.4 M NaOH, 1 M NaCl. 
Neutralization buffer: 0.5 M Tris-Cl, pH 7.2 with 1 M NaCl. 
3.2.5.3 Southern hybridization 
Southern hybridizations were carried out at high stringency in phosphate-SDS 
hybridization buffer. Initially, the membrane was prehybridized for 2 hours at 68°C in 
0.1 mL of prehybridization solution per cm2 of membrane in a sealed plastic bag. A 
double-stranded DNA probe was labeled with [α-32P]dCTP using the MegaprimeTM 
DNA labeling kit (see chapter 3.2.4.3). The labeled probe was denatured by heating 
for 5 minutes at 100°C, chilled on ice and added directly to the prehybridization 
solution (1×106 cpm/mL). Incubation was continued at 68°C for 12-16 hours.  
The membrane was removed from the plastic bag and transferred into 100-200 mL 
of phosphate-SDS washing solution. After gentle agitation on a platform shaker for 10 
min the membrane was transferred to fresh washing buffer prewarmed to 68°C in a 
water bath. After 10 min the fluid was replaced by fresh solution and the washing was 
repeated again for a total of three washes at 68°C. The membrane was briefly dried on 
air for a few minutes. The still damp membrane was wrapped in plastic foil and 
exposed to a PhosphorImager screen and then to X-ray film as described in chapter 
3.2.4.3. 
Phosphate-SDS hybridization buffer: 0.5 M sodium phosphate (pH 7.2), 7% 
SDS, 1mM EDTA and 0.2 mg/mL denatured salmon sperm DNA. 0.5 M 
phosphate buffer is 134 g of Na2HPO4•7H2O, 4 mL of 85% H3PO4 
(concentrated phosphoric acid), H2O to 1 liter. 
Phosphate-SDS washing solution: 40 mM sodium phosphate, 0.1% SDS. 
3.2.6 Mapping of DNase I hypersensitive sites  
Treatment of nuclei with limited amounts of DNase I was used to reveal sites in 
chromatin that are hypersensitive to the nuclease (Stalder et al., 1980). About 4×107 
cells were harvested into ice cold PBS and washed twice with 25 mL of ice-cold PBS 
without calcium and magnesium salts. The cells were spun down by centrifugation of 
the suspension at 1,000 G for 5 min at room temperature and resuspended in 5 mL cell 
lysis buffer. The suspension was homogenized by squeezing the lysed cells five time 
out of a 10 mL pipet held hard on the bottom of a 50 mL centrifuge tube. A 10 µL 
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aliquot of the cell lysate was mixed with an equal volume of 0.4% Trypan Blue dye, 
and the solution was examined under a microscope equipped with a 20× objective. 
Lysed cells and nuclei take up the dye and appear blue, whereas unlysed cells are 
impermeable to the dye and remain translucent. The incubation was continued on ice 
until >80% of cells were lysed. The cell lysate was adjusted to 30 mL with cell lysis 
buffer and the nuclei were spun down at 1500 rpm at room temperature for 5 min. The 
nuclear pellet was resuspended in 1 mL nuclei digestion buffer. 
A series of dilutions of the standard 10× DNase I solution (20, 40 and 60 µg/mL) 
was set up in nuclei digestion buffer and stored on ice until used. For the mapping, 
250 µL aliquots of nuclei were transfered to a series of 2 mL tubes and digested with 
DNase I for 3 minutes at 22°C in a waterbath by adding 2.5 µL 100 mM CaCl2. The 
final DNase I concentration was 2, 4 and 6 µg/mL for three digests. The reaction was 
stopped by adding 250 µL proteinase K digestion buffer, and incubation was 
continued for 16 hours at 50°C with rotation. After three gentle and careful 
extractions of the digestion mixtures with phenol/chloroform the DNA was 
precipitated with the addition of 3 volumes of ice-cold ethanol. After 30 minutes on 
ice the DNA precipitates were collected by centrifugation at 3000g for 15 min at 4°C. 
The supernatant was decanted and the last drops of ethanol drained from the tubes on 
a paper towel. 200 µL of TE were added to each tube and the DNA was allowed to 
redissolve under rotation overnight. The concentration of the resuspended DNA was 
determined by measuring A260. The DNA samples were digested with the appropriate 
restriction enzyme, and restricted fragments were separated by agarose gel 
electrophoresis. Southern blotting and hybridization were performed as described in 
chapter 3.2.5 (Cockerill, 2000). The 380 bp DNA probe used for indirect endlabeling 
of the target fragment was amplified from LNCaP genomic DNA by standard PCR.  
Cell lysis buffer: 60 mM KCl, 15 mM MgCl2, 10 mM Tris, pH 7.4, 300 mM 
sucrose, 0.1 mM EGTA, and 0.1 mM Pefabloc (Roth, Karlsruhe). 
Nuclei digestion buffer: 60 mM KCl, 15 mM NaCl, 5 mM MgCl2, 10 mM Tris, 
pH 7.4, 300 mM sucrose, 0.1 mM EGTA. 
Proteinase K digestion buffer: 100 mM Tris-HCl, pH 8.0, 40 mM EDTA, 2% 
SDS, 0.2 mg/mL proteinase K. 
3.2.7 Cloning and subcloning 
SCGB 2A1 promoter fragments were amplified from the P1 clone ICRFP700J1347Q6 
that contains four secretoglobin genes (Ni et al., 2000). The upstream PCR primer 
 38
Materials and Methods 
defined the upstream truncation point and provided an Xho I site for cloning (see 
chapter 3.1.5). The downstream primer contained the SCGB 2A1 promoter sequence 
from +50 to +32 followed by a Kpn I recognition site used for cloning (see 3.1.5). The 
PCR was carried out for 30 cycles at 94°C for 40 sec, 57°C for 40 sec and 72°C for 30 
sec, followed by a final extension at 72°C for 5 min. Amplified PCR fragments were 
purified by using the Qiaquick PCR purification kit (QIAGEN, Hilden), and restricted 
with XhoI and Kpn I and ligated into pGAW. The vector was digested with Xho I and 
Kpn I, alkaline phosphatase treated and agarose gel purified using the GFXTM PCR 
DNA and gel band purification kit (Amersham Biosciences, Freiburg). The ligation 
reaction was carried out with 20 ng insert fragment, 100 ng vector and 0.1U T4 DNA 
Ligase in 20 µL 1× Ligase reaction buffer for 14 h at 16°C. Ligation reactions were 
transformed into competent E. coli DH5α (see chapter 3.2.9). The sequences of all 
constructs were checked (Seqlab, Göttingen) across the promoter/luciferase border 
using the Glprimer2 (Promega, Mannheim).  
Plasmid DNA for transfections was prepared from transformed E. coli DH5α 
using Nucleobond PC 500 columns (Macherey & Nagel, Düren). The quality of all 
plasmids (ratio supercoiled vs. nicked better than 70:30) was checked by agarose 
gelelectrophoresis before transfection. 
For subcloning of promoter fragments into the TK vector (See chapter 3.1.6), Xho 
I fragments were ligated into Xho I linearized vector. When the inserts were 
oligonucleotides containing the sequence from –59 to –28, the vector could not be 
dephosphorylated. The direction of the inserts was confirmed by sequencing. 
3.2.8 PCR-mediated mutagenesis 
Point mutations were introduced at specific sites by producing two overlapping 
mutant fragments via PCR (left and right arms) that were joined together by PCR 
directed homologous recombination (Klug et al., 1991). 
In a first PCR the left arm was generated from a suitable wild type promoter 
deletion construct, using as upstream primer the one which was also used to define the 
truncation point of this deletion construct (see chapter 3.1.5) and which contained an 
Xho I site for cloning. The downstream primer contained the desired mutation(s) (see 
Fig. 3.3) and, hence, is called the mutation primer (see chapter 3.1.5). 
The right arm was also generated by PCR from the same wild type construct. The 
upstream primer was complementary to the mutation primer used for the left arm (see 
chapter 3.1.5) and the downstream primer was the downstream primer SCGB 2A1 
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UTR+50/KpnI-3′ (see chapter 3.1.5) also used to generate all promoter deletion 
constructs that contained a Kpn I recognition site for cloning. Left and right arms 
were therefore partially overlapping (see Fig. 3.3). 
Left and right arms were agarose gel purified with the GFXTM PCR DNA and gel 
band purification kit (Amersham Biosciences, Freiburg) and used as templates 
(approximately 1 ng each) to create the chimeric full-length mutation fragment by 
PCR mediated recombination (Klug, et al. 1991). Upstream and downstream primer 
were the same as used in the 1. PCR for generating the left and right arm (see Fig. 
3.3). All PCRs were carried out with PfuTurbo polymerase for 30 cycles with 30 sec 
at 94°C, 40 sec at 58°C and 30 sec at 72°C, followed by a final extension at 72°C for 
7 min. 
The amplified PCR fragments were purified with the Qiaquick PCR purification 
kit (QIAGEN, Hilden) and were restricted with Xho I and Kpn I, followed by gel 
purification using the GFXTM PCR DNA and gel band purification kit (Amersham 
Biosciences, Freiburg). The ligations and transformations were carried out as 
described in chapter 3.2.7. 
 
 
 
Fig. 3.3 Schematic diagram of PCR-mediated mutagenesis.  
 
 
3.2.9 Preparation of competent E. coli and transformation 
For the preparation of competent E.coli, an inoculating loop was used to streak E. coli 
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DH 5α directly from a frozen stock onto an SOB agar plate. The plate was incubated 
for 16 hours at 37°C. One colony was picked and grown in 5 mL LB medium 
overnight. The next day a 250 mL SOB culture containing 20 mM MgSO4 was 
inoculated with 1 mL overnight culture. The cells were grown for 2.5-3.0 hours at 
37°C, under monitoring the growth of the culture every 20 minutes. 
When the culture had reached an OD600 = 0.5±0.1, the cells were harvested by 
centrifugation at 3,000 G for 15 min at 4°C. The medium supernatant was decanted, 
and the tubes were kept in an inverted position for 1 minute to allow the last traces of 
medium to drain away. The cells were resuspended in 100 mL TB buffer and stored 
on ice for 10 minutes. The cells were collected again at 3,000 G for 15 minutes at 4°C.  
The buffer was decanted and the tubes were again put in an inverted position for 
1 minute to allow the last traces of buffer to drain away. The cells were collected in 
one 50 mL Falcon tube by resuspending finally in 15 mL TB buffer. After gently 
mixing the buffer with 1050 µL DMSO (7% v/v), the mixture was kept on ice for 10 
minutes. 200 µL aliquots were dispensed into 1.5 mL chilled, sterile microfuge tubes. 
Competent cells were snap frozen immediately by immersing the tightly closed tubes 
in liquid nitrogen. The competent cells were stored at -70°C until needed. 
For transformations no more than 25 ng of plasmid in a volume not exceeding 
3 µL was used for 50 µL competent cells. The tubes were swirled gently to mix the 
DNA and bacteria. The tubes were stored on ice for 30 minutes. The tubes were 
transferred to a heatblock preheated to 42°C. After exactly 90 seconds the tubes were 
put on ice again. After 1-2 minutes cooling 200 µL of SOC medium were added to 
each tube. Incubation of the tubes for 45 minutes in a shaking incubator allowed the 
bacteria to recover and to establish antibiotic resistance. 50 µL transformed competent 
cells were plated onto 90 mm agar LB plates containing the appropriate antibiotic 
(usually 50µg/ml ampicillin). The plates were stored at room temperature until the 
liquid had been absorbed. The plates were inverted and incubated at 37°C overnight. 
Colonies were screened by plasmid mini preparations and diagnostic restriction 
enzyme analysis and/or by direct DNA sequence analysis. 
TB buffer: 10mM HEPES, 55 mM MnCl2, 15 mM CaCl2, 250 mM KCl, before 
adding MnCl2 adjust pH to 6.7 with KOH. 
 41
Materials and Methods 
3.2.10 Transfections and reporter gene assays 
3.2.10.1 Transfection of LNCaP and HeLa cells with the calcium phosphate 
method 
Calcium phosphate forms an insoluble precipitate with DNA which attaches to the cell 
surface and is internalized by cells through endocytosis (Jordan et al., 1996). 
24 hours before transfection, exponentially growing LNCaP or HeLa cells were 
harvested by trypsination and replated at a density of 1×105 to 4×105 cells/cm2 in 
Falcon 50 mL tissue culture flasks in RPMI 1640 or DMEM medium, respectively, 
supplemented with 10% charcoal treated FCS (4,5 ml medium per flask). The cultures 
were incubated for 20-24 hours at 37°C in a humidified incubator with an atmosphere 
of 5% CO2. RPMI medium was changed for DMEM one hour before transfection 
because RPMI 1640 forms a granular precipitate with calcium phosphate that is not 
internalized efficiently by the cells. 
The calcium phosphate-DNA coprecipitate was prepared as follows: 5 µg of 
construct DNA and 0.5 µg pRSV-β-gal (pCH110, see chapter 3.1.5, internal standard) 
were added into 250 µL of 250 mM CaCl2 in a sterile 5 mL plastic tube. One volume 
of this 2× calcium-DNA solution was mixed with an equal volume of 2× HeBS 
solution at room temperature by immediately tapping the tube. After exactly 1 minute 
the calcium phosphate-DNA suspension was added to the plates (into the 4.5 mL 
medium above the cell monolayer). The flask was gently rocked to mix medium and 
suspension which then turns yellow-orange and becomes turbid. This step was carried 
out as quickly as possible because the efficiency of transfection declines rapidly once 
the DNA precipitate is formed (Jodan et al., 1996). 
100 mM chloroquine diphosphate was diluted 1:1,000 directly into the medium 
after the addition of the calcium phosphate-DNA coprecipitate. The concentration of 
chloroquine added to the growth medium and the time of treatment are limited by the 
sensitivity of the cells to the toxic effect of the drug. The optimal treatment time of 
chloroquine for LNCaP and HeLa cells was empirically determined to be 4 hours. 
After treatment with DNA and chloroquine the medium was removed by aspiration, 
and the monolayer was washed once with PBS (see chapter 3.1.3). 1.5 mL of 15% 
glycerol in 1×HeBS were added to each flask and left on the cells for exactly 2 min 
which was the time tested to be optimal for LNCaP and HeLa cells. The glycerol 
containing medium was removed by aspiration, and the cells were washed with PBS 
(see chapter 3.1.3). 5 mL of prewarmed complete growth medium were added with or 
without hormones. The cells were incubated again at 37°C in a humidified incubator 
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with an atmosphere of 5% CO2. 
2× HEPES-buffered saline (HeBS): 21 mM HEPES, 0.7 mM Na2HPO4, 
137mM NaCl, 5 mM KCl, 6 mM dextrose, pH 7.1 (very critical). 
3.2.10.2 Luciferase assay 
To assay the transfected cells for transient expression of the introduced luciferase 
gene the cells were harvested 48 hours after transfection. The cells were washed three 
times at room temperature with PBS without calcium and magnesium salts. PBS was 
added and removed gently because LNCaP cells can be easily displaced from the dish 
by vigorous pipetting. 350 µL of ice-cold cell lysis buffer was then added to the flasks. 
The buffer was distributed gently and the lysed cells were scraped from the dish using 
a rubber policeman. Cell lysates were collected in 1.5-mL microfuge tubes and 
cleared by centrifugation at 13,000 g for 5 min at 4°C. 
The luciferase assay was performed by adding 100 µL of cell lysate into 
individual luminometer tubes containing 360 µL of luciferase assay buffer at room 
temperature. Light was measured with an AutoLumat 953 luminometer (Berthold, 
Bad Wildbad) by injecting 100 µL of 0.2 mM luciferin solution into the sample tubes 
and measuring light output over 10 sec (Brasier et al., 1989). 
Cell lysis buffer: 1%(v/v) Triton X-100, 25 mM glycylglycine, pH 7.8, 15 mM 
MgSO4, 4 mM EGTA and 1 mM DTT. 
Luciferase assay buffer: 25 mM glycylglycine, pH 7.8, 15 mM potassium 
phosphate, pH 7.8, 15 mM MgSO4, 4 mM EGTA, 2 mM ATP and 1 mM DTT. 
3.2.10.3 β-Galactosidase assay 
For the β-galactosidase assay, 40 µL of cell lysate were incubated with 60 µL of 
4 mg/mL ONPG sodium phosphate solution and 250 µL buffer Z. After 1 hour 
incubation at 37°C the reaction was stopped by adding 100 µL 1 M Na2CO3, and the 
optical density of the solutions was measured at a wavelength of 420 nm in a 
spectrophotometer. Controls contained 40 µL of cell extract from mock-transfected 
cells. In addition, the positive controls should include 1 µL of a commercial 
β-galactosidase solution (50 units/mL). One unit of β-galactosidase is defined as the 
amount of enzyme that will hydrolyze 1 µM of ONPG substrate in 1 minute at 37°C 
(Young et al., 1993). 
The concentration of total protein in the lysate was determined by the Bradford 
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assay (Bradford, 1976), using the Protein-Assay reagent (BioRad, München). Reagent 
background RLU were subtracted from sample RLU values and normalized for 
protein concentration. β-galactosidase results were used to normalize for plate-to-plate 
variations in transfection efficiency. 
Buffer Z: 60 mM Na2HPO4, 40 mM NaHPO4, 10 mM KCl, 1 mM MgSO4, 50 
mM β-Mercaptoethanol, pH 7.8. 
Chloroquine (100 mM): Dissolve 52 mg of chloroquine diphosphate in 1 mL of 
deionized distilled H2O. Sterilize the solution by passing it through a 0.22 µm 
filter; store the filtrate in foil-wrapped tubes at -20°C. 
3.2.11 Preparation of nuclear extracts 
Nuclear extracts of LNCaP and HeLa cells were prepared according to Andrews and 
Faller, 1991, with some modifications. 5×107 cells were harvested and collected by 
centrifugation at 250 G for 10 minutes at room temperature. The cells were rinsed 
several times with PBS (see chapter 3.1.3) without calcium and magnesium salts. The 
cell suspension was then transferred to a 2 mL microfuge tube. Cells were pelleted 
again and resuspended in 1 mL buffer A by flicking the tubes. After 10 minutes 
swelling on ice, the suspension was vortexed 10 seconds. Samples were centrifuged 
for 10 seconds and the supernatant was discarded. The pellet was resuspended in 
buffer C and incubated on ice for 20 minutes. Cellular debris was removed by 
centrifugation at maximum speed for 5 minutes at 4°C, and the supernatant was 
dialyzed twice for 2 hours each in buffer D. The supernatant was divided into aliquots 
of 100-200 µL which were snap-frozen in liquid nitrogen and stored at -70°C. Before 
freezing the protein concentration was determined using the Bradford method (see 
3.2.10.3). 
Buffer A: 10 mM HEPES-KOH, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM 
DTT, 0.2 mM PMSF. 
Buffer C: 20 mM HEPES-KOH, pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF. 
Buffer D: 20 mM HEPES-KOH, pH 7.9, 20% glycerol, 100 mM KCl, 0.2 mM 
EDTA, 0.5 mM DTT and 0.5 mM PMSF. 
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3.2.12 DNase I footprinting 
3.2.12.1 End-labeling of the DNA probe 
A 32P-end-labeled 432 bp Xho I/Kpn I fragment from pGAW (-382) Luc which 
contains the sequence from -382 to +50 of the SCGB 2A1 promoter was used for the 
DNase I footprinting experiments.  
For labeling of the lower strand, 6 µg pGAW (-382) Luc construct were digested 
with Xho I for 40 min at 37°C in 20 µL restriction enzyme buffer. The 3′-recessed end 
was labeled by using Klenow fragment and filling in with dATP, dTTP, dGTP and 
[α-32P]dCTP. The restriction enzyme and Klenow fragment were inactivated for 10 
min at 70°C before digestion with the second restriction enzyme Kpn I was started. 
After 40 min digestion, the sample was loaded onto a 5% native polyacrylamide gel. 
The gel was run in 1×TBE buffer at 10 V/cm until the bromophenol blue dye had 
reached the bottom of the gel. 
For labeling of the upper strand, the pGAW (-382) Luc construct was digested 
with Kpn I for 40 min at 37°C in 20 µL restriction enzyme buffer. The 3′-protruding 
ends were labeled with T4 DNA ploymerase in the presence of [α-32P]dCTP. T4 DNA 
polymerase rapidly digests 3′-protruding termini and then continues to remove 
nucleotides until a G residue (in this case) is encountered on the template strand. 
when a complementary radiolabeled C residue is incorporated into the DNA fragment. 
The reaction was stopped by heating to 70°C for 10 min. After 40 min digestion with 
the second restriction enzyme Xho I, the sample was loaded onto a 5% native 
polyacrylamide gel and the gel was run in 1×TBE buffer at 10 V/cm until the 
bromophenol blue dye had reached the bottom of the gel. 
After electrophoresis the gel plates were separated and the one with the gel 
attached was wrapped in plastic foil. Four filter paper snippets were laid 
asymmetrically on the wrapped gel, and a few microliter of radioactive solution were 
applied to each of them. After covering and fixing the filter snippets with adhesive 
film the gel was exposed to Kodak BioMax X-ray film (Integra Biosciences, 
Fernwald) for 2 min in order to locate the labeled fragment. A clean sharp scalpel was 
used to cut out the segment of the gel containing the band of interest. The gel slice 
was transferred to a microfuge tube and soaked in 400 µL TE (pH 8.0) overnight. The 
DNA probe extracted from the gel slice was ethanol precipitated and then dissolved in 
TE (pH 8.0) buffer. 
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3.2.12.2 Maxam-Gilbert sequencing reactions 
Maxam-Gilbert G-reaction was performed and used as high-resolution size markers. 
About 20×104 cpm of labeled fragment were diluted in 200 µL TE buffer and 1 µL 
dimethylsulfate (DMS, Sigma,) was added. After 3 min the reaction was stopped by 
adding 50 µL DMS stop solution. The nucleic acids were precipitated with 750 µL 
ethanol for 15 minutes at -70°C and collected by centrifugation at maximum speed for 
15 minutes at 4°C in a microfuge. The pellets were rinsed with 1 mL of 70% ethanol, 
centrifuged again, and dried in the vacuum-concentrator to remove last traces of 
ethanol. 
The base-modified DNA was resuspended in 100 µL of 10% (v/v) piperidine by 
vortexing. The tube was incubated for 30 minutes at 90°C, and sealed with a safety 
cap to prevent the lid from popping open during heating. Afterwards the piperidine 
was evaporated to dryness in a vacuum concentrator. The DNA was dissolved in 
20 µL of H2O and evaporated to dryness once again. The amount of radioactivity 
remaining in the tube was measured by Cerenkov counting. The DNA fragments were 
dissolved in formamide loading buffer (see chapter 3.1.3) at about 5,000 cpm/µL 
buffer. Before loading onto the sequencing gel the tubes were heated at 90°C for 5 
minutes to denature the DNA and then chilled on ice (Maxam and Gilbert, 1977). 
DMS stop solution: 1.5 M sodium acetate (pH 7.0), 1 M β-mercaptoethanol, 250 
µg/mL yeast tRNA. 
3.2.12.3 DNase I digestion 
About 7×104 cpm of labeled fragment were incubated with 30 µg nuclear extract 
protein in the presence of 2 µg poly (dI-dC) in a 25 µL reaction volume in 1× binding 
buffer. The nuclear extract was preincubated with the unspecific competitor poly 
(dI-dC) for 1 minute to decrease nonspecific binding of proteins to the radiolabeled 
DNA fragment. The labeled SCGB 2A1 promoter fragment was subsequently added 
to the mixture and incubation was continued for 20 minutes at room temperature. The 
final Mg2+ and Ca2+ concentration was adjusted to 5 mM and 1mM, respectively, by 
adding 3 µL of a Mg2+/Ca2+ solution. 
2 µL of a DNase I dilution (Roche, Mannheim, dissolved in 1× binding buffer) 
containing 20, 40 or 60 ng DNase I, were added to the binding reaction and incubated 
for exactly 1 minute at 20°C. The reactions were stopped by adding 100 µL of 
DNase I stop buffer containing proteinase K. After 40 min digestion at 45°C samples 
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were extracted twice with phenol/chloroform. The aqueous phases were transferred to 
fresh microfuge tubes, and nucleic acids were precipitated with 2.5 volumes of 
ethanol. The ethanolic solutions were chilled for 15 minutes at -70°C, and precipitates 
were collected by centrifugation at maximum speed for 15 minutes at 4°C. The pellets 
were rinsed with 1 mL of 70% ethanol, centrifuged again and dried in the vacuum 
concentrator. 
The DNA pellets were dissolved in 5-10 µL of formamide loading buffer (see 
chapter 3.1.3) by vigorous vortexing and denatured by heating to 90°C for 3-5 
minutes. Samples were loaded onto a 6% polyacrylamide sequencing gel that was 
prerun for at least 30 minutes before loading. About 20,000 cpm/sample were loaded, 
followed by the sequence ladder and control samples. The gel was run at sufficient 
constant power to maintain a gel temperature of 50°C until the bromophenol blue dye 
had reached the bottom of the gel. After separating the glass plates, the gel was 
transferred onto Whatman 3 MM paper and dried under vacuum at 80°C on a gel 
dryer (BioRad, München) for approx. 1 hour. The dried gel was exposed to a 
phosphorimage screen for 12 hours and analyzed on a Fuji PhosphorImager 
FLA3000G (Raytest, Straubenhardt). 
2× Binding buffer: 20 mM HEPES-KOH, pH 7.9 (critical), 17% glycerol, 100 
mM KCl, 0.2 mM EDTA and 0.4 mM DTT. 
Mg2+/Ca2+ solution: 50 mM MgCl2, 10 mM CaCl2. 
DNase I stop buffer: 20 mM Tris, pH 7.6, 20 mM EDTA, 0.5% SDS, 100 ng/ mL 
glycogen, 100 µg/mL proteinase K. 
6% Polyacrylamide sequencing gel: 15 mL 40% acrylamide/bis (19:1) stock 
solution, 20 mL 5×TBE, 42 g urea, 29.7 mL H2O. 
3.2.13 Oligonucleotides and EMSA 
A pair of complementary single-stranded oligonucleotides was heated to 95°C for 
5 min in 100 µL of annealing buffer in a water bath and cooled to room temperature 
over 2 hours. The final concentration of the double-stranded oligonucleotide was 
50 ng/µL. About 50 ng double stranded DNA was labeled by filling in the ends with 
[α-32P] dCTP and Klenow fragment. Labeled double-stranded DNA was purified over 
a NickTM column (Amersham Biosciences, Freiburg) according to the instructions 
provided by the manufacturer. 
For electrophoretic mobility shift assays 3 µg nuclear extract were preincubated 
with 0.5 µg unspecific competitor poly (dI-dC) in 1× binding buffer (see chapter 
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3.2.12.3) for 10 min on ice. Subsequently about 2×104 cpm of labeled double-stranded 
oligonucleotide were added to yield a final volume of 20 µL, and incubation was 
continued at room temperature for another 15 min. The competition experiments were 
performed by preincubating the extracts with 50 ng of unlabeled oligonucleotide 
(approx. 100 fold molar excess). Samples were loaded on a 4% native polyacrylamide 
EMSA gel (acrylamide/bisacrylamide ratio 39:1). 
The gel was run in 0.5×TBE buffer at 160-200 V and 20 mA for 2 hours. After 
electrophoresis was complete the gel plates were separated, the gel was transferred to 
a piece of blotting paper and dried for approx. 1 hour at 80°C under vacuum in a gel 
dryer (BioRad, München). The dried gel was exposed to a phosphorimage screen for 
2 hours and analyzed on a Fuji PhosphorImager FLA3000G (Raytest, Straubenhardt).  
Annealing buffer: 10mM Tris-HCl, pH 8.0, 1 mM EDTA, 30 mM KCl. 
3.2.14 Protein expression and purification 
3.2.14.1 Preparation of the expression construct 
The cDNA for SCGB 2A1 cloned into the Eco RI (5′) and Xho I (3′) sites of pBS(SK) 
(Stratagene, Amsterdam) was kindly provided by Jian Ni, Human Genome Sciences, 
Rockville, Maryland, U.S.A. In order to generate a bacterial expression construct in 
pRSETB (Invitrogen, Karlsruhe), the cDNA in pBS(SK) was amplified with the 
upstream primer 5′-caaggatccgGGCTGCAAACTCCTGGAG-3′ and the T7 primer 
5′-TAATACGACTCACTATAGGG-3′ as downstream primer. The upstream primer 
contained a Bam HI site for subcloning (underlined) followed by the coding sequence 
of SCGB 2A1 starting with GGC for glycin 21 of the pro-protein. The cycle 
conditions for a standard PCR with Goldstar Taq polymerase (Eurogentec, Seraing, 
Belgium) were: 2 min initial denaturation at 96°C, 30 cycles of denaturation for 1 min 
at 95°C, annealing for 30 sec at 52°C, extension for 30 sec at 73°C and a final 
extension for 5 min at 73°C. The 450 bp fragment was ethanol precipitated in the 
presence of ammonium acetate, digested with Bam HI/ Xho I and purified by agarose 
gel electrophoresis. The 410 bp restriction fragment was recovered from the agarose 
gel by cutting out the piece of agarose containing the fragment, freezing and thawing 
the piece of agarose three times and centrifuging it at 12, 000 G at 4°C for 30 min. 
The concentration of the restriction fragment in the supernatant was estimated by 
agarose gel electrophoresis, and some 20 ng were used in a standard ligation reaction 
with 100 ng of Bam HI and Xho I restricted and phosphatase treated pRSETB. 
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Recombinant clones were picked, and the sequence was verified using the T7 primer 
as sequencing primer (Seqlab, Göttingen). SCGB 2A1 is expressed as a fusion protein 
with a six histidine tag at the amino terminus followed by the Xpress epitope 
(trademark of Invitrogen) and an enterokinase cleavage site thus adding 33 amino 
acids to the 75 amino acid SCGB 2A1 sequence (see Fig. 3.2-C). The apparent 
molecular weight of the fusion protein is 12.4 kDa. 
3.2.14.2 Expression of SCGB 2A1 in E. coli 
Positive E. coli strain BL21 (DE3) clones containing the expression construct were 
selected from ampicillin resistant transformants and inoculated in 1 mL LB medium. 
To optimize expression conditions, 5 mL of LB medium containing 50 µg/mL 
ampicillin were inoculated with 50 µL of overnight culture. The cultures were 
incubated for >2 hours at 37°C in a shaking incubator until cells reached mid-log 
phase (OD600=0.8).  
1 mL of each uninduced culture (zero-time aliquot) was transferred to microfuge 
tubes. The tubes were centrifuged at maximum speed for 1 minute at room 
temperature in a microfuge immediately. The supernatants were removed by 
aspiration. The pellets were resuspended in 100 µL of 1× SDS gel-loading buffer. The 
remainder of each culture was induced by adding IPTG to a final concentration of 
1 mM and incubation was continued at 37°C with aeration. At various time points 
during the induction period (e.g., 0.5, 1, 2 and 3 hours), 1 mL of each culture was 
transfered to a microfuge tube, the OD600 was measured in a spectrophotometer, and 
each pellet was resuspended like the zero-time aliquot. The samples were heated to 
100°C for 3 minutes. All tubes were centrifuged at maximum speed for 1 minute at 
room temperature in a microfuge, and stored on ice until the samples were collected 
and ready for loading on a gel. The samples were warmed to room temperature and 
0.15 OD600 units (of original culture) were loaded onto an 18% SDS-polyacrylamide 
gel. The gel was run at 8-15 V/cm until the bromophenol blue reached the bottom of 
the resolving gel. The gel was stained with Coomassie Brilliant Blue as described in 
3.2.3.2. As the results showed (Fig. 4.13), best expression conditions were obtained 
with 3 hours of induction using 0.5 mM IPTG at 37°C. 
For large scale expression, 5 mL of an overnight culture was inoculated into 
500 mL LB (supplemented with 100 µg/mL ampicillin) in a 2 L Erlenmeyer flask and 
incubated at 37°C to an optical density of OD600=0.8. Expression was induced by 
adding solid IPTG to a final concentration of 0.5 mM (60 mg for 500 mL). Incubation 
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continued at 37°C for 3 h, when the cells were harvested by centrifugation (GSA rotor, 
5,000 rpm, 10min, RT) and lysed in 6 mL of 6M guanidine-HCl pH 8.0 by shaking 
overnight at 4°C. The debris was removed by centrifugation (SS34 rotor, 18,000 rpm, 
5 min, 4°C) and the supernatant was transferred to a new tube. 
3.2.14.3 Purification of histidine-tagged SCGB 2A1 protein 
2 mL of Ni2+-NTA-agarose resin (Qiagen, Hilden) were filled into a BioRad polyprep 
column. The resin was packed under gravity flow. The column was washed with 
10 mL water; charged with Ni2+ by applying 8 mL 0.1 M NiSO4; washed twice with 
10 mL water; equilibrated with 10 mL 6M guanidine-HCl pH 8.0; loaded with the 
bacterial lysate supernatant (see chapter 3.2.14.2); washed with 10 mL 6M 
guanidine-HCl pH 8.0; and washed with 10 mL 6M guanidine-HCl pH 6.0. The 
histidine-tagged SCGB 2A1 protein was eluted with 7 mL 6M guanidine-HCl pH 5.0. 
All media were applied to the column by means of a peristaltic pump with the flow 
rate adjusted to approx. 1ml/min. 
In order to renature the protein, guanidine was removed by dialysis against 
500 mL dialysis buffer. After 2 hours of dialysis at 4°C, dialysis buffer was exchanged 
for fresh one and dialysis continued for another 3 h. Precipitated protein (precipitation 
occurs in the second half) is removed by centrifugation (SS34 rotor, 13,000 rpm, 5 
min, 4°C). After Bradford protein assay (see chapter 3.2.10.3) the cleared solution 
was divided into 200 µL aliquots and frozen in liquid nitrogen. The total yield of 
purified protein was approximately 5mg per liter of bacterial culture. A sample was 
analysed on an 18% SDS-PAGE stained with Coomassie blue. 
Dialysis buffer: 10 mM HEPES pH7.8, 50 mM KCl, 1 mM DTE, 8.5% glycerol 
and 0.1 mM Pefabloc (Roth, Karlsruhe). 
3.2.15 Antibody preparation 
One New Zealand rabbit (approx. 3 kg) was immunized with recombinant His-tagged 
SCGB 2A1 produced in E. coli (see 3.2.14). Before the immunization protocol was 
started some 5-10 mL of preimmune serum was collected. 175 µg of protein in 1 mL 
dialysis buffer (10 mM HEPES pH7.8, 50 mM KCl, 1 mM DTE, 8.5% glycerol and 
0.1 mM Pefabloc) were mixed with the same volume of GERBU Adjuvant 100 (Fa. 
GERBU, Gaiberg) and injected under the rabbit’s back skin at four different locations 
(first immunization). After four weeks a boost was performed with 80 µg of protein 
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mixed with 1 mL of GERBU Adjuvant 100. A second boost was performed with the 
same amount of protein six weeks after starting the immunization protocol. Ten days 
after the second boost, a blood sample was drawn, and the clotted blood was stored at 
4˚C overnight. Serum was removed from the clot by centrifugation at 10,000 G for 10 
min at 4˚C and tested in a Western blot against recombinant and native SCGB 2A1 
from tears. When the test was positive the rabbit was sacrificed and all serum 
collected. Sodium azide was added to 0.02 % (w/v), and the serum was stored in 
aliquots at –20˚C. 
3.2.16 Western blotting 
Proteins were separated in an 18% SDS polyacrylamide gel and electro-transferred to 
a nitrocellulose membrane (ECL nitrocellulose membrane, Amersham Biosciences, 
Freiburg) at 140mA for 90 min using a semi-dry blot apparatus (Fastblot B33, 
Biometra, Göttingen) according to the instructions provided by the manufacturer. The 
membrane was blocked with 5% (w/v) skimmed milk powder (Becton Dickinson) in 
PBS for 2 hours and incubated overnight at 4°C with the rabbit anti-SCGB 2A1 
antibody (see chapter 3.2.15) diluted 1:1,000 in PBS containing 5% (w/v) skimmed 
milk powder. After washing twice in PBS, the membrane was incubated for 1 hour at 
room temperature with an HRP-conjugated anti-rabbit IgG antibody diluted 1:10,000 
in PBS containing 5% (w/v) skimmed milk powder. After washing twice in PBS, the 
membrane was incubated with ECL Detection Reagent (1:1 mixture (v/v) of Reagent 
1 and Reagent 2) for 60 sec (Amersham Biosciences, Freiburg). The membrane was 
wrapped in plastic foil and exposed to Kodak BioMax X-rayfilm for 1–15 min 
(Integra Biosciences, Fernwald). 
3.2.17 Immunostaining 
Tissue samples from a prostate carcinoma (PC), benign prostate hyperplasia (BPH), 
fetal prostate tissue (1, 3 and 6 months of gestation) and prostate tissue from an 
adolescent subject, were either fixed in Bouin’s solution or in 4% formaldehyde. After 
fixation the tissue was embedded in paraffin at 65°C for 4 hours. 5 µm sections were 
used for the immunostainings and were kindly provided by Gerhard Aumüller, 
Universität Marburg. 
In order to remove paraffin, praraffin embedded tissue sections were washed three 
times in xylene for 5 min, three times in 100% ethanol for 3 min, twice in 96% 
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ethanol for 3 min, once in 90% ethanol for 3 min, once in 80% ethanol for 3 min, 
once in 70% ethanol for 3 min, and once in 50% ethanol for 3 min. 
After a final wash with distilled water for 3 min, the sections were digested with 
20µg/mL Proteinase K in PBS for a time that was empirically determined to be 
optimal (usually 15-30 min). After digestion, slides were washed twice in PBS and 
incubated with the rabbit anti-SCGB 2A1 antibody (1:300 diluted in PBS, see chapter 
3.2.15) at 25°C for 120 min. Negative controls were performed with preimmune 
serum. Slides were washed in PBS five times and a Cy 3-labeled anti-rabbit secondary 
antibody (Dianova, Hamburg. 1:400 diluted in PBS) was added at room temperature 
for 45 min. Slides were washed four times in PBS and mounted with Gelvatol 
(Burkard Scientific, Uxbridge, UK). The results were analyzed under a fluorescence 
microscope equipped with camera (Leica, DMLB). 
For staining cells in tissue culture, adherent cells were prepared by growing on a 
coverslip, and then fixed and permeabilized in acetone/methanol (1:1, v/v) for 2 min 
at room temperature. The samples were air-dried without a PBS wash. Once cells 
were fixed and permeabilized, the same steps were performed as in tissue staining. 
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4. RESULTS 
4.1 SCGB 2A1 is expressed in the prostate 
In northern blot analyses using poly (A)+ RNA from multiple human tissues, SCGB 
2A1 was shown to be strongly expressed in pancreas, prostate, testis and ovary (Ni et 
al., 2000). More tissues were examined in an RT-PCR study (Zhao et al., 1999). This 
sensitive assay confirmed strong expression in prostate, testis and ovary and also 
showed strong expression of SCGB 2A1 in mammary gland, uterus, trachea, kidney, 
thymus and salivary gland. In order to find a suitable cell culture model for studying 
expression at the molecular level the cell type that is actively transcribing SCGB 2A1 
in the prostate was identified by in situ hybridization.  
4.1.1 SCGB 2A1 expression is localized to the glandular epithelium 
The prostate consists of 30-50 branched tuboalveolar glands. Their discharging ducts 
are polymorphic and can be voluminous or tight and branched. The glandular 
epithelium is variable and can be simple or stratified columnar as well as cuboidal and 
transitional and is made up of three epithelial cell types, secretory main cells, basal 
cells and a small number of neuroendocrine cells. Paraffin embedded sections of a 
normal prostate were hybridized in situ with 35S labeled sense and antisense RNA 
probes generated from the SCGB 2A1 cDNA inserted into pBluescript SK. For 
microscopic analysis autoradiograms were developed as shown in Fig. 4.1. The 
antisense probe yielded a strong hybridization signal in the prostate epithelium that 
showed the typical glandular folds (Fig. 4.1.A). Hybridization with the sense probe 
resulted in background staining only (Fig. 4.1.B). Bright field illumination in 
combination with Hematoxylin staining confirmed that the hybridization signal 
resides in the epithelial layer (Fig. 4.1.C). 
4.1.2 Expression of SCGB 2A1 in LNCaP cells is induced by androgen 
Because SCGB 2A1 expression was localized to the glandular epithelium, the prostate 
expression was analyzed in the well-established and characterized cell line LNCaP. 
The LNCaP cell line was established in 1977 by J.S. Horoszewicz et al., from a left 
supraclavicular lymph node of a 50-year-old Caucasian male with confirmed 
diagnosis of metastatic prostate carcinoma (Horoszewicz et al., 1980; Murphy, 1980). 
The LNCaP cell line is androgen responsive and, thus, enables the investigation of 
androgen inducibility of SCGB 2A1 expression. 
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Fig. 4.1 Localization of SCGB 2A1 expression in the prostate.  
A, Darkfield micrograph showing in situ hybridization with a 35S-labeled antisense 
probe. The glandular epithelial cells are strongly labelled. B, Darkfield micrograph 
showing in situ hybridization with a 35S-labeled sense probe. Note the background 
staining only. C, Brightfield micrograph showing in situ hybridization with a 35S-labeled 
antisense probe together with histochemical hematoxylin staining. Epithelial cells 
appear light blue, stromal cells dark blue. The majority of silver grains is found in and 
around epithelial cells. 
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Total RNA was prepared from LNCaP cells grown in the absence of the androgen 
DHT, or after treating them with DHT for different time intervals. HeLa cell RNA was 
used as a control. A northern blot was performed with these RNAs and hybridized 
with an SCGB 2A1 cDNA probe and with an 18S rRNA probe. Fig. 4.2 shows that 
basal expression of SCGB 2A1 in LNCaP cells is low if cells are cultivated in 
medium made up with charcoal treated serum. If non-charcoal treated serum is used, 
basal expression is significantly higher (data not shown). After six hours SCGB 2A1 
was maximally induced by DHT. Quantification of hybridization signals with a 
PhosphorImager and normalization for 18S rRNA expression yielded a 21-fold 
induction of expression at the 6h time point. No expression of SCGB 2A1 was 
observed in HeLa cells. 
 
 
Fig. 4.2 Northern blot analysis of the expression of SCGB 2A1 in 
LNCaP cells.  
Total RNAs were prepared from HeLa cells and LNCaP cells treated 
without DHT, or with DHT for different times (0.5 h, 6 h, 24 h). 
Analysis was performed with 30 µg of total RNAs. Blot was 
hybridized with a 32P-labeled SCGB 2A1 cDNA probe and with an 
18S rRNA probe as loading control. 
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4.2 A hormone dependent chromatin alteration occurs in the SCGB 2A1 
promoter 
SCGB 2A1 expression is androgen dependent in LNCaP cells. But sequence analysis 
of the promoter could not reveal any classical androgen responsive element. For direct 
genomic action of the androgen receptor a few AR specific AREs have been described 
(Claessens et al., 2001), but such a specific ARE could also not be identified. 
Therefore, in a directed approach, DNase I hypersensitive (DH) sites were mapped in 
order to identify functionally relevant promoter elements. DH sites represent local 
perturbations of the nucleosome array in nuclei rendering them accessible to 
nucleases or DNA-binding factors in general.  
Nuclei were isolated from LNCaP cells grown in the presence or absence of DHT. 
Nuclei from HeLa cells and naked DNA were used as controls. Nuclei were treated 
with increasing amounts of DNase I. For naked DNA one tenth of the amounts used 
for nuclei was employed. Purified DNA was digested with the restriction enzyme Xba 
I, generating a 11 kb genomic fragment spanning from -3 kb to +8 kb of the SCGB 
2A1 gene as indicated in Fig. 4.3-B. Restricted DNA samples were separated on an 
agarose gel, and analyzed by Southern blotting with a 380 bp probe located at the 5′ 
end of the Xba I fragment, from -2455 to -2176 upstream of the transcription start site 
(Fig. 4.3-B and chapter 3.2.6). 
As shown in Fig. 4.3-A, one prominent hypersensitive site (HS) was detected in 
the proximal promoter of the SCGB 2A1 gene at approximately ~100 bp. This HS 
was hormone-dependent because it only appeared in samples from LNCaP cells that 
were treated for 6 or 24 hours with DHT, but it was absent in samples from untreated 
cells or cells that were treated with DHT for only one hour. The HS also appeared to 
be specific, because it could not be detected in naked DNA and in nuclei from HeLa 
cells. In another experiment (data not shown), DNA purified from DNase I treated 
nuclei was digested with Xho I, producing a restriction fragment of about 10 kb from 
+1.7 kb upstream of the SCGB 2A1 gene start point of transcription to some 8 kb 
downstream. The hybridzation probe was placed at the 3′ end of this fragment in order 
to detect the HS from downstream. Both mapping results confirmed a strong DNase I 
hypersensitive site in the proximal promoter region of the SCGB 2A1 gene after 
androgen treatment. 
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Fig 4.3 Mapping of DNase I hypersensitive sites in the SCGB 2A1 gene. 
(A) Southern blot analysis of Xba I digested genomic DNA from DNase I treated 
samples. Nuclei were isolated from LNCaP cells treated without DHT (lane 1, 2) or 
with DHT for 1h (lane 3, 4), 6h (lane 5, 6) or 24h (lane 7, 8), respectively. Naked 
DNA (lane 9, 12, 13) and HeLa nuclei (lane 10, 11) were used as negative controls. 
Nuclei were incubated with increasing concentrations of DNase I as indicated. The 
Southern blot was hybridized with a PCR amplified probe located at the 5′ end of the 
Xba I restriction fragment. The intact 10 kb Xba I fragment, a non-specific 
hypersensitive site (NS) present in all samples and an LNCaP specific HS (HS) are 
indicated. 
(B) Schematic representation of the SCGB 2A1 gene. Black bars represent the three 
exons of the SCGB 2A1 gene. A horizontal arrow indicates the position and length of 
the hybridization probe. The position of the specific HS is indicated by a vertical 
arrow. 
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4.3 The proximal promoter (-136/+50) of the SCGB 2A1 gene is sufficient for 
both constitutive and androgen-induced expression 
The mapping of DNase I hypersensitive sites in the SCGB 2A1 gene indicated that 
only the gene’s promoter is responsible for the regulation by androgens. In order to 
confirm this result and to more precisely delineate the androgen responsive region 
promoter deletions were cloned in front of the luciferase reporter gene (Fig. 3.2-A and 
Fig. 4.4). The different promoter fragments were amplified from a human P1 clone 
that was shown to contain at least three genes of the secretoglobin gene cluster, 
among them SCGB 2A1 (Ni et al., 2000; SCGB 2A1 is called LGB in this reference). 
The primers were also used to artificially introduce restriction sites for cloning (Xho I 
at the 5′-end and KpnI at the 3′-end; see also chapter 3.2.7 of Materials and Methods). 
As deletion endpoints -53, -136, -382, -575, -963, -1314 and -1476 bp, respectively, 
were chosen. All constructs were sequenced from the luciferase gene into the insert 
for verification of at least some 400 bp. Transient transfections into LNCaP cells were 
performed by the calcium phosphate DNA co-precipitation method. All results were 
corrected for plate to plate variations in transfection efficiency by normalization for 
β-galactosidase activity obtained by cotransfecting a constant amount of an 
RSV-β-Gal expression construct. 
The transient transfection results are shown in Fig. 4.4, upper panel. For all 
constructs the basal level of transcription is low and varies only by a factor of two. 
After addition of the androgen DHT the longer promoter constructs with endpoints 
from -1476 to -575 are induced approximately 11-fold. When the region between -575 
and -382 is deleted transcription is induced by a factor of 23 indicating the loss of a 
negative element. Deleting further down to -136 bp reduces the induction level to 
15-fold suggesting that one or more positive acting elements are eliminated. But only 
when the proximal promoter from -136 to -53 bp was removed hormone regulation 
was abolished. These transfection results identified the proximal promoter as 
androgen responsive region, independently confirming the results obtained from the 
DNase I HS mapping experiment. When the same constructs were transfected into 
HeLa cells, no hormone responsiveness was observed (data not shown). 
In order to test if the identified hormone responsive region can be functionally 
transferred to a heterologous promoter, the SCGB 2A1 promoter fragment starting at 
-136 and terminating at -53 was cloned in front of the Herpes simplex virus thymidine 
kinase promoter directing expression of a reporter gene (HSV-tk-Luc). Surprisingly, 
this construct is not androgen responsive in LNCaP cells (Fig. 4.4, lower panel) like  
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Fig 4.4 Transient transfection of LNCaP cells with reporter gene constructs 
containing SCGB 2A1 promoter fragments. 
The left panel schematically shows the 5′ promoter deletions of the SCGB 2A1 gene 
that were linked to the luciferase reporter gene (Luc, upper part), or to the luciferase 
gene under control of the HSV tk promoter (tk-Luc, lower part). The numbers indicate 
start and end point of the promoter fragments relative to the transcription start point. 
The right panel shows the results of transient transfection assays. LNCaP cells were 
transiently transfected with 5 µg of the indicated construct and co-transfected with 
0.5 µg pRSV-β-gal as internal standard. The cells were treated with 10-8 M DHT alone 
or together with 5×10-6 M bicalutamide as indicated. Cell extracts were prepared and 
the luciferase activity was determined. The values were normalized for β-gal activity 
and protein concentration as described in Materials and Methods. The luciferase 
activity of the (–53/+50)-Luc construct (about 8,000 RLU in a typical assay) in the 
absence of DHT was set to 1-fold. 
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another construct containing a longer piece of the SCGB 2A1 promoter (-382/-53), 
indicating that the androgen responsive region is no longer intact. Therefore, in 
another set of constructs the 3´-end of the promoter pieces was shifted to -28 bp, 
immediately upstream of the TATA box. By inclusion of 25 more bp at the 3′-end, 
androgen responsiveness could be fully restored in both constructs, (-136/-28)-tk-Luc 
and (-382/-28)-tk-Luc. Apparently, the androgen responsive region had been 
destroyed by setting the deletion endpoint at -53. Close inspection of the sequence 
between around -50 and -28 bp revealed a peculiar dimeric inverted repeat type 
GC-box (dim-IR-GC box) but clearly not a classical or non-classical androgen 
response element. Even the small promoter piece -59/-28 just containing the 
dim-IR-GC box is sufficient to confer full androgen responsiveness to the tk promoter 
[(-59/-28)-tk-Luc]. The level of induction by DHT is comparable to the induction 
level of the SCGB 2A1-Luc constructs. Note that the tk promoter itself, containing a 
single GC-box (see chapter 3.1.6), is induced 2-3 fold by DHT.  
The nonsteroidal AR- antagonist bicalutamide (Casodex®, AstraZeneca, Wedel), 
was used to explore the possible participation of the AR. A more than 500 fold molar 
excess (5×10-6 M) bicalutamide over DHT was used to antagonize androgen action. 
The transient transfection results (Fig. 4.4, upper panel) show that induction by DHT 
of the (–136/+50)-Luc and (-382/+50)-Luc constructs is abolished, indicating that the 
AR is involved in the androgen response. 
4.4 The dim-IR-GC box of the SCGB 2A1 promoter specifically responds to 
androgens but not to glucocorticoids 
Although the dim-IR-GC box has no resemblance to an androgen response element it 
could not be excluded that steroid hormone receptors directly bind to and act through 
this element. Therefore, the (-382/+50)-Luc and the (-59/-28)-tk-Luc constructs were 
again transfected into LNCaP cells and tested for glucocorticoid induction because 
any androgen response element is also fully or sometimes partially responsive to 
glucocorticoids (Fig. 4.5). As positive control the promoter of the prostate specific 
antigen (PSA) was used that contains a very strong androgen and glucocorticoid 
response unit (Cleutjens et al., 1997). Because the LNCaP cells do not contain 
endogenous glucocorticoid receptor an expression construct for GR was cotransfected. 
As Fig. 4.5 shows the PSA-Luc construct responded to androgens with a 230-fold 
increase in transcription of the reporter gene. With the glucocorticoid dexamethasone 
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the induction was still 110-fold. This represents the typical response pattern of a 
steroid hormone response unit and also demonstrated that the GR expression construct 
was able to express functional glucocorticoid receptor. Contrary to the results 
obtained with the PSA-Luc construct the SCGB 2A1 constructs (-382/+50)-Luc and 
(-59/-28)-tk-Luc did not at all respond to dexamethasone whereas they did respond to 
the androgen DHT as previously shown. Thus the dim-IR-GC box functions androgen 
specific. 
 
 
 
Fig 4.5 The SCGB 2A1 promoter does not respond to glucocorticoids. 
5 µg SCGB 2A1 (-382/+50)-Luc, (-59/-28)-tk-Luc and PSA-Luc constructs were 
transfected into LNCaP cells. 0.5 µg pRSV-GR were cotransfected as indicated. 
0.5 µg pRSV-β-gal were always cotransfected as internal standard. The cells were 
treated with 10-8 M DHT or 10-8 M DEX as indicated at the bottom. The fold 
induction of luciferase activity is shown after normalization for β-gal activity and 
protein amount. 
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4.5 DNase I footprints with nuclear extracts from LNCaP and HeLa cells identify 
three functional elements 
The transfection experiments with promoter deletion/reporter gene constructs showed 
that in the proximal promoter of the SCGB 2A1 gene at least two binding sites for 
positively acting transcription factors are located. In order to identify their positions 
and cognate regulatory factor candidates, DNase I footprinting experiments were 
performed with nuclear extracts from LNCaP cells grown in the presence or absence 
of DHT and from HeLa cells. Both strands of the -382/+50 Xho I/Kpn I promoter 
fragment were 3´-end labeled before DNase I footprinting reactions were set up (Figs. 
4.6 and 4.7). In the lower strand (Fig. 4.6) two strong footprints (from-186 to -155 and 
-136 to -109) were detected. The cognate binding proteins are of a ubiquitous nature 
because the same footprints are produced with HeLa nuclear extract. Another weak 
but LNCaP-specific footprint starts at position -36 and ends at an upstream position 
that could not be clearly identified (somewhere before -76). This weak footprint 
overlaps with the previously identified dim-IR-GC box.  
On the upper strand (Fig. 4.7) two strong footprints (from -178 to -156 and -129 to 
-104) were identified with LNCaP and HeLa nuclear extracts that were largely 
overlapping with the strong footprints of the lower strand. In the region of the 
dim-IR-GC box (-59 to -28) again no clear footprint could be detected, but in the 
vicinity of position -21 and within the TATA box an unusual and LNCaP-specific 
hypersensitive site is apparent (shown by an asterisk).  
None of the footprints was androgen dependent. The footprinted region -178 to 
-156 is missing in the (-136/+50)-Luc reporter construct that showed an 
approximately one third lower activity than the (-382/+50)-Luc construct that includes 
this element (Fig. 4.6).  
A search for transcription factor binding sites in the SCGB 2A1 promotor using 
the Transfac database and the programme MatInspector (http://transfac.gbf.de/ 
TRANSFAC/ or http://www.gene-regulation.com) clearly revealed the transcription 
factor NF-Y as the prime candidate being responsible for the footprint from -129 to 
-104 (upper strand) and -136 to -109 (lower strand) that overlaps a canonical 
CCAAT-box. For the element -178 to -156 (upper strand) and -186 to -155 (lower 
strand), Transfac came up with no clear candidate, but the similarity of the footprint 
core (TTGGA in the lower strand) with the nuclear factor 1 core sequence (TTGGC) 
suggested to test NF1 for causing this footprint.  
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Fig. 4.6 DNaseI footprinting of the -382/+50 SCGB 2A1 promoter fragment. 
The lower strand of the -382/+50 Xho I/Kpn I promoter fragment was 3′-end labeled 
at the upstream end. In lanes 1 and 10 Maxam-Gilbert G-reactions of the same 
fragment were applied. Per reaction 30 µg of nuclear extract were used from cells as 
indicated (lanes 4-9). No extract was used for samples 2 and 3 (naked DNA). For each 
extract two different amounts of DNase I were used as shown above each lane. 
Footprints are indicated on the right and the numbers refer to the distance from the 
start site of transcription. 
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Fig. 4.7 DNaseI footprinting of the -382/+50 SCGB 2A1 promoter fragment.  
The upper strand of the -382/+50 Xho I/Kpn I promoter fragment was 3′-end 
labeled at the downstream end. In lane 1 a Maxam-Gilbert G-reaction was 
applied. 30 µg of nuclear extract were used from cells as indicated (lanes 
4-12). No extract was used for samples 2 and 3 (naked DNA). For each 
sample two or three different amounts of DNase I were used as shown above 
each lane. Footprints are indicated on the right, and the numbers refer to the 
distance from the start site of transcription. The asterisk indicates a 
hypersensitive site. 
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4.6 The ubiquitous proteins NF-Y, NF1 and Sp family factors bind to the SCGB 
2A1 promoter in vitro 
In order to identify the factors binding to the three promoter elements previously 
characterized the most likely candidates were tested in Electophoretic Mobility Shift 
Assays (EMSAs) for in vitro binding. 
4.6.1 NF-Y binds to the CCAAT-box of the SCGB 2A1 promoter 
The previously reported footprint from –104 to –129 (upper strand) and from –109 to 
–136 (lower strand) includes a canonical CCAAT box. Therefore, the sequence from  
–100 to –124 was used as a probe (SCGB 2A1 NF-Y box, Table 4.1) in EMSAs with 
nuclear extracts from LNCaP and HeLa cells. As shown in Fig. 4.8, nuclear extract 
from HeLa cells (lane 11), from LNCaP cells grown in the absence of DHT (lane 12) 
or in the presence of DHT (lane 13) contain factor(s) that form a single DNA-protein 
complex band. This complex can be fully competed with a 50-fold molar excess of an 
unlabeled oligonucleotide that contains the well-characterized major 
histocompatibility complex class II Ea Y box (Caretti et al., 1999; lane 14). Full 
competition is also achieved with a 50-fold molar excess of the unlabeled SCGB 2A1 
NF-Y box (lane 15), whereas an SCGB 2A1 NF-Y box with two point mutations in its 
CCAAT-motif (lane 16) as well as an oligonucleotide with a random but defined 
sequence (lane 17) do not compete at all. Moreover, a polyclonal antibody directed 
against one of the three NF-Y subunits (CBF-A) was able to specifically supershift the 
complex (lane 18) whereas a rabbit preimmune serum was not (lane 19). 
Exactly the same picture was obtained with the Ea Y-box probe. HeLa nuclear 
extract (lane 2) or nuclear extract from LNCaP cells grown in the absence (lane 3) or 
presence of DHT (lane 4) do contain the ubiquitous factor NF-Y and produce the 
NF-Y DNA-complex that has the same mobility as the complex observed with the 
SCGB 2A1 NF-Y box. Competition and supershift results were also identical (lanes 
5-9). Therefore, it can be concluded that the SCGB 2A1 NF-Y box is a bona fide 
binding site for NF-Y in vitro. 
Table 4.1 Oligonucleotides used in NF-Y EMSAs 
SCGB 2A1 NF-Y box: 5′-AGCTGGCTGTGTTCCC ′ ATTGGTGTACACT-3
3′-CCGACACAAGGGTAACCACATGTGAAGCT-5′ 
Ea-Y box: 5′-AGCTGGCTGTTTTCTG ′ ATTGGTTAAAACT-3
3′-CCGACAAAAGACTAACCAATTTTGAAGCT-5′ 
SCGB 2A1 NF-Y mut: 5′-AGCTGGCTGTGTTCCCATGAGTGTACACT-3
3′-CCGACACAAGGGTA ′ CTCACATGTGAAGCT-5′ 
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Fig. 4.8 NF-Y is binding to the SCGB 2A1 promoter in vitro. 
An EMSA was performed with 4 µg of nuclear extract from HeLa and LNCaP cells 
grown in the presence (+) or absence (LNCaP) of DHT and the Ea-Y box (lanes 1-9) and 
the putative SCGB 2A1 NF-Y box (lanes 10-19) as probe. Competitions with unlabeled 
oligonucleotides were as follows: no competitor (lanes 1-4 and 10-13); Ea Y-box (lanes 5 
and 14); 2A1 NF-Y box (lanes 6 and 15); 2A1 NF-Y mut (lanes 7 and 16); an 
oligonucleotide of random sequence (lanes 8 and 17). NF-Y antibody is used in lanes 9 
and 18 for supershifts. The positions of free probe, NF-Y/DNA complex and supershifted 
complex are indicated on the right. 
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4.6.2 NF1 recognizes a binding site with one substitution in each canonical half 
site 
The DNase I footprints showed another strongly protected region from –156 to –178 
(upper strand) and –155 to –186 (lower strand). Inspection of this region using 
MatInspector predicted HNF3 beta, C/EBP and Oct 1 as candidates for the footprint 
causing transcription factor. But none of these factors could be identified in EMSAs 
using the sequence from –179 to –163 as a probe. Therefore, other candidates were 
looked for by eye. Because this sequence contained an inverted repeat with five 
intervening nucleotides and each half site had only one substitution compared to a 
canonical NF1 half site (see chapter 5.6), NF1 was tested in an EMSA (Fig. 4.9). The 
result shows that the probe produces a single protein-DNA complex when nuclear 
extracts from HeLa cells (lane 2) and from LNCaP cells grown in the absence (lane 3) 
or presence (lane 4) of DHT were used. Unlabeled SCGB 2A1 NF1 probe (lane 5) and 
an oligonucleotide containing a canonical NF1 binding site (lane 8) do compete for 
the formation of this complex, but an oligonucleotide of random but defined sequence 
as well as a mutant SCGB 2A1 NF1 probe containing two substitutions in the center 
of the core motif (lane 7) do not. This indicates that NF1 or a member of the NF1 
family indeed can bind to the element. Because the consensus NF1 probe competes 
better than the wild-type SCGB 2A1 NF1 probe, the affinity of NF1 to the SCGB 2A1 
NF1 element is lower than to the consensus element. Furthermore, the recombinant 
NF1 DNA-binding domain is also able to bind to the SCGB 2A1 NF1 probe, but 
because the molecular weight of this truncated NF1 protein is smaller than the 
wild-type protein the cognate protein-DNA complex has a higher mobility (lane 9).  
 
 
Table 4.2 Oligonucleotides used in NF1 EMSAs 
SCGB 2A1 NF1 element: 5′-AGCTAGA AGGGA ATA-3′ TTGTC TCCAA
3′-TCTAACAGTCCCTAGGTTTATAGCT -5′ 
Canonical NF1 element: 5′-CCTTTGGCACTGTGCCAAAG-3′ 
3′-GAAACCGTGACACGGTTTCC-5′ 
SCGB 2A1 NF1 mut: 5′-AGCTAGATTGTCAGGGATAAAAATA-3′ 
3′-TCTAACAGTCCCTATTTTTATAGCT -5′ 
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Fig. 4.9 NF1 is binding to the SCGB 2A1 promoter in vitro.  
An EMSA was performed with the putative SCGB 2A1 NF-1 binding site. The probe 
was incubated without (lane 1) or with 4 µg of nuclear extract from HeLa (lane 2) or 
LNCaP cells grown in the presence (lanes 4-8) or absence of DHT (lane 3). 
Competitions were performed with: unlabeled probe (lane 5), oligonucleotide of 
random sequence (lane 6), a mutant probe (lane 7) and a canonical NF1 probe (lane 
8). In lane 9, 25 ng of a truncated NF1 protein that contains the DNA-binding domain 
only were used. 
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4.6.3 Sp family proteins recognize a dimeric inverted repeat type GC box 
Initially when promoter fragments terminating at upstream position –53 were 
transferred to the tk promoter androgen responsiveness could not be restored in gene 
transfer experiments with LNCaP cells (Fig. 4.4). Therefore, new constructs were 
tested with an SCGB 2A1 promoter endpoint at –28, immediately upstream of the 
TATA box, which were indeed able to confer androgen responsiveness to the tk 
promoter. This result strongly indicated that the region from somewhere around –53 
up to –28 is responsible for androgen sensitivity. Close inspection revealed an 
extended inverted repeat, with each half site of the repeat having homology to the 
GC box. Accordingly, this complex element was called a dimeric inverted repeat 
GC box (dim-IR-GC box). Surprisingly, it appeared as if ubiquitous factors were 
responsible for mediating the hormone response.  
In an EMSA it was investigated if Sp family proteins indeed can bind to the 
dim-IR-GC box in vitro (Fig. 4.10). With nuclear extracts from HeLa or LNCaP cells 
grown in the presence or absence of DHT the typical protein-DNA complex pattern of 
the Sp family, consisting of three major bands, appears when either a consensus GC 
box (lanes 10-13) (Suske, 1999) or the SCGB 2A1 dim-IR-GC box (lanes 1-4) is used 
as a probe. When an oligonucleotide probe of random but defined sequence is used in 
50-fold molar excess no competition is observed (lanes 5 and 14) with either probe. 
But the unlabeled GC box fully competes with the formation of Sp-DNA complexes 
on the dim-IR-GC box (lane 6), and the unlabeled dim-IR-GC box strongly competes 
with the formation of Sp-DNA complexes on the GC box (lane 15). Direct competitor 
comparisons (not shown) indicated that the affinity of Sp factors to the dim-IR-GC 
box is lower than to the consensus GC box.  
The use of antibodies directed against the two most common ubiquitous Sp factors 
Sp1 and Sp3 (a gift of Guntram Suske, University of Marburg) unequivocally showed 
that the observed DNA-protein complexes do contain the two proteins. Rabbit anti 
Sp1 antiserum is able to supershift the upper complex band of the Sp1/Sp3-DNA 
double band (lanes 7 and 16). Likewise rabbit anti Sp3 antiserum was able to 
supershift the lower complex band of the mentioned double band (lanes 8 and 17) as 
well as a complex band of lower mobility. The latter one is due to short Sp3 isoforms 
that originate from internal start codons (Kennett et al., 1997; Suske, 1999). Both 
antisera together supershift all oberserved major complex bands (lanes 9 and 18). All 
supershifts are more complete with the dim-IR-GC-box than with the consensus GC 
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box, demonstrating again that the affinity of Sp1 and Sp3 for the dim-IR-GC box is 
lower than for the consensus GC box. 
In order to find out if both GC boxes of the dim-IR-GC box do equally contribute 
to Sp factor binding three mutant oligonucleotide probes with three substitutions in 
either the distal, the proximal or both GC boxes (Table 4.3) were tested in EMSAs 
(Fig. 4.11). Three guanines in each GC box were substituted for thymines in order to 
fully abrogate Sp factor binding to the mutated GC box. The distal GC box mutant 
only had a moderate negative effect on the binding of Sp1 and Sp3 (lane 2), whereas 
the proximal GC box mutant had virtually no effect (lane 3). Contrary to the single 
box mutants the double GC box mutant displayed a complete loss of Sp factor binding 
(lane 4). Instead of the three Sp/DNA complex bands another less sharp band is 
observed with similar mobility as the smaller Sp3 isoform/DNA complex. But the 
addition of a mixture of Sp1 and Sp3 antisera could not supershift this band, 
excluding the presence of Sp factors in this apparently unspecific complex (lane 5). 
Therefore, both GC boxes synergistically contribute to the observed binding of Sp 
factors to the dim-IR-GC box, but the distal GC box seems to have a dominant role. 
 
Table 4.3 Oligonucleotides used in dim-IR-GC box EMSAs 
SCGB 2A1 dim-IR-GC box 
 5′-TCGAATTCCT ′ GGGAGGGACTAAGGTGCCTCCCTGGGGA-3
3′-TAAGGACCCTCCCTGATTCCACGGAGGGACCCCTAGCT-5′ 
GC box 
 5′-AGCTTCCGTTG ′ GGGCGGGGCTTCACG-3
3′-AGGCAACCCCGCCCCGAAGTGCTCGA-5′ 
Distal GC box mut 
 5′-TCGAATTCCTTTGAGTGACTAAGGTGCCTCCCTGGGGA-3
3′-TAAGGA ′ AACTCACTGATTCCACGGAGGGACCCCTAGCT-5′ 
Proximal GC box mut 
 5′-TCGAATTCCTGGGAGGGACTAAGGTGACTCAATGGGGA-3
3′-TAAGGACCCTCCCTGATTCCAC ′ TGAGTTACCCCTAGCT-5′ 
Double GC box mut 
 5′-TCGAATTCCTTTGAGTGACTAAGGTGACTCAATGGGGA-3
3′-TAAGGA ′ AACTCACTGATTCCACTGAGTTACCCCTAGCT-5′ 
The sequences of the oligonucleotides used in EMSAs are listed, and the core 
motifs are shown in bold, the mutation sites are underlined. 
 
 70
Results 
 
Fig. 4.10 The dim-IR-GC box is a binding site for Sp family proteins in vitro. 
4 µg of the indicated nuclear extracts were incubated with the SCGB 2A1 dim-IR-GC 
box (lanes 2-9) and a canonical GC box probe (lanes 11-18). Competitions with 
unlabeled oligonucleotides were as follows: no competitor (lanes 1-4 and 10-13); 
oligonucleotide of random sequence (lanes 5 and 14); GC box (lane 6); dim-IR-GC 
box (lane 15). Anti Sp1 and Sp3 antibodies were used in lanes 7-9 and 16-18 as 
indicated. Sp factor-DNA complexes and supershifts are indicated on the right. 
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Fig. 4.11 Distal and proximal GC box of the dim-IR-GC box synergistically 
contribute to Sp factor binding. 
Different wild type and mutant dim-IR-GC box probes were used in an EMSA with 
nuclear extract from LNCaP cells grown in the presence of DHT. The sequences of 
oligonucleotides used are provided in Table 4.1. All probes had the same length (42 
nucleotides) after filling in with Klenow enzyme. Anti Sp1 and Sp3 antisera were 
added in lane 5. 
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4.7 NF-Y is functionally important for basal promoter activity whereas binding 
of NF1 participates in and binding of Sp factors mediates the androgen 
response 
Previously Electrophoretic Mobility Shift Assays showed that NF-Y, NF1 and Sp 
factors do bind to cognate elements of the SCGB 2A1 promoter in vitro. In order to 
demonstrate that the binding of these factors is also functionally relevant, mutations 
were introduced into each factor binding site. Promoter fragments carrying those 
mutations were cloned in front of the luciferase reporter gene and transfected into 
LNCaP prostate cells (Fig. 4.12).  
For NF-Y, which was shown to bind to the promoter’s CCAAT box, the CCAAT 
core sequence was mutated to CTCAT. An oligonucleotide containing this mutated 
sequence was no longer able to compete for the NF-Y/CCAAT box complex (Fig. 4.8, 
lanes 7 and 16). The same two point mutations introduced into the SCGB 2A1 
promoter terminating at –136 lead to an approximately 30% decrease in reporter gene 
activity under basal conditions (no hormone added) as well as under induced 
conditions (DHT added). The same result is obtained when the mutations were 
introduced into the promoter terminating at –382 (Fig. 4.12). Therefore, NF-Y seems 
to be generally required for promoter activity but not for hormone induction.  
For NF1 the core of the identified binding site was mutated from TTGGA to 
TTTTA in the context of the promoter terminating at -382. These two point mutations 
also abrogate NF1 binding as shown by an EMSA (Fig. 4.9) in which an 
oligonucleotide containing the mutated sequence was no longer able to compete for 
the NF1/DNA complex (lane 7). Abrogation of NF1 binding leads to a some 40% 
decrease in induced transcription but to a slight increase in basal transcription (Fig. 
4.12). Thus, NF1 seems to be involved in transmitting the hormone response. The 
activities of the –136/+50 wild type promoter and the –382/+50 promoter containing 
the NF1 mutations at around position –175 are very similar. This indicates that the 
SCGB 2A1 promoter from –136 up to –382 does contain only one functionally 
important positive element which is the NF1 binding site. 
In order to investigate the functional importance of the dim-IR-GC box, the same 
mutations that were used in investigating DNA-binding in EMSAs (Table 4.3) were 
introduced into the promoter extending from –382 to +50 (Fig. 4.12). Mutation of the 
distal GC box, which has a moderate effect on Sp factor binding (Fig. 4.11, lane 2), 
has a dramatic effect on hormone induced transcription of the reporter gene (Fig. 4.12) 
leading to a 75% decrease in expression (down to 6-fold induction upon addition of 
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hormone). Mutation of the proximal GC box, that has virtually no effect on Sp factor 
binding (Fig. 4.11, lane 3), still leads to a moderate decrease in DHT induced 
expression of the reporter (down by 55%, 11-fold induction left). When both GC 
boxes are mutated, which leads to abrogation of Sp factor binding (Fig. 4.11, lane 4), 
the hormone response of the mutated reporter is almost abolished (Fig. 4.12, 2-fold 
induction left). All mutants only have a weak effect on the basal expression level, with 
the double mutant showing the biggest effect (50% decrease).  
These transfection results identify binding of Sp factors to the dim-IR-GC box as 
being functionally required for mediating the androgen response of the SCGB 2A1 
gene. 
 
Fig 4.12 Binding of NF1, NF-Y and Sp factors is functionally important for 
SCGB 2A1 promoter activity and androgen induction.  
The left panel provides a schematic representation of the SCGB 2A1 reporter 
constructs. The NF-1 binding site is symbolized by a filled circle, the NF-Y binding 
site by a filled square and the distal and proximal GC boxes of the dim-IR-GC box are 
indicated by arrows. Mutations are indicated by a cross or vertical bars. Numbers 
refer to the position relative to the transcription start site. Please note that the –53/+50 
construct is truncated within the distal GC box. 
The right panel shows the cognate luciferase assay results. LNCaP cells were 
transiently transfected with 5 µg of the indicated construct and co-transfected with 0.5 
µg of pRSV-β-gal as internal standard. The cells were treated with 10-8 M DHT as 
indicated. The assay results were normalized for β-gal activity and protein amount as 
described in Materials and Methods. 
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4.8 Expression and purification of SCGB 2A1 and preparation of a rabbit 
antiserum 
For immunohistochemical investigations Robert Lehrer, UCLA, U.S.A, kindly 
provided two rabbit polyclonal anti SCGB 2A1 antibodies that were directed against 
different peptides of the protein (C1 against: KLLEDMVEKTINSDIS, C2 against: 
DSDAAAEAMGKFKQ). Unfortunately, none of them was sensitive enough in 
immunostaining, so that they could not be utilized. Therefore, the coding sequence of 
SCGB 2A1 starting with GGC for glycine 21 of the pro-protein was cloned into the 
bacterial expression vector pRSETB (see chapter 3.2.14.1), and the His-tagged protein 
was expressed in E. coli BL21 (DE3). Fig. 4.13 shows that after three hours of IPTG 
induction the fusion protein has become the major bacterial protein. His-tagged SCGB 
2A1 was expressed in a 500 ml preparative culture, purified over a Ni-NTA agarose 
column and renatured by dialysis. The native purified protein was used in a standard 
immunization protocol for one rabbit (see chapter 3.2.15). 
 
 
Fig. 4.13 Optimization of expression conditions. 
A culture of E. coli BL21 (DE3) harboring the SCGB 2A1 expression plasmid 
was induced with 0.5 mM IPTG at 37°. At various time points cells were 
harvested, lysed in SDS loading buffer and loaded on a 18% SDS-PAGE. After 
electrophoresis the gel was stained overnight with a colloidal Coomassie 
solution. 
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The polyclonal anti His-tagged SCGB 2A1 antiserum was generated by a standard 
immunization and boost programme with the purified protein (chapter 3.2.15). The 
purified protein was characterized in a Western blot using the C2 anti-peptide 
antibodies (Figure 4.14, panel A) and later on in comparison with the generated 
polyclonal antiserum directed against recombiant full length SCGB 2A1 (Figure 4.14, 
panel B). Bacterially expressed (lane 2) as well as native protein from tear fluid (lane 
3) always appear as a characteristic double band with the band of lower mobility 
being most likely a protein dimer.  
 
 
Fig. 4.14 Western blot analysis of recombinant SCGB 2A1. 
(A) 10 ng of recombinant His-tagged SCGB 2A1 were run on a 15% 
SDS-PAGE (lane 1). The blot was developed with the polyclonal rabbit 
antiserum C2 directed against the peptide DSDAAAEAMGKFKQ (gift of 
Robert Lehrer). (B) 10 ng of recombinant His-tagged SCGB 2A1 (lane 2) 
were run together with 5 µl of tear fluid (lane 3) on a 15% SDS-PAGE. 
This blot was developed with the newly generated polyclonal rabbit 
antiserum. The higher molecular weight band most likely is a protein 
dimer. Due to His-tagging the recombinant protein (lanes 1 and 2) has a 
higher molecular weight than the native protein (lane 3).  
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4.9 Localization of SCGB 2A1 in prostate tissue 
The generated anti human SCGB 2A1 antiserum was used to investigate SCGB 2A1 
expression in different developmental and pathological stages of the prostate (Fig. 
4.15). Immunohistochemical staining was performed with 6 months fetal and adult 
prostate tissue sections, as well as with sections from a benign prostate hyperplasia 
and a prostate cancer. Distinct labeling of the basal cells and the apical plasma 
membrane of the epithelial secretory cells is observed in fetal (A) and adult (B) 
prostate tissue, and in the prostate cancer section (D, E), whereas the BPH section 
showed no immunoreactivity (C). In order to visualize the BPH sample, 
immunostaining was performed with an anti-myosin antibody (Dianova, Hamburg) (G) 
and nucleic acids were stained with DAPI (H) on sections derived from the same 
paraffin-embedded BPH tissue sample.  
Prostate cancer derived LNCaP cells do express SCGB 2A1 and show strong and 
diffuse cytoplasmic immunoreactivity, whereas HeLa cells only show a slight increase 
in background labeling (Fig. 4.16). 
 
A B 
C D 
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 Fig. 4.15. Immunohistochemical localization of SCGB 2A1 in prostate tissue sections. 
Paraffin embedded prostate tissue sections were immunostained with the anti-SCGB 2A1 
polyclonal rabbit antibody followed by a Cy 3-labeled anti-rabbit secondary antibody. (A) 
Fetal prostate (original magnification 200×), ducts have small lumina or are closed yet and 
appear as cell clumps. (B) Adult tissue (original magnification 200×), duct lumina are large 
and regular. (C) Benign Prostate Hyperplasia (original mgnification 200×), ducts are 
invisible on this section. (D, E) Prostate Carcinoma (original magnification in D is 200×, and 
E shows a 600× magnification of the lower left gland visible in D). Size, shape and spacing 
of ducts are irregular. (F) Negative control with preimmune-serum as first antibody on the 
adult tissue. All negative controls on other sections looked like in F for example. 
Benign Prostate Hyperplasia tissue sections: (G) Proliferated stromal muscle cells were 
stained around the ducts with an anti-myosin antibody followed by a Cy 2-labeled anti-rabbit 
secondary antibody. (H) Nucleic acids were stained with DAPI. 
The basal cells (open arrows) and the apical plasma membrane of secretory cells (closed 
arrows) are intensely labeled in the fetal gland, in normal glandular epithelium, and in cancer 
tissue, whereas the BPH section shows no immunoreactivity. 
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Fig. 4.16. Immunohistochemical staining of SCGB 2A1 in LNCaP and HeLa cells. 
Cells were grown in tissue culture on a coverslip, fixed by acetone/methanol (50%/50%, 
v/v) and immunostained with the anti-SCGB 2A1 polyclonal rabbit antibody followed 
by a Cy 3-labeled anti-rabbit secondary antibody. 
(A) LNCaP cells show an intense cytoplasmic immunoreactivity. (B) Negative control 
with preimmune antiserum as first antibody. (C) HeLa cells show no specific 
immunoreactivity. (D) HeLa cells, negative control. (The original magnification is 600× 
for all micrographs). 
 
 
 79
Discussion 
5. DISCUSSION 
5.1 Expression of SCGB 2A1 in the prostate 
The prostate gland surrounds the urethra at the base of the bladder and contributes 
some 30% in volume to the seminal fluid. In adult humans the prostate has the size of 
a chestnut, lacks discernible lobular organization and consists of 30-50 branched 
tuboalveolar glands. The prostate is a prime androgen target that requires testosterone 
for growth, development, differentiation and function. 
Within the prostatic epithelium (see Figure 5.1) are at least three distinct cell types 
that can be distinguished by morphological and functional characteristics. The 
predominant cell type is the luminal cell, a differentiated androgen dependent cell 
type that produces secretory prostate-specific proteins like acid phsophatase, prostate 
specific antigen, IgA and transferrin. At the molecular level, luminal cells are 
characterized by expression of androgen receptor, cytokeratins 8 and 18 and the cell 
surface marker CD57 (Verhagen et al., 1988; Sherwood et al., 1990). The second 
major epithelial cell type is the basal cell, which is found between the luminal cells 
and underlying basement membrane and forms a continuous layer. The basal cells can 
be identified by the marker proteins cytokeratin 5 and 14, CD44, as well as androgen 
receptor (Verhagen et al., 1988; Sherwood et al., 1990). Finally, the third cell type is 
the neuroendocrine cell, a minor population of uncertain developmental origin, which 
is believed to provide paracrine signals that support the growth of luminal cells (Bui 
and Reiter, 1998; De Marzo et al., 1998). Neuroendocrine cells are androgen 
independent, dispersed throughout the basal cell layer and express chromogranin A, 
serotonin and various neuropeptides (Di Sant’Agnese, 1992; Di Sant’Agnese, 1995). 
 
Fig. 5.1 Schematic depiction of the 
cell types within a human prostatic 
duct (from Abate-Shen and Shen, 
2000).  
Note that the rare neuroendocrine cells 
are morphologically indistinguishable 
from basal cells. 
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Based on observations that some transient populations of prostatic epithelial cells 
having both basal and luminal characteristics (Verhagen et al., 1992; Bonkhoff et al., 
1994), it was proposed that there exists a stem cell reservoir within the prostatic 
epithelium. This stem cell compartment represents a subpopulation of androgen 
independent basal cells. These stem cells would give rise to a transiently proliferating 
compartment composed of pluripotent androgen responsive cells that in turn generate 
the prostatic basal cells, differentiated luminal cells and possibly also the 
neuroendocrine cells (Bonkhoff and Remberger, 1996; De Marzo et al., 1998). But 
some other studies support the hypothesis that the neuroendocrine cells are derived 
from a second prostatic stem cell lineage, different from the urogenital sinus lineage 
(Aumüller et al., 1999; Aumüller et al., 2001). This dual stem cell compartment 
theory would overcome a number of findings that are difficult to explain by a single 
stem cell compartment, such as constant and low number of neuroendocrine cells, 
their asymmetric distribution within the gland, and their androgen insensitivity. 
In the prostate expression of SCGB 2A1 has been localized to the epithelial cells 
lining the secretory ducts by in situ hybridization (see chapter 4.1.1). Immunostaining 
experiments further localized SCGB 2A1 expression to both the glandular luminal 
cells and the basal cells (see chapter 4.9). Expression in basal cells is an unusual 
finding because only the luminal cells have been shown to express the 
prostate-specific secretory proteins investigated so far. But one study could show that 
basal cells isolated by differential cell sorting can produce prostatic secretory proteins 
when cocultured with stromal cells (Liu et al., 1997). Due to the fact that the basal 
cells are also androgen sensitive it would be no surprise to find some proteins that are 
secreted by the luminal cells also being expressed by the basal cells. It would be 
interesting now to immunostain SCGB 2A1 in combination with other basal and 
luminal cell specific markers in order to confirm this point. 
In prostate tissue sections the expression of SCGB 2A1 was observed in different 
specimens including fetal gland, normal adult gland and prostate cancer, whereas the 
benign prostate hyperplasia (BPH) is negative (see chapter 4.9). 
Unlike the adult prostate, the fetal prostate is under the influence of maternal 
placental hormones, as well as of the hormones produced by the fetus itself. 
Beginning in week 10 of gestation the prostate begins to develop under the action of 
fetal androgens. SCGB 2A1 protein is already detectable in the 6-month fetal prostate 
similar to other differentiation markers like estrogen receptor beta and PSA (Adams et 
al., 2002). 
 81
Discussion 
In benign prostatic hyperplasia (BPH), proliferation of stromal and activated 
smooth muscle cells plays an important role in the induction and progression of the 
disease. In figure 4.15 (G), it can be seen that the fibromuscular stroma invades the 
basal cell layer and the zone of secretory epithelial cells which confirms that the tissue 
slide showing no reactivity with SCGB 2A1 antiserum (Fig. 4.15 (C)) was indeed a 
BPH tissue slide. Genes that are expressed in the prostate can be sorted into two 
groups. They are either expressed in normal prostate tissue, BPH as well as prostate 
cancer or are expressed in normal prostate tissue, only weekly expressed in BPH and 
not at all expressed in prostate cancer, so that there is a correlation with differentiation 
status. But in case of SCGB 2A1 expression is observed in normal and cancer tissue 
whereas expression in BPH is lacking. If this result can be confirmed with a larger 
number of BPH samples, SCGB 2A1 would have a potential for becoming a 
diagnostic marker in the differentiation of BPH versus prostate cancer. 
Whereas in many cancers differentiation markers of the originating cell type are 
no longer detectable, in the very slow growing prostate cancer typical marker proteins 
continue to be expressed. The paradigm of such a marker is PSA that is similarly 
expressed in normal prostate tissue, BPH and cancer tissue and is the main test in the 
management of prostate cancer (Gelmini et al., 2003). Because PSA concentrations 
relate to age, prostate size, and the presence of prostate cancer, but can also be raised 
after ejaculation, riding a bike, prostate biopsy, surgery, or prostatitis, the validity of 
PSA as diagnostic marker is much under discussion (Frankel et al., 2003). Like PSA 
SCGB 2A1 is also expressed in prostate cancer, and due to its different mode of 
regulation by androgens it might be interesting to compare its expression in androgen 
dependent versus androgen independent cancers. 
5.2 SCGB 2A1 is a new target gene for androgens in the prostate with a different 
kinetics of mRNA induction than the gene encoding prostate specific antigen 
When LNCaP cells are treated with 10-8 M DHT over 24 hours expression of steady 
state SCGB 2A1 mRNA levels increase slowly. Compared to a low but detectable 
basal expression in the absence of androgens, the maximum SCGB 2A1 mRNA level 
in the presence of DHT (21-fold increase over basal) is obtained after six hours and 
stays that high for at least 24 hours (Fig. 4.1). This response identifies SCGB 2A1 as a 
new class of androgen target gene in the prostate. Although many androgen-regulated 
genes have been identified, for most of them only limited information on the 
mechanism of regulation is available. In a few genes functional androgen response 
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elements (AREs) mediating a direct genomic action of the androgen receptor have 
been characterized. Among the genes that have been studied in most detail are the rat 
prostatic binding protein subunit C3(1) (Claessens et al., 1990) and the human prostate 
specific antigen (PSA, also called kallikrein 3, hKLK3) gene (Cleutjens et al. 1996; 
Cleutjens et al., 1997; Riegman et al., 1991). Because the PSA gene has also been 
investigated extensively in LNCaP cells, the promoter of this gene was used here as 
an example of direct genomic control of the androgen receptor. The PSA promoter 
contains two functionally active androgen response regions, an enhancer region at 
–4.2 kb and a promoter region in the proximal 400 bp (Cleutjens et al., 1996; 
Cleutjens et al., 1997). The latter only provides a low level of androgen regulation 
(4-6 fold induction) dependent on the presence of two AREs, ARE-I at –170 bp and 
ARE-II at –394 bp. ARE-III, presumably together with other still unknown elements 
in the enhancer for full androgen regulation (some 3000-fold induction). ARE-I and 
ARE-III closely resemble the ARE consensus sequence, whereas ARE-II is a low 
affinity AR binding site deviating considerably from the consensus sequence. In the 
absence of androgen, PSA mRNA is expressed at a low basal level in LNCaP cells 
when analyzed by Northern blotting with total RNA (Wolf, D.A. et al., 1992). But in 
the presence of 3.3 nM synthetic androgen mibolerone, the PSA mRNA level rises 
continuously within 4-72 hours. In the presence of 1 nM synthetic androgen R1881, 
mRNA levels reached the maximum level already after 24 hours (Riegman et al., 
1991). Another example for a gene that is under direct genomic control of the 
androgen receptor in the prostate is the human prostate-specific glandular kallikrein-1 
(hKLK2). hKLK2 mRNA is not detectable in LNCaP cells in the absence of hormone 
when analyzed by Northern blotting (Young et al., 1992). But in the presence of 3 nM 
mibolerone the steady state hKLK2 mRNA level rises continuously, very similar to the 
PSA message, from 5-24 hours. Compared to PSA and hKLK2 the kinetics of SCGB 
2A1 induction is different because the steady state mRNA level in the presence of 
androgen is rising faster and reaches its maximum already after 6 hours. The steady 
state mRNA level is mainly determined by the rate of transcription initiation and the 
mRNAs half life. In case of PSA androgens strongly induce transcription initiation in 
less than 3 hours as determined by nuclear run-on assays. Run-on acitivity decreases 
already after 24 hours whereas steady state levels continue to increase up to 72 hours. 
This was explained by showing that the PSA mRNA half life is considerably increased 
in the presence of hormone (Wolf, D.A. et al., 1992). Therefore, the comparatively fast 
androgen response seen in the SCGB 2A1 Northern could be explained by a short 
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mRNA half life in the absence of hormone combined with a strong and fast androgen 
effect on mRNA stability.  
5.3 The kinetics of androgen induction of a DNase I hypersensitive site in the 
SCGB 2A1 promoter indicates an indirect non-genomic hormone response 
The control regions in a gene can often be localized by mapping DNase I 
hypersensitive sites (DH sites). Genes contain discrete sequences of DNA that are 
sensitive to DNase I cleavage in chromatin, and the pattern of these so-called 
hypersensitive sites changes depending on the activation state of the gene (Weintraub 
and Groudine, 1976). By comparing the pattern of hypersensitive sites obtained by 
cleavage of a non-induced gene with that obtained when the gene is actively 
transcribed or induced, regions that participate in gene regulation can be identified. A 
major strength of this approach is that it makes no a priori assumptions about the 
locations of control sequences and allows a quick investigation of several kb of DNA 
for potential regulatory sequences. 
During interphase of the eukaryotic cell cycle, the bulk of DNA is assembled into 
highly folded nucleoprotein filaments. This is even true for euchromatic regions of the 
genome which are actively undergoing RNA transcription, DNA replication, DNA 
repair or recombination. Today we know that these processes can function efficiently 
in the chromatin environment due to the actions of two classes of highly conserved 
chromatin remodelling enzymes. The first class includes enzymes that covalently 
modify the nucleosomal histones (e.g. by acetylation, phosphorylation, methylation 
and ADP-ribosylation) and, at least in the case of histone acetylation by histone acetyl 
transferases (HATs), these covalent modifications can destabilize the folding of 
nucleosomal arrays and promote RNA transcription (Fischle et al., 2003) The second 
class of enzymes is composed of multi-subunit complexes (like SWI/SNF etc.) that 
use the energy of ATP hydrolysis to disrupt histone-DNA interactions and thus modify 
chromatin structure (Peterson, 2000). Independent of the exact mechanism that leads 
to a change in chromatin structure, mapping of DNase I hypersensitive sites is ideally 
suited to identify potential regulatory regions in an unknown target gene as a first step 
in promoter analysis. 
There are in general two possibilities to map hypersensitive sites. The most 
popular one, that was also used here, involves the isolation of nuclei from cells or 
tissue of interest followed by incubation of the intact nuclei with varying amounts of 
DNase I (Cockerill, 2000). Alternatively cells of interest can be permeabilized and 
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then treated directly with DNase I without prior isolation of nuclei (Aasland and 
Stewart, 1999). 
Having shown that SCGB 2A1 is expressed androgen-dependent in LNCaP cells, 
DH sites were mapped in the absence and presence of hormone. Within a 10 kb Xba I 
fragment encompassing the SCGB 2A1 gene including 3 kb upstream of exon 1 and 
3.3 kb downstream of exon 3 an androgen dependent DH site appeared in the 
proximal promoter at position –100 bp +/- 50 bp. A time course experiment revealed 
that it takes six hours of hormone treatment until the DH site becomes maximally 
accessible for DNase I. Compared to other steroid hormone dependent DH sites in 
other genes this androgen response in the SCGB 2A1 gene appears rather delayed. By 
using chromatin immunoprecipitation it was shown that androgen induces robust 
recruitment of androgen receptor, members of the p160 coactivator family, 
CREB-binding protein/p300 and RNA polymerase II specifically to the enhancer of 
the PSA gene within 30 min (Louie et al., 2003; Jia et al., 2003). Therefore it appears 
that a promoter which is under direct genomic control of the androgen receptor or a 
different steroid hormone receptor does respond to a hormone signal in less than 60 
min when DH sites, run on transcription (Adom et al., 1991) or receptor recruitment 
are measured. But the kinetics of DH site induction by androgen in the SCGB 2A1 
promoter does not fit into this picture because after one hour of induction with DHT 
no hypersensitivity could be observed. This observation led to the hypothesis that its 
androgen response could be mounted by a non-genomic, non-ARE-mediated indirect 
mechanism. 
5.4 Promoter deletion analyses identify a dimeric inverted repeat GC box as the 
“androgen responsive element” 
Reporter gene constructs that were under the control of SCGB 2A1 promoter 
fragments terminating between –1476 and –575 were induced approximately 11-fold 
by the androgen DHT in LNCaP cells (Fig. 4.3). When the promoter was shortened to 
position – 382 the induction level was roughly doubled to 23-fold indicating the loss 
of a negatively acting element. It is known that eukaryotic transcription is regulated 
not only by activators but also by repressors. Many eukaryotic genes are subject to 
both repression and activation. Most eukaryotic repressors are also modular proteins. 
Similar to activators, they usually contain a single DNA-binding domain, one or a few 
repression domains, and can control transcription when they are bound at sites 
hundreds to thousands of base pairs from a start site. 
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Further shortening the promoter to position –136 again reduced the induction level 
to 15-fold indicating that a positively acting element is located between –382 and 
–136. Because the low basal transcription level is also somewhat reduced when the 
two constructs (–382/+50)-Luc and (–136/+50)-Luc are compared, it is not clear from 
these experiments if this element has a positive effect on both basal and induced or 
mainly on induced transcription.  
When the promoter fragment (–53/+50) was tested in transfections with LNCaP 
cells androgen induction was abolished. Therefore, androgen responsiveness is 
located in the fragment –136 to –53 which coincides with the position of the androgen 
inducible DNase I hypersensitive site (see Fig. 4.4, upper panel).  
In order to evaluate the contribution of the androgen receptor in androgen 
induction bicalutamide (Casodex, ICI 176334) was used as a specific inhibitor of the 
androgen receptor in LNCaP cells (Veldscholte et al., 1992a). This compound is the 
most widely used competitive AR antagonist and was shown to stabilize AR 
association with cytosolic heat shock protein complexes in LNCaP cells preventing 
nuclear translocation (Veldscholte et al., 1992b). In a recent study using prostate 
cancer tissue it was shown that bicalutamide-liganded AR can translocate into the 
nucleus. Moreover, specific DNA binding by the bicalutamide-liganded AR was 
demonstrated in vivo using a VP16-AR fusion protein and was confirmed by 
chromatin immunoprecipitation. Nonetheless, bicalutamide could not stimulate 
interactions between the AR N and C termini or recruitment of steroid receptor 
coactivator proteins. Apparently bicalutamide stimulates the assembly of a 
transcriptionally inactive AR on DNA (Masiello et al., 2002). Because bicalutamide 
was able to abrogate DHT induced reporter gene expression in LNCaP cells 
transfected with the two constructs (–382/+50)-Luc and (-136/+50)-Luc it can be 
concluded that the androgen recpetor is required for mediating the hormone response. 
In order to investigate if the androgen responsive region acts as an autonomous 
element, the fragment (–136/–53) was cloned in front of the Herpes simplex virus 
thymidine kinase promoter (HSV-tk) and tested in gene transfer experiments (see 
chapter 4.3, lower panel). The tk promoter used in these experiments terminated at 
position -90 and contained one GC box and the TATA box and was slightly inducible 
by androgens by a factor of 2-3 fold. Because the resultant (–136/-53)-tk-Luc 
construct as well as the (–382/-53)-tk-Luc construct were not more inducible than the 
tk basic construct itself, the length of the SCGB 2A1 promoter fragment was extended 
another 25 bp up to position –28 in order to exclude that the “androgen responsive 
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element” was destroyed at the proximal border (-53). Surprisingly, androgen 
responsiveness is restored in the constructs (–136/-28)-tk-Luc and (–382/-28)-tk-Luc 
demonstrating that indeed the “androgen responsive element” overlaps with 
position –53. The level of androgen inducibility is comparable to the longer SCGB 
2A1 promoter luciferase constructs. As minimal fragment that was able to confer this 
level of androgen inducibility to the tk promoter the fragment (–59/-28) was identified 
that is shown in Fig. 5.2. 
 
Fig. 5.2 Sequence of the dim-IR-GC box in comparison to the GC box 
consensus and the ARE consensus.  
A distal and a proximal GC box are oriented as an inverted repeat with 
4 intervening nucleotides. The two half sites containing the GC boxes are 12 bp 
long (indicated by arrows) and slightly exceed the length of a GC box (9 bp, 
each of 3 zinc fingers contacting 3 nt each). Both repeats are almost identical 
with 2 substitutions. A consensus GC box and consensus ARE (HRE) are shown 
for comparison. Numbers refer to the position of the start point of transcription. 
A close look at the sequence of this minimal fragment immediately revealed its 
extended palindromic nature. Both half sites are 12 bp long separated by 4 bp 
intervening sequence (see Fig. 5.2). The sequence of both half sites deviates in only 2 
positions and is very GC rich. Although a canonical androgen response element 
(ARE), defined as a binding site for the androgen receptor (AR), is of an inverted 
repeat type (i.e. palindromic) with three intervening arbitrary nucleotides (Beato, 1989) 
the identified androgen response element, defined as an element that confers an 
androgen response, shows no resemblance to such a classical ARE. An AR binding site 
is not specific for the androgen receptor but is also recognized by glucocorticoid, 
progesterone and mineralocorticoid receptors (Beato, 1989) and, hence, is often called 
more general a hormone response element (HRE). But in case of the androgen receptor 
a few peculiar receptor-selective HREs have been described (Claessens et al., 2001) 
which are characterized by being non-palindromic and of a direct repeat type. 
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Therefore, from sequence comparisons it is very unlikely that the SCGB 2A1 ARE is a 
binding site for the androgen receptor. Instead, it’s GC content and the GGACCC core 
motif of each half site immediately suggested that both half sites are GC boxes and, 
thus, binding sites for Sp family transcription factors (Suske, 1999). Hence, the SCGB 
ARE was named a dimeric inverted repeat GC box (dim-IR-GC box). 
5.5 Unresponsiveness of the dim-IR-GC box towards glucocorticoids excludes the 
presence of a cryptic HRE 
Although there was no indication whatsoever that the dim-IR-GC box is or 
contains a hormone responsive element, defined as a binding site for androgen, 
glucocorticoid, progesterone or mineralocorticoid receptors, the possibility remained 
that a cryptic binding site does exist. Therefore, the androgen and glucocorticoid 
responses of the SCGB 2A1 and PSA promoters were compared in LNCaP cells (see 
chapter 4.4). The PSA promoter contains two functionally active androgen response 
regions (see chapter 5.2), which contain multiple HREs that have been shown to be 
responsive to androgens and glucocorticoids alike (Cleutjens et al., 1997). Because 
LNCaP cells do not express the glucocorticoid receptor (Schuurmans et al., 1988) it 
had to be ectopically expressed from a cotransfected GR expression construct. As 
shown before, the PSA promoter responds strongly to the androgen DHT and the 
glucocorticoid dexamethasone. This demonstrates that the GR expression construct as 
well as the whole experimental setup were functioning as expected. Contrary to the 
PSA promoter the SCGB 2A1 promoter did not respond to DEX at all even if the GR 
was expressed. Instead there was a slight repression of basal activity in the presence 
of DEX and GR. This result shows that a cryptic but functional HRE does not exist in 
the SCGB 2A1 promoter because an androgen-specific HRE with 100% androgen 
selectivity has not been described yet.  
5.6 NF-Y is functionally important for full promoter activity 
DNase I footprinting of the –382/+50 SCGB 2A1 promoter fragment revealed two 
strong footprints at positions –186/-155 and –104/-136. Because these footprints were 
not only observed with nuclear extracts from DHT induced or uninduced LNCaP cells 
but also with HeLa nuclear extract they are likely caused by ubiquitous proteins. 
Sequence analysis in combination with a presumably ubiquitous nature of the 
footprinted proteins led to the hypothesis that the distal footprint was due to binding 
of nuclear factor 1 (NF1) and the proximal footprint due to binding of nuclear factor 
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Y (NF-Y). This hypothesis was confirmed in EMSAs demonstrating in vitro that 
LNCaP and HeLa nuclear extract proteins recognize a NF1 binding site at around 
–167 and a CAAT-box at around –110 within the center of the footprinted regions. 
Transfection of reporter gene constructs with binding site mutants that were shown in 
EMSAs to abrogate DNA-binding showed that NF-Y is functionally important for 
basal promoter activity whereas NF1 also participates in mediating the androgen 
response. 
The CCAAT motif is one of the most common DNA-binding elements present in 
the promoters of about 30% of all mammalian genes as a nucleotide comparison of 
502 unrelated RNA polymerase II promoters implies (Bucher, 1990). The motif is 
most often found between 80 and 100 bp upstream of the transcription start site, and 
the sequences around the CCAAT box are highly conserved when orthologous genes 
are compared. Similarly, the SCGB 2A1 CCAAT box is located at position –110 but 
orthologous genes have not been characterized in their promoter regions yet. 
NF–Y, also called CCAAT-binding factor (CBF), is a unique DNA-binding protein 
that interacts with the CCAAT motif that is also called a Y-box. The affinity of NF-Y 
binding to DNA varies depending on the sequences flanking CCAAT. High-affinity 
CBF-binding sites have been defined by PCR-mediated random binding site selection 
and yielded the consensus 5'-[T/C][A/G][A/G] CCAAT CA-3' (Bi et al., 1997). A 
survey of 178 NF-Y binding CCAAT boxes confirmed the absolute requirement for 
the 5 nt CCAAT core and also pointed to specific flanking sequences - C, Pu, Pu on 
the 5'-side and C/G, A/G, G, A/C, G on the 3'-side - required for efficient binding 
(Mantovani, 1998). The flanking sequences of the SCGB 2A1 CCAAT box 
(5'-ACA-CCAAT-GGGAA-3') show a very good match with the flanking sequence 
consensus on the 3' side and a poor match (one out of three) on the 5' side. Together 
with the results obtained from EMSA competition experiments with the high affinity 
mouse MHC II Ea Y–box (see chapter 4.6.1) one can conclude that the SCGB 2A1 
CCAAT motif also possesses a comparably high affinity for NF-Y. 
It is known that several proteins can bind to CCAAT motifs. But among them, 
only NF-Y requires a very high degree of sequence conservation. Other 
CCAAT-binding proteins include CTF/NF1 and CCAAT/enhancer binding protein 
(C/EBP), but their binding sites often do not contain the complete CCAAT core. 
Hence, NF-Y can be distinguished from other CCAAT binding proteins on the basis of 
DNA sequence requirements (Maity and Crombrugghe, 1998). 
Promotors with CCAAT motifs can be divided into three groups based on the 
 89
Discussion 
effect of a CCAAT mutation on promotor activity (Maity and Crombrugghe, 1998). 
Group 1 promotors like the one in the mouse MHC class II Ea (Dorn et al., 1987) 
show a decreased basal transcription in the absence of stimulatory agents. In group 2, 
promoters are activated by adding an inducing or withdrawing a repressing agent, 
with transcriptional stimulation requiring an intact CCAAT motif. Group 3 promotors 
are regulated during cell proliferation and several of them contain multiple CCAAT 
motifs. Consequently, and due to the fact that a mutation in the Y-box is only affecting 
basal transcription, the SCGB gene possesses a group 1 CCAAT motif. 
NF-Y consists of three subunits B, A and C that have been separately described as 
CBF A, B and C, respectively (Maity and de Crombrugghe, 1996). In each subunit, 
the segment needed for formation of the NF-Y-DNA complex is conserved from yeast 
to man (Chodosh, et al. 1988). Interestingly, CBF A and C contain a domain that is 
homologous to the histone-fold motif of eukaryotic histones. The histone fold motifs 
of CBF subunits A and C interact with each other to form a stable heterodimer that 
associates with subunit B to form a heterotrimeric NF-Y molecule (see Fig. 5.3) that 
is then able to bind to DNA (Sinha, et al. 1996; Kim, et al. 1996). None of the NF-Y 
subunits individually, or the NF-Y BC heterodimer alone can bind to DNA, but only 
the heterotrimeric complex. 
 
Fig.5.3 The heterotrimeric NF-Y molecule binds to DNA (from 
Maity and Crombrugghe, 1998).  
The nucleotide sequence represents a consensus NF-Y binding site 
(CCAAT in the lower DNA strand). A, B, C are the cognate NF-Y 
subunits. Portions of NF-Y A and C outside the heterotrimeric complex 
contain transcriptional activation domains. Note: Subunit NF-Y A 
corresponds to CBF-B, NF-Y B corresponds to CBF-A, and NF-Y C 
corresponds to CBF–C. 
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Although this heterotrimeric complex is the functional NF-Y entity, differential 
expression of subunit B under specific conditions has been observed in several cell 
lines that also resulted in an alteration of NF-Y dependent promoter activity. This cell 
specific alteration of subunit B synthesis results in variable NF-Y activity in different 
cells, which suggest that, although NF-Y is a ubiquitous transcription factor, 
differential expression of NF-Y subunits can occur during growth and differentiation 
of individual cell lineages (Maity and de Crombrugghe, 1998). In some promoters, the 
Y box may be a target for regulation. In embryonic tissues, another protein, called the 
CCAAT-displacement protein (CDP), binds to CCAAT boxes, preventing NF-Y from 
recognizing them (Kim et al., 1997). 
One way through which NF-Y might regulate transcription is by cooperative 
interactions with other sequence specific transcription factors. The liver-specific 
serum albumin promoter for example contains a NF-Y binding site that is adjacent to 
a strong binding site for C/EBP. NF-Y and C/EBP activate transcription 
synergistically in liver nuclear extracts in vitro. However, this transcriptional 
synergism is not observed when the NF-Y binding site is moved 10 bp away from the 
C/EBP site. Thus, the precise positioning of C/EBP and NF-Y binding sites in the 
albumin promoter is required for optimal formation of a stable transcription complex 
(Milos and Zaret, 1992). 
Another example is the MHC class II Ea promoter, which contains a stereospecific 
alignment of a so called X box and a Y box. A mutation in the Y box, abrogating 
NF-Y binding, also abolishes in vivo binding of transcription factors recognizing the 
X box. But vice versa, mutations in the X box have only little effect on NF-Y binding 
in vivo. These and other results indicate that NF-Y has a crucial role in establishing 
proper promoter occupancy that may be related to its histone fold motifs (Wright et al., 
1994; Linhoff et al., 1997). The requirement for a precise location of NF-Y binding 
sites might also explain why the CCAAT motif is found in the –80 region. 
5.7 NF1 participates in the androgen response 
The NF1 family of DNA binding proteins has been implicated in the transcriptional 
activation of many eukaryotic genes that are ubiquitously expressed, or hormonally, 
nutritionally and developmentally regulated. The NF1 family is composed of four 
members in vertebrates including NF1-A, NF1-B, NF1-C and NF1-X (Richard, 2000). 
Transcripts of each of the four NF1 genes are differentially spliced, yielding as many 
as nine distinct proteins from a single gene. Products of the four NF1 genes differ in 
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their abilities to either activate or repress transcription. Although binding sites for 
NF1 proteins within the promoters of several tissue-specific genes have been shown 
to be essential for their expression, it is unclear which NF1 gene functions in specific 
tissues during development. The finding that NF1 binding sites are functional in both 
DNA replication and gene expression was one of the earliest indications that the same 
protein could be important in both processes (Jones et al., 1987). 
NF1 was originally identified as a host-encoded protein required for efficient 
initiation of adenovirus replication in vitro (Nagata et al., 1982) and was later shown 
to be involved in the transcriptional regulation of a large number of cellular genes. 
NF1 proteins bind to DNA as homodimers and heterodimers, all of which appear to 
recognize the “consensus binding” site TTGGC(N5)GCCAA with the same apparent 
affinity. NF1 can also specifically bind to individual half sites (TTGGC or GCCAA) 
although with somewhat reduced affinity (Meisterernst et al., 1988). 
Experimental analyses as well as computer predictions suggest that NF1 does not 
require a defined spacing between both DNA half sites (Roulet et al., 2000). 
Increasing the spacer length from 5 to 6 or 7 bp has relatively mild effects on DNA 
binding, whereas the deletion of only one base pair does not allow simultaneous 
interaction of two NF1 molecules with both half sites. Due to this flexible DNA 
binding mode the sequence specificity of this protein cannot be represented by a 
simple consensus sequence or weight matrix. 
All deviations from the fully palindromic DNA site decrease NF1 binding. The 
most deleterious substitutions are found at position 3, whereas single or double 
mutations located at the downstream border of the core TTGGC show little effect 
(Roulet et al., 2000). Results from testing a series of DNA binding sequence variants 
argue against a binding model in which any substitution leads to the loss of only one 
specific amino-acid base-pair interaction. Roulet et al. showed that a generalized 
profile of the NF1 binding sequence can be used to accurately predict the binding 
affinity. The sequence of the identified NF1 binding site in the SCGB2A1 promoter is 
TTGTC(N5)TCCAA and contains one base substitution in each half site separated by 
a 5 bp spacer. Using the Roulet-profile the predicted score of this sequence is 73 that 
compares very well with predicted scores and experimental values for other well 
characterized binding sites in natural promoters like in the alpha-globin (predicted 73, 
experimental 87) and c-myc (63/65) genes or the HIV-LTR (70/73) (Roulet et al., 
2000). 
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The prototypical NF1 protein is composed of an N-terminal DNA-binding/ 
dimerization domain (DBD) and C-terminal transcriptional activation and/or 
repression domains. There is a very strong conservation in the DBDs of all four NF1 
members (Meisterernst et al., 1989; Rupp et al., 1990) but no detectable sequence 
homology with other known DBDs and thus the NF1 DBD may be structurally 
distinct. Four cysteine residues are conserved between all NF1 DNA-binding domains, 
and three of the four residues are required for DNA-binding activity (Bandyopadhyay 
and Gronostajski, 1994). The fourth cysteine residue, while not essential for 
DNA-binding activity, makes NF1 factors sensitive to oxidative inactivation. The 
feature of oxidation sensitivity is shared by a number of transcription factors and may 
play a role in the cellular response to oxidative damage (Abate et al., 1990; 
Guehmann et al., 1992). 
While the NF1 DNA-binding/dimerization domain is often described as a 
~200-220 amino acid domain encoded predominantly by a single exon, the minimum 
size of this domain may differ slightly between the four NF1 genes. The 
DNA-binding affinity of NF1 increases with the length of C-terminal extensions 
(Mermod et al., 1989; Meisterernst et al., 1989). However, the differences in binding 
affinity may be due to improved protein folding of the larger molecules rather than to 
additional DNA contacts. NF1 proteins bind to DNA as homodimers, but the 
formation of heterodimers has been shown between products of all four chicken NF1 
genes, with few or no differences being observed in DNA-binding affinity, specificity, 
or stability of the dimers (Kruse and Sippel, 1994). 
Fig. 5.4 Models for NF1 function in 
vivo (from Gronostajski, 2000). 
(A) One mechanism how NF1 homo- or 
hetero-dimers may regulate transcription 
is by direct interactions with components 
of the basal transcription apparatus, co- 
activators or co-repressors in order to 
recruit them to specific promoters. (B) A 
second mechanism may operate through 
displacement of other site-specific 
transcription factors, nucleosomes, or 
other factors from promoters. (C) The 
third mechanism involves the cooperative 
recruitment of specific NF1 isoforms by 
adjacent site specific transcription factors.  
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NF1 factors activate transcription through multiple mechanisms as shown in Fig. 
5.3 (Gronostajski, 2000). The best-studied mechanism involves a direct interaction 
with basal transcription factors. The largest isoform, NF1-C, has a C-terminal ~100 
amino acid proline rich domain (Mermod et al., 1989) that contains a single copy of 
the heptapeptide repeat occurring in the C-terminal domain of RNA polmerase II 
(CTD) (Meisterernst et al., 1989). When linked to heterologous DNA-binding 
domains this 100 residue proline-rich domain stimulates transcription five to ten fold 
in mammalian cells (Mermod et al., 1989; Seipel et al., 1992) whereas its deletion 
drastically reduces transactivation (Chaudhry et al., 1998). This domain has been 
shown to interact in vitro with human TFIIB (Kim and Roeder, 1994) and yeast TBP 
(Xiao et al., 1994). Deletion of the CTD repeat abolishes both the interaction with 
TFIIB and transactivation in yeast. C-terminal regions of NF1-C outside this 
proline-rich domain increase transcription approximately three fold, suggesting that 
the two regions cooperate in activating transcription (Mermod et al., 1989). The other 
three NF1 genes also encode proteins with proline rich C-termini, but none of them 
contains a perfect match to the CTD repeat. Thus it is unclear whether the mechanism 
of activation is the same for all human NF1 members. 
A second mechanism proposes the displacement of repressive histones, either by 
direct competition for DNA binding or by interactions of histones with the proline 
rich transactivation domain of NF1-C. Such a mechanism may be of particular 
importance for promoters known to contain positioned nucleosomes, such as the 
mouse mammary tumor virus (MMTV) promoter (Chaudhry et al., 1999). It is also 
likely that specific interactions between NF1 and various coactivator proteins play a 
role in transcriptional activation. One specific coactivator interacting with the 
proline-rich domain is TAFII55, which also interacts with a number of other 
transcription factors including Sp1, YY1, USF and HIV TAT (Chiang and Roeder, 
1995). Interactions of NF1 with other factors such as pirin (Wendler et al., 1997) and 
Ski protein (Tarapore et al., 1997) have also been observed. 
NF1 proteins and their cognate binding sites have been shown to affect the 
expression of genes regulated by a number of signal transduction pathways, including 
those controlled by insulin (Cooke and Lane, 1999), camp (Chu et al., 1991), and 
steroid hormones (Garlatti et al., 1996; Chaudhry et al., 1999). It is difficult to 
determine whether the effects of some hormones/growth factors on NF1 proteins are 
direct or indirect, since the expression of NF1 proteins can be affected by the growth 
and differentiation state of the cell. In case of the MMTV promoter the response to 
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steroid hormones is markedly decreased by mutation of a NF1 binding site 
immediately downstream of a hormone response element, suggesting a functional 
synergism between receptor and NF1 (Chavez and Beato, 1997). The DNA binding 
domain of NF1 is already sufficient for enabling such a synergism with the 
glucocorticoid receptor which led to the model of NF1 being an architectural factor 
that keeps the chromatin open as soon as chromatin remodelling preceding 
transcription has been initiated by steroid hormone receptors (Di Croce et al., 1999). 
5.8 Sp family factors confer androgen regulation of the SCGB 2A1 gene 
DNase I footprinting of the –382/+50 SCGB 2A1 promoter fragment also revealed a 
weak footprint immediately upstream of the TATA box. The borders could not be 
unequivocally determined, but its main characteristic is the absence of a block of 
pyrimidines at around position –60 in the lower strand and a hypersensitive thymidine 
(-21) within the TATA box in the upper strand. These features are only observed with 
nuclear extracts from DHT treated or untreated LNCaP cells but not or significantly 
weaker with nuclear extract from HeLa cells (see chapter 4.5). 
Within these limits the “androgen response element”, meaning the element that is 
responsible for induction of the gene by androgens, could be identified between –59 
and –28 as the dim-IR-GC box. When the dim-IR-GC box was placed in front of the 
minimal thymidine kinase promoter, consisting of a TATA box and one GC box, 
transcription of a reporter gene could be induced by the androgen DHT but not at all 
by the glucocorticoid dexamethasone (see chapter 4.4). But if the “androgen response 
element” of the SCGB 2 A1 promoter would represent or contain a binding site for the 
androgen receptor, responsiveness towards glucocorticoids has to be expected because 
a typical steroid hormone response element for androgens is also responsive for 
glucocorticoids, progestins and mineralocortiocids (Cleutjens et al., 1997; Beato and 
Klug, 2000; Ham et al., 1988). 
So far no androgen receptor binding site has been described that is completely 
unresponsive towards glucocorticoids. A few elements show selective but not specific 
induction by the androgen receptor when compared to the glucocorticoid receptor. 
Among them are the two AREs in the rat probasin promoter as well as the functional 
intronic ARE in the rat C3(1) gene. All three elements still show 1.6- to 7-fold 
residual induction by glucocorticoids in transfection experiments (Claessens et al., 
2001). These androgen-selective elements can be viewed as a direct repeat of the 
5′-TGTTCT-3′ half site with three intervening nucleotides. Therefore, Claessens et al. 
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suggested that selectivity is achieved by the androgen receptors ability to bind as a 
head-to-tail dimer to such a direct repeat which is thought to be impossible for the 
glucocorticoid receptor (Claessens et al., 2001). Contrary to these identified 
androgen-selective elements the SCGB 2A1 “androgen response element” represents 
an inverted repeat. Altogether there is no indication that the dim-IR-GC box is or 
contains a binding site for the androgen receptor. 
To test if Sp family proteins indeed can bind to the dim-IR-GC box, EMSA 
experiments were performed. The complex pattern, competition behaviour and the use 
of antibodies recognizing Sp proteins unequivocally showed that the dim-IR-GC box 
can hardly be differentiated from a classical GC box probe. Competition experiments 
with unlabeled dim-IR-GC box and GC box probes indicated that the affinity of Sp 
factors to the dim-IR-GC box is only somewhat lower compared to the consensus GC 
box. 
Sp factors form two subgroups within the family of Sp/XKLF transcription factors 
(Philipsen, and Suske, 1999) of which subgroup 1 include the four members Sp1, Sp2, 
Sp3 and Sp4. Sp1 is a single polypeptide of approximately 100 kDa, but appears as a 
double band in western blots, which is most likely due to posttranslational 
modifications, such as glycosylation or phosphorylation. Sp3 has four different 
isoforms, two long isoforms of 110-115 kDa (G. Suske, unpublished observation) and 
two approximately 60-70 kDa truncated variants. All four proteins are translated from 
the same gene but from different start codons, including a very rare AUA start codon 
for the long isoform (Hernandez et al., 2002). 
Because Sp1 and Sp3 are ubiquitous proteins and indistinguishable in their 
DNA-binding specificity, complexes of the dim-IR-GC box with Sp1 and the four 
isoforms of Sp3 were observed in the EMSA experiments. The complex of lowest 
mobility is in fact a triplet (Dennig et al., 1995; G. Suske, unpublished observation) 
that becomes apparent when antisera against Sp1/Sp3 are used. The lower two 
complex bands of the triplet contain the two long isoforms of Sp3, the upper one is 
Sp1. The specific complex with high mobility is also a doublet (Dennig et al., 1995) 
that was not resolved here and contains the two small Sp3 isoforms. 
The dimeric nature of the SCGB 2A1 Sp binding site implicates that Sp1 or Sp3 
homodimers or Sp1/Sp3 heterodimers might bind to this element. Unfortunately we 
do know very little on how Sp molecules bind to DNA in general since no crystal 
structure is known yet. From other transcription factors containing three C2H2 type 
zinc fingers, like Zif268, we can infer that a monomer binds to its cognate DNA 
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element with each finger recognizing a DNA triplet. If only one molecule of Sp1 or 
Sp3 would bind to a consensus GC box one could expect two Sp1/3 molecules 
binding to a dimeric binding site. Although the EMSA separates molecules according 
to size, charge and especially form and not only to size one would expect different 
mobilities for Sp complexes with the dim-IR-GC box and for Sp complexes with the 
consensus GC box. But although the lengths of the dim-IR-GC box and GC box 
probes are different the mobilities of Sp/dim-IR-GC box and Sp/GC box complexes 
are apparently identical. For Sp1 it is well known that it can form multimeric 
complexes by homotypic interactions (Mastrangelo et al., 1991). Therefore, the Sp1 
DNA complex may be composed of Sp1 molecules that are bound directly to DNA 
and Sp1 molecules that are tethered to the DNA bound molecules through 
protein-protein interactions (Lee et al., 1998). Because Sp1 and Sp3 are present in 
most cells the situation is even more complex and deserves thorough investigation. In 
the human uPA gene, the proximal promoter contains a GC-rich region which can 
bind either Sp1 or Sp3, as monomers or multimers, but not a combination of the two 
factors (Ibanez-Tallon et al., 2002). 
All members of the Sp family exhibit very similar structural features (Suske, 1999, 
Philipsen, and Suske, 1999). Their highly conserved 81 amino acid DNA binding 
domain (DBD) contains three C2H2-type zinc fingers close to the C-terminus and 
glutamine rich activation domains adjacent to serine/threonine stretches in their 
N-terminal regions. Due to the high conservation of the DBD Sp1, Sp3 and Sp4 
recognize a GC box with virtually the same affinity (Hagen et al., 1992, 1994). Each 
zinc finger of Sp1 recognizes a DNA triplet via specific interactions with a 
recognition helix. Molecular dynamics simulations suggest that the triplets TGG, GGG, 
and GAG are preferred in triplet position 1. Triplet position 3 is preferred by TGG, 
GGG, GAG, GGA, or GAA, whereas triplet position 2 is more restrictive in that only 
GCG or GAG are tolerated here, and GGG is strongly excluded (Marco et al., 2003). 
The strong preference for GCG and GAG in triplet position 2 is also evident in the 
Sp1 binding site matrix of MatInspector (http://www.gene- regulation.com). Out of 
108 biologically proven mammalian Sp1 binding sites GCG occurred in triplet 
position 2 in 80 cases, whereas in 19 cases the triplet GAG was found. In 9 cases 
GTG was found. A “GA box” like in the SCGB 2A1 promoter was also demonstrated 
in the promoter of the rat α2A-adrenergic receptor gene (Handy and Gavras, 1996), 
and in the promoter of the growth hormone gene (Vines and Weigent, 2000). 
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Fig. 5.5 Comparison of the distal and proximal GC boxes of the 
dim-IR-GC box with predicted preferred triplets for GC boxes in 
the three triplet positions 1-3 (Marco et al., 2003).  
The dim-IR-GC box contains the three consecutive DNA triplets TGG GAG GGA 
in the distal GC box, and AGG GAG GCA in the proximal GC box (see Fig. 5.5). 
Each of the three triplets in the distal GC box is a predicted preferred one, whereas 
only the triplet in position 2 of the proximal GC box is the preferred GAG. The other 
two triplets are similar to preferred ones but not identical. Therefore, the distal GC 
box is a predicted high affinity Sp binding site, and the proximal site can be expected 
to show only moderate high or low affinity. This prediction is in agreement with the 
results from EMSA experiments. When the distal GC box was mutated this has a 
moderate negative effect on the binding of Sp1 and Sp3. Most likely, the residual 
binding is due to binding of Sp1/3 to the lower affinity proximal binding site. 
Contrary to the distal GC box mutant, the proximal GC box mutant shows very little 
effect if at all because the high affinity distal box is still intact. When both GC boxes 
were mutated in the double GC box mutant Sp factor binding was abrogated (see 
Fig.4.11). This result also shows that the individual mutations in the distal and 
proximal GC boxes were “lethal” because otherwise residual binding had been 
observed in the double mutant. The same dim-IR-GC box mutations were introduced 
into the –382/+50 luciferase reporter gene construct. The transfection results 
confirmed that the distal GC box is functionally more important for mediating the 
androgen response than the proximal GC box. A 26-fold induction of luciferase 
expression by androgen is decreased to a 6-fold induction when the distal GC box is 
mutated, and to a 11-fold induction in case of the proximal mutation. The double 
mutant only shows a residual two fold androgen inducibility. Therefore, abrogation of 
Sp factor binding leads to a virtual loss of androgen inducibility of the SCGB 2A1 
promoter so that Sp factors must be involved in mediating the androgen response. 
 98
Discussion 
5.9 How can Sp 1/3 indirectly mediate androgen induction of the SCGB 2A1 
gene? 
Several recent studies have shown that some hormone-responsive genes either do not 
contain a corresponding hormone responsive element within their promoters or only a 
non-fuctional half site. Instead the hormone response is mediated via binding sites for 
Sp family transcription factors. For example, in the cathepsin D gene a composite 
GC-box/half site ERE element is required for estrogen induction (Krishnan et al., 
1994). If the GC-box part is mutated and binding of Sp factors thus abrogated, 
estrogen induction is lost. A similar element responsible for estrogen induction was 
identified in the gene encoding heat shock protein 27 (Porter et al., 1996). Mutation of 
the ERE half site did not affect estrogen induction in transfection experiments. 
Moreover, Sp1 and ER were shown to physically interact, and the DNA binding 
domain of the ER is not required for the functional synergism of both factors (Porter 
et al., 1997). In both cases a ternary complex of Sp1, ER and the GC-box/half site 
ERE probe have been shown in electrophoretic mobility shift assays. Likewise 
estrogen induction of the retinoic acid receptor α1 gene is functionally dependent on 
the integrity of two Sp binding sites (Sun et al., 1998). Again hormone induction is 
dependent on the presence of the estrogen receptor, but its DNA binding domain is not 
required. Another example is the induction of ubiquitin (UbC) expression by 
glucocorticoids in muscle cells mediated by Sp1 and MEK1, neither the rat nor human 
UbC promoter sequences contain a consensus glucocorticoid-response element 
(Marinovic, et al., 2002). One of the functionally required GC boxes in the UbC 
promoter is also located immediately upstream of the TATA box like the dim-IR-GC 
box element in the SCGB 2A1 gene. 
In some other HRE-containing genes the hormone response is modulated by Sp 
factors. In the promoter of the rabbit uteroglobin gene, for example, an adjacent Sp 
binding site is an essential part of a composite estrogen-responsive unit. The estrogen 
induced recruitment of Sp1, but not of the related transcription factor Sp3, mediates 
estrogen activation (Scholz et al., 1998). The mouse vas deferens protein (MVDP) 
promoter is androgen responsive and contains an ARE. Transient transfection assays 
revealed that site-directed mutations in the NF1 and Sp1 binding elements strongly 
reduced (NF1) or abolished (Sp1) androgen induced expression (Darne et al., 1997). 
A physical interaction of AR and Sp factors would be a straightforward 
explanation for the involvement of Sp factors in mediating a hormone response, either 
through a genomic route with the help of an HRE or non-genomic via protein-protein 
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interactions. Such a direct interaction of AR and Sp1 was detected by using a 
mammalian one-hybrid assay and coimmunoprecipitation experiments (Lu et al., 
2000). Lu et al. investigated the promoter of the cyclin-dependent kinase inhibitor p21 
that contains a canonical androgen responsive element and six binding sites for Sp 
factors. It was found that deletion of the ARE did not fully eliminate androgen 
responsiveness whereas mutation of the third Sp binding site nearly eliminated basal 
activity as well as androgen responsiveness. Contrary to this report, Sp1 could not be 
detected in a general AR interaction screen based on specific binding of cytoplasmic 
and nuclear proteins to immobilized AR (C.L. Bevan, unpublished observation). p21 
transcription can also be activated by progesterone which is again mediated by Sp1. 
The third and fourth Sp binding sites are essential for progesterone induction. Sp1 and 
CBP/p300 have been shown to associate with a stably integrated flag-tagged PR in a 
multiprotein complex (Owen, et al., 1998). 
An interaction between AR and Sp factors could also be mediated by some 
bridging protein. In 1998 small nuclear RING finger protein (SNURF) was discovered 
in a yeast two hybrid assay using the DNA binding domain of AR as a bait (Moilanen 
et al., 1998). SNURF interacts with AR in a hormone-dependent fashion in both yeast 
and mammalian cells and enhances not only androgen, glucocorticoid, and 
progesterone receptor-dependent transactivation but also basal transcription from 
steroid-regulated promoters. SNURF was shown to enhance Sp1 binding to GC boxes 
via the RING finger domain, and to interact and cooperate with Sp1 in transcriptional 
activation (Poukka et al., 2000). Therefore, SNURF was suggested to act as a 
functional link between steroid- and Sp1-regulated transcription and could be 
involved in mediating the androgen response of the SCGB 2A1 promoter.  
SCGB 2A1 expression could also be induced by androgens via the Src/Shc/Erk 
pathway because steroid hormones have been shown to stimulate this signaling 
pathway like growth factors (Migliaccio et al., 2002). Treatment of human prostate 
carcinoma-derived LNCaP cells with androgen or oestradiol triggers simultaneous 
association of androgen receptor and estrogen receptor β with Src, activates the 
Src/Raf-1/Erk-2 pathway and stimulates cell proliferation (Migliaccio et al., 2000). 
This mechanism is not limited to cell lines derived from human mammary or prostate 
cancers but is also detected in osteoblasts, osteocytes and embryonic fibroblasts where 
activation of the Src/Shc/ERK pathway by estrogens and androgens has an 
antiapoptotic effect (Kousteni et al., 2001). 
Interestingly, like many other transcription factors, Sp1 is subject to 
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post-translational modifications that can influence its activity. Early evidence for the 
significance of these processes was obtained when recombinant Sp1 produced in E. 
coli turned out to be a less-effective transactivator in vitro than Sp1 purified from 
HeLa cells (Kadonaga et al., 1988). The two major types of posttranslational 
modifications that are thought to be involved in transcription regulation by Sp1 are 
glycosylation and phosphorylation. Sp1 becomes phosphorylated at its N-terminus by 
DNA-dependent protein kinase and cyclin A-CDK (Fojas de Borja et al., 2001). The 
C-terminus of Sp1 can also be phosphorylated which has been linked to cell cycle 
progression from G0 to G1. In vitro data suggest that the unknown kinase that 
mediates this phosphorylation specifically targets serine residues in the most 
N-terminal zinc fingers 1 and 2 (Black et al., 1999). These mentioned 
phosphorylations do not seem to affect DNA-binding activity, but there are several 
reports that also link Sp1 phosphorylation with decreased or increased binding affinity 
(Bouwman and Philipsen, 2002). In some cases, increased binding through 
phosphorylation has been correlated with enhanced transcactivation. One report 
implicates Erk 2 in Sp1 phosphorylation that leads to enhanced DNA-binding 
(Merchant et al., 1999). Apparently, certain kinases can specifically regulate the 
transcriptional activivity of distinct Sp factors. But it is likely that there are also forms 
of phosphorylation that have a similar effect on different Sp factors (Bouwman and 
Philipsen, 2002). 
Other post-translational modifications of Sp1/Sp3 could also be under hormone 
control and thus regulate the transcriptional activity of Sp1 or Sp3. In this context it 
should be mentioned that Sp3 is a target for acetylation and SUMOylation. On many 
reporter constructs containing multiple Sp-binding sites, Sp3, unlike Sp1, is inactive 
or only a very weak activator of transcription (Hagen et al., 1994). The molecular 
basis for the inactivity of Sp3 under these conditions has been mapped to an inhibitory 
domain (ID) located between the second glutamine-rich activation domain and the 
zinc finger region (Dennig et al., 1996). A single lysing residue in the IKEE sequence 
within this domain is absolutely required for inhibitor function, and this lysine was 
shown to be acetylated in vivo. Deletion of this inhibitory domain can abolish the 
acetylation of Sp3, suggesting that this lysine residue is a target for this modification 
(Braun et al., 2001).  
Lysine residues in proteins can also be targets for SUMOylation. Small 
ubiquitin-like modifier 1 (SUMO-1) together with two related proteins, SUMO-2 and 
SUMO-3, form a small protein family. All three proteins can be covalently linked to 
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the ε-amino group of lysine residues. Contrary to ubiquitination, the addition of 
SUMO can modulate the ability of proteins to interact with their partners, alter their 
patterns of subcellular localization and control their stability. It seems to be clear that 
SUMO influences many different biological processes, but recent data suggest that it 
is particularly important in the regulation of transcription (Verger et al., 2003). 
Physiologic signals that increase or decrease the extent of sumoylation may thus have 
a significant influence on the activity of select transcription factors (Freiman and 
Tjian, 2003). Interestingly, the same lysine in Sp3 that seems to be acetylated in vivo 
is also subject to SUMOylation. Mutational analyses of the SUMO motif (IKEE) 
revealed that the SUMOylation correlates with inactivity of Sp3 (Sapetschnig et al., 
2002; Ross et al., 2002). The role of acetylation vs. SUMOylation has to be 
reconsidered, therefore, because it is also possible that SUMOylation of this lysine 
residue leads to acetylation of another unidentified lysine residue within the Sp3 
molecule. 
Enzymes that catalyze the conjugation of SUMO–1 with its substrates are the 
SUMO-activating E1 enzyme and the SUMO-conjugating E2 enzyme, also called 
Ubc9. Recently, it was shown that PIAS1 is the SUMOylation-specific E3 ligase that 
conjugates SUMO-1 to Sp3 (Sapetschnig et al., 2002). If the extent of SUMOylation 
is influenced by hormone this could be achieved for example via modulation of the 
activity of one or all of these three enzymes. Therefore, the extent of SUMOylation of 
Sp3 in response to DHT was looked at in LNCaP cells, but no change could be 
observed (A. Sapetschnig, unpublished observation). Nevertheless, this preliminary 
result should be considered with caution because SUMOylation is transient and very 
sensitive towards removal by SUMO-specific isopeptidases. 
Fig. 5.6 summarizes the various mechanisms by which the expression of SCGB 
2A1 could be rendered androgen responsive through the dim-IR-GC box. 
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Fig. 5.6 Possible mechanisms for the induced expression of SCGB 2A1 through 
the dim-IR-GC box. 
Sp1 and Sp3 can bind to the dim-IR-GC box and could recruit hormone (symbolized 
by a steroid molecule) activated AR together with coactivators via SNURF. 
Alternatively post-translational modifications like phosphorylation of Sp1 or 
SUMOylation of Sp3 could be under androgen control. NF1 seems to augment the 
hormone response. NF-Y that is made up of its three subunits, NF-Y A, B and C is 
required for basal expression only. The preinitiation complex that is forming on the 
TATA box by binding of TATA box binding protein (TBP) and TBP associated factors 
(TAFs) followed by a number of general transcription factors (GTFs) and RNA 
polymerase II (pol II) is also indicated. 
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6. Summary 
The secretoglobins belong to a minority of proteins with unclear physiological 
function. In the past research in the field was dominated by work on the family 
founder member uteroglobin and its orthologs. This was mainly due to the fact that 
some 20 to 30 years ago uteroglobin served as a first model for a steroid hormone 
binding protein, as the steroid hormone receptors had not been cloned yet. Later on it 
served as a model gene to study gene regulation by steroid hormone receptors. Many 
new members of the secretoglobin family were identified in the past few years but 
remained poorly investigated in terms of gene regulation. 
Studying one of the new family members was thought to be promising in finding 
new clues concerning physiological function of the secretoglobins in general. Many 
family members are expressed in the genital tract of males and females where they 
might play a role in reproduction. One of the new members, lipophilin C 
(= lacryglobin, mammaglobin B, secretoglobin SCGB 2A1) was first shown to be 
expressed by the lacrimal glands in the form of a heterodimer with lipophilin A, 
another secretoglobin that is present in tears. Due to functional similarities of lacrimal 
and prostate glands it was not surprising to find SCGB 2A1 also being expressed in 
the prostate. Because expression was found to be under androgen control, gene 
regulation was investigated using the androgen responsive human prostate cancer cell 
line LNCaP. Relevant regulatory regions were identified in the genes chromatin by 
mapping DNase I hypersensitive sites before and after androgen induction. Only one 
prominent hypersensitive site appeared in the proximal promoter after 6 hours of 
androgen induction indicating an indirect response. Sequence analysis did not reveal 
any canonical or non-canonical androgen response element(s). DNase I footprinting 
identified two factors binding to the proximal promoter region that were found to be 
the ubiquitous transcription factors nuclear factor I (NF1) and CAAT-box 
transcription factor NF-Y. Analysis of promoter deletions using luciferase reporter 
constructs showed that 136 bp of the promoter still containing the NF-Y binding site 
are sufficient to confer androgen responsiveness to the reporter gene or the 
heterogenous HSV-tk promoter. Analyses of promoter constructs with mutations in the 
NF1 and NF-Y binding sites demonstrated that both factors significantly contribute to 
the basal activity, and that NF1 helps to mediate the androgen response. Eventually 
androgen responsiveness could be traced down to a dimeric inverted repeat GC box 
immediately upstream of the TATA box that is a binding site for Sp family 
transcription factors.  
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Therefore, androgen responsiveness in the SCGB 2A1 gene is mediated by an 
indirect mechanism that requires the androgen receptor but operates through a binding 
site for ubiquitous transcription factors of the Sp family, notably the well known 
factors Sp1 and Sp3. This response is androgen-specific because glucocorticoids in 
conjunction with the cotransfected glucocorticoid receptor were not able to activate 
SCGB 2A1 expression in LNCaP cells. Thus, SCGB 2A1 was unexpectedly identified 
as a target gene for a non-ARE mediated action of the androgen receptor. Future 
investigations will focus on the exact mechanism of this indirect hormone response. 
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